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List of Abbreviations 
 
APC  =  antigen presenting cell 
CPX = cyclophosphamide 
CR =  complete response 
CTLs =  cytotoxic T lymphocyte 
DC = dendritic cell 
DTH = delayed type hypersensitivity 
              test 
FMO = fluorescence minus one 
hGM-CSF = human granulocyte macro- 
                           phage-colony stimulating factor 
HSA = hemangiosarcoma 
hTyr = human tyrosinase 
ID = intradermal 
IFN-gamma = inteferon-gamma 
IL-10  = interleukin-10 
IL-12 = interleukin-12 
IL-6 = interleukin-6 
IM = intramuscular 
IT-EGT = intratumoral electro-  
                          gene transfer 
LF2000 = lipofectamine 2000 
MDSCs = myeolid derived suppressor 
                          cells 
MHC = major histocompatibility 
                          complex 
MSC = mesenchymal stem cells 
MST = median survival time 
 
 
 
 
MVD = microvessel density 
NED = no evidence of disease 
NK cells = natural killer cells 
NSAIDS  = non steroidal anti- 
                          inflammatory drugs 
PBMC = peripheral blood mononuclear 
                          cells 
PBS = phosphate buffered saline 
PD-1 = programmed cell death-1 
PDL-1 = programmed death ligand-1 
pDNA  = plasmid DNA 
PR = partial response 
PRRs = pattern recoginition receptors 
SC = subcutaneous 
SD = stable disease 
SEM = standard error of the mean 
TERT = telomerase reverse 
                          transcriptase 
TGF-β = transforming growth factor beta 
TLR = toll like receptor 
TMZ = temozolomide 
Tregs = regulatory T cells 
TSP-1 = thrombospondin-1 
TVT = transmissible venereal tumor 
VEGF = vascular endothelial growth 
                          factor 
VEGFR-2 = vascular endothelial growth 
                          factor-2
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1. Introduction 
The first proof of concept for cancer immunotherapy dates back to the late eighteen hundreds 
when William Coley demonstrated that tumor regression occurred in patients after local 
injection of Streptococci or a mixture of Streptococcus pyogenes and Serratia marcescens 
(Coley’s toxins). However, Coley’s work was criticized by many colleagues and his concept 
did not break through. Now, more than 100 years later, cancer immunotherapy is on its 
revival and it is considered a new cornerstone in cancer treatment.
1
 This is for instance 
evidenced by Science’s selection of cancer immunotherapy as Breakthrough of the Year in 
2013 and by recent multi-million to billion deals in the pharmaceutical industry concerning 
immunotherapeutic drugs.
2-4
  
 
The long road to success for immunotherapy can be explained by the enormous complexity of 
interactions between tumor cells and the immune system. These interactions are summarized 
by the term tumor immunoediting and can lead to three possible outcomes; elimination, 
equilibrium or escape.
5
 The importance of immunoediting was first recognized in 
experimental models, where genetic modification of immune pathways greatly influenced 
tumor development. Swann and Smyth describe evidence for the three phases of tumor 
immunoediting in humans.
5
 Maybe the ultimate confirmation of the ability of the immune 
system to control tumor growth is the multitude of immune suppressive mechanisms 
universally present in tumors, apparently necessary for their existence. Indeed, it is well 
established that the capability to evade immune control is an essential hallmark for tumor 
growth.
6
 
 
If we look at the most important immunological players in tumor control, dendritic cells 
(DCs) can be identified as the master regulators of the immune response. DCs present tumor 
antigens to the adaptive immune system and depending on their interaction with T cells this 
will lead to tolerance or immunity.
7
 DCs interact with T cells on three levels. The first level 
involves the binding of an antigen-major histocompatibility complex (MHC) to an antigen 
specific T cell receptor. On a second level, costimulatory signals (e.g. CD80, CD86, CD40 
ligand) bind to stimulatory (e.g. CD28) or inhibitory (e.g. CTLA-4) receptors on T cells. 
Lastly, cytokines secreted by DCs form the third level of interaction of DCs with T cells.
8
 No 
one signal can be categorized as tolerogenic or immunogenic at its own, the result on the 
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immune response depends on the integration of several signals from DCs and the 
differentiation state of the interacting T cells.
8
 Interleukin-10 (IL-10) and transforming growth 
factor-beta (TGF-β) 1 are major inducers of tolerogenic DCs, whereas immunogenic DCs are 
most classically induced by toll like receptor (TLR) signaling but also TLR-independent 
activation is described.
9,10
 CD8 cytotoxic lymphocytes (CTLs) are considered the main 
effector cells in tumor immunity. Their effector functions require binding of the T cell 
receptor to MHC-peptide complex on the tumor cells and include interferon-gamma (IFN-
gamma) secretion, the death receptor pathway and the granule exocytosis pathway. IFN-
gamma has diverse antineoplastic effects, including direct anti-proliferating and pro-apoptotic 
effects on tumor cells, inhibition of angiogenesis and stimulation of the innate immune 
system.
11
 The death receptor pathway involves the binding between the death receptor ligand 
on the surface of CTLs and a death receptor on the tumor cell, resulting in apoptosis of the 
latter (the FAS-ligand/receptor pathway).
12
 In the granule exocytosis pathway, perforins and 
granzymes are secreted by exocytosis toward the target cell. They work cooperatively in 
inducing apoptosis of the target cell, perforin as membrane disrupting protein facilitating the 
delivery of the apoptosis triggering granzymes. Effector cells themselves are not affected 
because during the secretion of these granules, cathespin B is sequestered on the cell 
membrane which inactivates perforin that would diffuse back to the effector cell.
13
 Apart from 
CTLs, also natural killer cells (NK cells) can contribute to immune-mediated cell killing, with 
similar effector mechanisms as CTLs but they do not require priming by DCs for activation or 
MHC-binding with the target cell.
14
 Different factors present in tumors can lead to a cytotoxic 
response of NK cells, including MHC-I downregulation and the expression of NK2GD 
ligands on tumor cells.
15
  
 
Despite the potential of the immune system to eliminate cancer cells, tumors develop because 
of cancer induced immunosuppression. Tumors use multiple mechanisms to survive even in 
the presence of tumor reactive CTLs, either naturally present or induced by immunotherapy. 
Tumor cells downregulate MHC-I and/or immunogenic antigens, thereby avoiding CTLs 
recognition.
16
 More downstream, resistance against immune cell induced apoptosis has also 
been demonstrated, by blocking the death receptor pathway or by interfering with the 
perforin/granzyme pathway.
12
 Tumor cells can even turn the tables and cause apoptosis of 
CTLs. For example, some tumor cells express the FAS-ligand, resulting in T cell apoptosis 
when binding to the FAS-receptor on T cells.
17
 Tumor cells can also expose programmed 
death-ligand 1 (PDL-1) on their surface. Binding of PDL-1 to programmed cell death 1 (PD-
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1), a death receptor present on activated T cells, causes inhibition and apoptosis of tumor-
infiltrating T cells.
18
 Additionally, tumor cells that express the tryptophan degrading enzyme 
indoleamine 2,3-dioxygenase will cause apoptosis of CTLs, as CTLs are very sensitive to 
tryptophan depletion.
19
 Secretion of immune suppressive cytokines by tumor cells can also 
have a direct effect on effector immune cells.
20
  
 
Fig. 1:Interactions defining an anti-tumor immune response and potential immunotherapeutic interventions. 
Adapted from Restifo et al.
21 
 
Apart from these direct interactions between tumor cells and immune effector cells, a major 
mechanism of immune evasion involves the accumulation of immune suppressive regulatory 
T cells (Tregs) and myeloid derived suppressor cells (MDSCs) in the tumor 
microenvironment. The most important cytokines involved in Treg induction are TGF-β and 
IL-10.
22
 Tregs suppress CTLs as well as NK cell-mediated cytotoxicity and also have an 
effect on B cells, CD4 cells and DCs.
23
 This Treg mediated immune suppression ranges from 
cell-to-cell contact dependent mechanisms (e.g. CTLA-4) to the secretion of cytokines (e.g. 
IL-10, TGF-β). MDSCs are a population of immature myeloid cells, induced by several 
cytokines of which VEGF and G(M)-CSF are important examples. MDSCs have the potential 
to inhibit CTLs, DCs, and NK cells as well as to expand Tregs. They exert their immune 
suppressive effect by secretion of enzymes (e.g. arginase 1, nitric oxidase 2) and cytokines 
(e.g. IL-10, TGF-β) as well as by contact dependent mechanisms through e.g. the exposure of 
PDL-1 on their surface.
24
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It is clear that, in order to be effective, cancer immunotherapy has to be a multimodal 
treatment. Potential immunotherapeutic interventions, acting on different levels of the 
immune response are illustrated in figure 1. Treatment modalities evaluated in this thesis 
include genetic tumor vaccination, interleukin-12 (IL-12) gene therapy and metronomic 
chemotherapy. Components were  selected based on their immunological synergistic action 
and practical feasibility in veterinary medicine, since a fast transition to clinical trials in 
veterinary patients was one of the goals of this thesis. 
 
2. Tumor vaccination  
Although tumor specific precursors of CTLs are naturally present in cancer patients, they are 
not efficiently activated.
25
 Tumor cells lack costimulatory signals and thus cannot activate T 
cells directly. Dendritic cells are responsible for tumor antigen presentation to T cells, but are 
not activated in a tumor environment because of a lack of stimulatory signals and the presence 
of tolerogenic signals induced by the tumor.
26
 Tumor vaccination can replace the natural 
antigen presentation pathway and thus induce the generation of tumor-specific CTLs, a first 
important step towards effective immunotherapy.  
2.1. Tumor antigens 
Based on their expression pattern, antigens used in tumor vaccination can be divided into five 
major categories: differentiation antigens, cancer/testis antigens, mutational antigens, 
ubiquitous antigens and viral antigens.
27
 Differentiation antigens are overexpressed in a given 
type of cancer but they are also expressed in the corresponding normal tissue. Examples 
include prostate specific antigen and tyrosinase. They are suboptimal targets for vaccination 
due to self-tolerance mechanisms and the risk of autoimmune disease. However, these issues 
are of less importance for differentiation antigens that are only expressed during the earlier 
stages of differentiation. Differentiation antigens have been broadly used because they were 
first identified. Cancer/testis antigens form the second category of antigens and are expressed 
in germ line tissue and different types of cancers. Germ line tissue lacks MHC expression, 
therefore these antigens are considered tumor-specific. Hence, tolerance and autoimmunity is 
not a major issue. An overview of the different cancer/testis antigens can be found in the 
review of Caballero et al.
28
 The third category of antigen comprises mutational antigens 
which result from mutations and are strictly tumor-specific. Strong immune responses can be 
General introduction 
9 
 
elicited against these antigens as tolerance is not an issue. Unfortunately their usage is limited 
because it is also patient specific or at least restricted to certain patients. One way to ensure 
that unknown mutational antigens are included into tumor vaccines is by using whole, 
autologous tumor cell vaccines.
29
 Ubiquitous antigens, the last category of tumor antigens, are 
expressed in many normal tissues and overexpressed in tumors. Tolerance and autoimmunity 
are two important concerns.
29
 The rationale behind their capacity to be effective without 
causing autoimmunity is that overexpression in tumor cells can reach the threshold for T cell 
recognition, breaking immune tolerance.
27
 A well-known antigen belonging to this group is 
Her2/neu.
29
 Lastly, for tumors with a viral etiology, vaccination against viral antigens is an 
attractive option because the foreign nature of the antigen limits problems with tolerance and 
autoimmunity. Different cancers are associated with viral infection; the most common human 
papilloma virus (HVP) induced cervical cancer.
30
 Two HPV vaccines for the prevention of 
cervical cancer have been approved and first clinical successes with therapeutic vaccines have 
been achieved.
31,32
 
 
Based on the origin of the tumor antigens one can distinguish three classes of antigens: 
autologous, allogeneic and xenogeneic antigens. Autologous antigens are isolated from the 
patient’s own tumor cells and thus represent a personalized therapy. Moreover, knowledge of 
the antigens expressed by the tumor is not necessary. The use of autologous antigens is often 
the only way to ensure that tumor specific mutational antigens are included in the vaccine. 
Autologous antigens can be included in tumor cell vaccines, DC vaccines (by loading DCs 
with tumor cell lysate, killed tumor cells or whole tumor RNA), peptide vaccines (by 
extraction of tumor associated peptides) and DC-tumor fusion vaccines. As a second class, 
allogeneic antigens are antigens from the same species as the patient, but from a different 
individual. Allogeneic antigens can be utilized in all tumor vaccine platforms (see point 2.2 
below) and mass production is feasible when they are used as a peptide/protein or genetic 
vaccine. A third class of tumor antigens are xenogeneic antigens which are derived from 
another species than the patient. By utilizing xenogeneic antigens it is possible to break 
immune tolerance to self-antigens and to induce a much stronger immune response.
33
 
Xenogeneic antigens can be administered as a recombinant peptide/protein or genetic vaccine 
or can be included in tumor cell or DC vaccines. 
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2.2. Vaccine platforms 
Tumor vaccines can be administered via different platforms. Tumor cell vaccines consist of 
lysed or killed tumor cells obtained from the patient (i.e. autologous tumor cell vaccines) or 
from tumor cell lines derived from another patient (i.e. allogeneic tumor cell vaccines). 
Because tumor cells have acquired strategies to escape immune surveillance their preparation 
for vaccination purposes is critically important.
34
 A great advantage of tumor cell vaccines is 
that the tumor antigens do not need to be identified and that it evokes an immune response 
against a broad range of antigens. Moreover, they contain epitopes for both CD8
+
 and CD4
+
 T 
cells resulting in a stronger anti-tumor response and greatly diminishing the chance of tumor 
escape compared to single epitope vaccines.
34
 Autologous tumor cell vaccines are a 
completely patient-specific therapy. Disadvantages include the need of a sufficient amount of 
tumor cells and the problems concerning standardization, quality control and large-scale 
production. Allogeneic tumor cell vaccines pose less problems concerning manufacturing 
than autologous vaccines, but the advantage of a patient-specific therapy is lost.  
 
Cancer vaccines based on DCs that are loaded with tumor antigens have gained much 
attention in the field of immunotherapy. The first step in the production of these DC vaccines 
is the isolation of dendritic precursor cells from the patient’s blood or bone marrow. These 
precursor cells are subsequently differentiated into DCs and loaded with tumor antigens. The 
source of the tumor antigen can be (synthetic) tumor peptides, (recombinant) tumor proteins, 
whole tumor cells, plasmid DNA or mRNA encoding a tumor antigen. There have been 
promising reports of efficacy with DC vaccines; however large scale application of these 
vaccines is limited due to their labor-intensive production.
35
 Nevertheless, Provenge®, the 
first approved therapeutic tumor vaccine for human use, is a DC vaccine.
36
  
 
Genetic vaccines are frequently used in cancer vaccination, because the intracellular synthesis 
of the target antigen has the capability of inducing robust T cell responses.
37
 DCs may acquire 
and present the antigen when the nucleic acids are directly delivered into the DCs after 
injection. Alternatively, they may acquire the tumor antigens indirectly via cross-priming, i.e. 
from keratinocytes or myocytes that have taken up and express the tumor antigen encoded by 
the nucleic acids.
33
 Genetic vaccines can be divided into two major groups: vaccines based on 
recombinant viruses and vaccines based on nucleic acids (plasmid DNA (pDNA) or mRNA). 
Bacterial plasmids are the first and most extensively used nucleic acid vectors. More recently, 
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in vitro transcribed mRNA is explored as an alternative.
38
 The major advantage of DNA and 
mRNA vaccines is that they can be easily designed and produced in vitro. However, 
transfection efficiency of naked nucleic acids is low. There are three main methods to 
enhance transfection efficiency; physical methods, chemical vectors and biological 
vectors.
39,40
 Viral vectored vaccines can induce good immune responses via the attraction and 
infection of antigen presenting cells (APC), but a major disadvantage is the induction of an 
immune response against the viral vector, making further boosts less effective.
29
 Moreover, 
antigenic competition can occur, where anti-vector responses dominate over vaccine-specific 
responses.
41
 Issues concerning large-scale production, stability and stringent safety 
requirements are other disadvantages of genetic vaccines based on viral vectors.
42
 Genetic 
vaccines are much more applicable for commercial use than tumor or DC based vaccines, but 
highly immunogenic tumor antigens have to be known and the immune response will be 
directed to only the antigen(s) encoded by the vaccine, allowing the development of escape 
mutants. The major advantage of genetic vaccines compared to peptide vaccines is that they 
are not restricted by MHC-haplotype.
33
 
 
MHC-restricted peptides are widely used as tumor vaccines. These vaccines are relatively 
easy to produce. However, the immune response is limited to the selected epitope(s), which 
may lead to the emergence of escape variants and hence insufficient clinical effects.
43
 
Furthermore, vaccines based on short peptides (8 to 10 amino acids long), which can be 
directly loaded into MHC molecules, are only applicable in patients that have the right MHC 
molecules for presenting these peptides. Vaccination with longer peptides containing multiple 
epitopes or full length proteins circumvents MHC restrictions, immune escape and induces 
also CD4
+
 T helper cells.
43
 These longer peptides and proteins are not able to bind directly to 
MHC molecules, but have to be taken up and processed by APC. This leads to the 
presentation of different class I and class II epitopes by the same APC, which is more 
efficient than independent presentation by different APCs. Therefore, long peptides or 
proteins are more effective than single peptide mixtures.
41
 However, the manufacturing of 
longer peptides or full length proteins is, compared to single-epitope peptides, more difficult.  
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2.3.  Tumor vaccination in veterinary medicine 
Preclinical vaccination studies in purpose bred laboratory dogs  
The immune response and possible adverse effects of veterinary tumor vaccines have been 
evaluated in healthy Beagles.
44-53
 Additionally, the clinical response of DNA and DC vaccines 
has also been studied in a dog cancer model, i.e. Beagles inoculated with transmissible 
venereal tumor (TVT) cells.
54,55
  
 
These preclinical studies resulted in three important conclusions. It is possible to evoke an 
anti-tumor immune response in healthy dogs and dogs with TVT, proving that there is a good 
foundation for the use of tumor vaccines in the battle against cancer. Apart from autologous 
antigens, chicken HSP70
54
, human tyrosinase
44
, canine telomerase reverse transcriptase 
(TERT)
45,56
, human her-2/neu
45,56
, human carcinoembryonic antigen
48,52
 and bovine 
disialoganglioside GD3
50
 were also examined as tumor antigens. The second conclusion 
concerns the safety of tumor vaccines. The dogs were monitored very closely, by means of 
clinical investigations and blood examinations.
45,48-51,53-56
 In some studies the presence of anti-
nuclear antibodies has been checked and in others histological analysis of the organs has been 
performed.
48,50
 No signs of autoimmunity or other abnormalities were detected. Two studies 
reported mild adverse effects. In one study, a DC vaccine was given in the popliteal lymph 
node and the authors noticed transient pyrogenic effects and slight lameness at the site of 
injection, which resolved without further treatment within 48 hours post injection.
48
 In 
another study, a mild and transient inflammatory reaction was seen at the site of injection 
after vaccination with tumor cells transfected with human granulocyte macrophage-colony 
stimulating factor (hGM-CSF).
51
 This was due to the localized production of hGM-CSF, 
which was intended to attract inflammatory cells to the injection site. In all of the other 
studies, no adverse effects or signs of autoimmunity were detected. These conclusions about 
immunogenicity and safety are true for tumor cell vaccines
51
, DC vaccines
46-50,55
 and genetic 
vaccines.
45,48,52,54,56
 Finally, these preclinical studies showed that, at least with TVT, a clinical 
response can be achieved using DNA and DC vaccines as sole therapy.
54,55
 It has to be 
mentioned that TVT is an immunogenic tumor that is quite unique in its behavior.
57
 
Therefore, TVT is not of great value as model for other tumor types. 
 
Purpose bred laboratory dogs have also been used to compare different delivery routes for 
DNA vaccines. These studies showed that DNA vaccination combined with electroporation is 
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superior in evoking a potent immune response in comparison to injection of DNA without 
electroporation. This is partly due to the fact that electroporation facilitates the cellular uptake 
of the DNA. Another explanation is the adjuvant effect of electroporation. Indeed, 
electroporation induces minimal and transient tissue damage resulting in local inflammation 
at the injection site.
58
 Without electroporation, both the intramuscular (IM) and intradermal 
(ID) administration of naked DNA induce an absent to minimal cellular immune response, 
with the ID route slightly better than the IM.
44
 However, significant humoral immune 
responses have been obtained after IM and ID administration of naked DNA and this response 
was higher after IM injection than after ID injection.
48
 Interestingly, needle-free injection 
systems, like Bioinjector® 2000 and Vitajet®, which use high pressure to force the dissolved 
DNA vaccine into the dermis or muscle result in a far better immune response than the 
traditional IM or ID route of administration.
44
 However, the needle-free transdermal route is 
less potent in evoking an immune response than the electroporation-based DNA delivery 
method.
54
 Nevertheless, a crucial advantage of the former technique is that it can be used on 
non-anesthetized veterinary patients. 
 
Clinical trials with canine tumor vaccines 
Trials assessing efficacy that included a statistical survival analysis  
The studies summarized in table 1 and 2 were designed to assess efficacy. However, before 
discussing these trials we want to draw the attention to some sore points. A limitation of many 
studies is the number of patients. The results of such small-scale studies should be considered 
as preliminary and need confirmation in larger studies. Mostly the authors emphasize this in 
their discussion but often no further research is done. Moreover, historical control groups are 
frequently used. The high risk of false positive results associated with single-arm trials makes 
them highly ineffective in predicting efficacy.
59,60
 Due to improved supportive care, earlier 
detection, better equipment and technology, expected outcomes can change over time. 
Moreover, interinstitutional variability in outcome is often large and selection bias can never 
be completely excluded.
59-61
 Therefore, the following paragraphs should be read with these 
considerations in mind.  
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Table 1: Clinical trials with tumor vaccines that resulted in a survival benefit for the vaccinated dogs  
Tumor type Vaccine 
type 
Number of 
patients 
Control group Variable Effect Reference 
Oral melanoma   DNA 
vaccine 
58 Published data 
(1999) 
25% lower 
percentile 
MST 
464 vs 156 days 
62
 
Digital melanoma DNA 
vaccine 
58 Published data 
(1995) 
MST 476 vs 365 days 
63
 
Melanoma Tumor cell 
vaccine 
283 Concurrent 
 
MST 610 vs 91 days 
(CS) /201 vs 
65.5 days (PS) 
64
 
Lymphoma Tumor cell 
vaccine 
11 Concurrent, 
placebo controlled 
MST >348 vs 197.5 
days 
65
 
Lymphoma DNA 
vaccine 
14 Recent historical 
cases from same 
institution 
Lower 95% 
CI MST 
57.6 vs 26 
weeks 
66
 
Hemangiosarcoma Tumor cell 
vaccine 
28 Recent historical 
cases from same 
institution 
MST 182 vs 133 days 
67
 
MST = median survival time, CI = confidence interval, CS = complete resection of  primary tumor, PS = partial resection of 
primary tumor 
 
Vaccines with a significant survival benefit  
Melanoma 
An important breakthrough in the treatment of canine melanoma and the field of tumor 
vaccination was achieved with a DNA vaccine encoding the human tyrosinase for the 
treatment of oral melanoma. Merial has commercialized this vaccine under the name 
Oncept™. It is the only veterinary therapeutic tumor vaccine licensed by the USDA. The 
licensing followed after a successful clinical trial that resulted in prolonged survival compared 
to historical control dogs.
68-70
 Recently, its potency was proven in digital malignant melanoma 
as well.
63
 Vaccination with a plasmid encoding murine tyrosinase and murine gp75 generated 
similar results.
63,68
 In all these studies, the pDNA encoding the xenogeneic tyrosinase was 
administered IM in a needle-free manner without electroporation, using the Bioinjector 
2000® or the Vitajet® device. The great advantage of this administration method is that, in 
contrast to electroporation, no general anesthesia is required. In early trials, it was 
administered four times weekly.
68,69
 This protocol was replaced by four biweekly injections 
followed by boosts every six months in more recent trials.
63,70
 An antibody response against 
human tyrosinase was present in three out of nine tested patients, with two of them also 
positive for antibodies against canine tyrosinase.
71
 A correlation between the antibody 
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response and the clinical response was observed, but this did not reach statistical significance. 
This correlation was not expected as tyrosinase is considered to be an intracellular protein and 
hence one would not expect that it can be recognized and targeted by antibodies. The authors 
speculated that tyrosinase is expressed at a low-level on the cell-surface of melanoma cells. 
Recently, it has been discovered that a peptide fragment of tyrosinase is indeed presented by 
MHC I class molecules at the surface of melanoma cells.
72
 Cellular immune responses were 
not investigated. Early preliminary trials with a heterogeneous patient population of 170 dogs 
suggested longer survival times than commonly found for oral melanoma.
68,69
 This was 
confirmed with a statistical survival analysis comparing 58 vaccinated dogs with a historical 
control group collected from published data. Only patients with stage II or III oral melanoma 
with no macroscopic evidence of the primary tumor at the start of vaccination were included 
in this study.
70
 As median survival time (MST) was not reached for vaccinated dogs, the 25% 
lower percentiles of the two groups were compared. This showed that 75% of vaccinated dogs 
were expected to live beyond 464 days versus 156 days for the control group. However, a 
very important weakness of this study is that survival data found in an article published in 
1999 were used to establish this historical control group.
70,73
 Nevertheless, the observed effect 
was considered large enough by the authors to exceed the confounding factors of a non-
randomized trial. Strictly speaking, to unambiguously prove the clinical efficacy of Oncept
TM
 
a randomized, placebo-controlled study should be performed. The same vaccine prolonged 
MST of 58 patients suffering from digital melanoma as well, although the effect is less 
spectacular: a MST of 476 days in comparison with 365 days for a historical control group 
found in the literature.
63
 The authors indicated a long interval between diagnosis and start of 
the vaccination for most patients as an important explanation for the lower efficacy of the 
vaccine in this study.  
 
A spectacular survival benefit for melanoma patients has also been seen in two trials with a 
tumor cell vaccine.
64,74
 Depending on the availability, autologous or allogeneic formolized 
tumor cells were injected together with xenogeneic cells genetically engineered to express 
human interleukin-2 (IL-2) and hGM-CSF. The vaccine was given subcutaneously (SC), five 
times weekly, followed by five times biweekly, five times monthly, five times every three 
months and then every six months until death or relapse. Before vaccination, all patients were 
treated with surgery and thymidine kinase suicide gene therapy, with the latter repeated in 
unresectable/incompletely removed or relapsed tumors. Immune responses were not 
monitored. An initial trial with 31 treated dogs reports a MST time of 370 days, significantly 
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higher than 76 days for concurrent non-randomized control dogs.
74
 More recently, results 
after 9 years of follow-up have been published for 283 patients receiving the combination 
treatment and 135 concurrent non-randomized control dogs.
64
 Median survival was 
significantly higher for dogs treated with the combination treatment, i.e. 610 versus 91 days 
for dogs with complete resection of the primary tumor and 201 versus 65.5 days for dogs with 
partial resection of the primary tumor. However, control dogs were treated with surgery alone, 
whereas vaccinated patients were treated with surgery, the adjuvanted vaccine and suicide 
gene therapy. It is therefore impossible to determine if and how extensive the vaccine 
contributed to the survival benefit. 
 
Lymphoma 
Lymphoma was the first tumor type to be explored in the field of veterinary tumor 
vaccination. A tumor cell vaccine proved, already in 1976, to be efficient in a small placebo 
controlled trial.
65
 This trial tested a tumor cell lysate, admixed with Freund’s complete 
adjuvant, in 11 patients with lymphoma. Dogs in complete remission after induction 
chemotherapy received the vaccine IM, two times with one week interval, followed by two 
injections with two weeks interval. The induction of an anti-tumor immune response was not 
investigated. A MST of > 348 days, which was significantly higher than 197.5 days in the 
placebo control group, was observed. Median remission period was also significantly higher 
in the vaccinated group, i.e. 133.5 versus 30.2 days. Surprisingly, no further studies with this 
vaccine have been reported. 
 
A gene-based vaccination approach consisting of a pDNA and an adenoviral vector encoding 
canine TERT has been tested for the treatment of lymphoma.
66
 Fourteen dogs with B cell 
lymphoma participated in this trial. Due to relapse soon after the interruption of the induction 
chemotherapy, maintenance chemotherapy was given during the vaccination period. TERT 
expression has been reported in the majority of canine tumors.
75-78
 In this study, all of the 
analyzed lymphoma samples were positive for TERT mRNA, confirming that TERT is a 
suitable target for immunotherapy in lymphoma.
66
 The vaccine regimen consisted of two 
injections of the adenoviral vector at a two-week interval followed by five successive pDNA 
vaccinations every two weeks. The vaccines were injected IM and electroporation was used 
directly after pDNA injection to facilitate its intracellular uptake. Routine application of this 
treatment by veterinary practitioners will be hampered by the need of an electroporation 
device and the fact that it requires general anesthesia of the dogs. Immune responses were 
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measured with an IFN-gamma ELIspot and were positive in the majority of patients. Median 
survival time could not be calculated for the vaccination group. The lower limit of the 95% 
confidence interval for overall survival for vaccinated dogs was 57.6 weeks, which is higher 
than 26 weeks for the historical control group. The latter consisted of recent cases treated in 
the same institute by the same veterinarians with the same chemotherapy protocol as the 
vaccinated patients. Such a historical control group minimizes the unwanted variability 
associated with a single-arm study. An increased remission period of 26 weeks compared to 
14 weeks in the historical control group was also observed. These encouraging results and the 
broad applicability across tumor types make this vaccine a very promising candidate for 
further clinical studies. 
 
Hemangiosarcoma 
Hemangiosarcoma has been evaluated as a possible target for tumor vaccination in one 
clinical trial.
67
 Twenty-eight dogs were immunized with an allogeneic tumor cell lysate 
vaccine with liposome-DNA complexes (lipoplexes) as adjuvant. The DNA in the lipoplexes 
did not code for an antigen. The dogs also received doxorubicin chemotherapy and the 
vaccine was administered intraperitoneally five times with two weeks interval followed by 
three injections once a month. Strong humoral responses were detected against the allogeneic 
tumor cells used in the vaccine. A control group was compiled from historical cases treated 
with doxorubicin in the same institutes that participated in this study. The MST in this control 
group was 133 days, while the vaccinated group had a statistically significant higher MST of 
182 days. Adverse effects were limited to those caused by the doxorubicin treatment. 
Although the prolongation of the MST with seven weeks reached statistical significance, it 
may however not be sufficient to convince many owners to pay for this treatment, on top of 
the chemotherapy. 
 
Vaccines that failed to obtain a significant survival benefit  
In the trials summarized in table 2 a statistical analysis was performed, but no survival benefit 
could be demonstrated. However, in these trials, spectacular results were sometimes seen in a 
small subset of patients, which is typical for tumor vaccination studies. An understanding why 
the same vaccine works in some patients but not in others is of great importance. Therefore 
the development of predictive biomarkers that allow identification of patients who might 
benefit from cancer vaccination would be of great help and would avoid premature 
abandonment of useful vaccines.
61
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Table 2: Clinical trials with tumor vaccines that did not result in a survival benefit for the vaccinated dogs  
Tumor 
type 
Vaccine type Number of 
patients 
Control group Variable  Reference  
Lymphoma  Tumor cell vaccine 58 Concurrent, randomized Survival  
79
 
Lymphoma  Tumor cell vaccine 26 Concurrent, randomized, 
placebo controlled 
Survival, duration 
first remission 
80
 
Lymphoma  Tumor antigen 
coated microbeads 
15 Recent published data Disease free interval 
81
 
Lymphoma  CD40-B cell vaccine 19 Recent historical cases 
from same institution 
Survival, time to 
progression 
82
 
 
Irradiated whole tumor cells, administered by intralymphatic injection, have been explored as 
a tumor vaccine for the treatment of lymphoma by Jeglum et al.
79,83
 The vaccination schedule 
consisted of two injections with two weeks interval, followed by another injection after one 
month and after six weeks. As with the other trials with lymphoma, only patients in complete 
remission after induction chemotherapy were included. The rationale behind intralymphatic 
injection was that the antigen is delivered where an immune response is initiated. The 
consequence is that the dogs had to be anesthetized for vaccination, which makes it less 
suitable for clinical use. Immune responses were not measured. A preliminary trial with 30 
patients suggested a longer MST and remission duration than documented for lymphoma in 
the literature.
83
 Later on the same vaccine was tested in more patients (n=58) and after a 
comparison with the randomized control group a trend towards longer survival was again 
observed. However, this trend did not reach statistical significance.
79
 
 
In a study of Turek et al. 26 patients with B cell lymphoma that were in complete remission 
received a vaccine consisting of tumor cells transfected with hGM-CSF.
84
 The vaccine was 
administered by an ID injection; four times weekly followed by four injections biweekly. 
Tumor specific immune responses were seen in every patient, measured with a delayed-type 
hypersensitivity (DTH) skin test. This placebo-controlled trial found no improvement in first 
remission duration and survival for dogs receiving the vaccine. There was no correlation 
between the result of the DTH skin test and the clinical response. 
 
Henson et al. came up with a new type of tumor cell vaccine that consists out of microbeads 
on which cell membrane fragments of autologous tumor cells are loaded.
81
 The authors chose 
this approach based on previously published data showing that presenting antigens on these 
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cell-sized silica microbeads is superior in eliciting a CTLs response. Dogs in complete 
remission after induction chemotherapy received three weekly SC injections of the vaccine 
together with SC injections of IL-2 and GM-CSF as adjuvants. This protocol was 
implemented in 15 patients with B cell lymphoma. Half of the patients showed evidence of an 
immune response detected with a DTH skin test. Vaccination resulted in similar survival 
times as historical control dogs collected from published data. No correlation between the 
DTH skin test and clinical response existed.  
 
Sorenmo et al. evaluated a vaccine that used CD40-activated autologous B lymphocytes 
(CD40-B cells) instead of DCs as APC.
85
 In a previous study, this group had established that 
canine CD40-B cells can act as APC and they described an efficient protocol for the 
generation of CD40-B cells from the peripheral blood of dogs.
86
 A great advantage over DCs 
is that a large number of CD40-B cells can be obtained from a small number of precursors. 
This requires less blood volume to procure sufficient numbers of APC for recurrent 
vaccinations. The CD40-B cells were loaded with autologous tumor RNA by means of 
electroporation.
85
 The vaccine was given to 19 patients suffering from lymphoma in complete 
remission, by three ID injections with two to three weeks interval. Immune response was 
evident in half of the patients when analyzed with an IFN-gamma ELIspot. It did not result in 
longer survival times when compared with matched historical control dogs, recently treated in 
the same institution. However, in the vaccinated group a greater percentage of dogs achieved 
secondary remission (7.7% versus 40%) and a prolonged lymphoma-specific survival after 
relapse. 
 
Trials assessing efficacy without a control group 
Lastly, there are also clinical trials with tumor vaccines that did not include a control group. 
These trials are summed up in table 3. Mostly, it is only stated if a clinical response was 
achieved. A clinical response is a complete response (CR; the disappearance of all lesions) or 
a partial response (PR; a decrease of greater than 30% in the sum of the greatest dimension of 
all lesions). Many authors consider stable disease (SD; a decrease less than 30% or an 
increase less than 20%) also as a positive effect.
87
 However, these criteria, developed for 
cytotoxic drugs that are expected to cause tumor shrinkage early in the treatment, are 
inadequate for the evaluation of tumor vaccines.
61,88-90
 Overall survival is the golden standard, 
but for exploratory trials this is not always a feasible endpoint. Progression free survival is a 
good alternative as a significantly shorter follow-up time is required.
61
 From these 
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preliminary trials, without any statistical comparison with a control group, no definite 
conclusions can be drawn. 
 
Hogge et al. evaluated an autologous tumor cell vaccine in patients with melanoma, 
osteosarcoma and fibrosarcoma.
91
 The tumor cells were genetically engineered to express 
hGM-CSF. Experiments in laboratory Beagles demonstrated the efficacy of this approach to 
attract inflammatory cells to the site of injection.
51
 Three ID vaccinations were given at 12 
day intervals to ten melanoma patients. Some patients had no macroscopic disease at the start 
of vaccination, others entered the trial with macroscopic tumor present. Immune responses 
were not evaluated. Three of the ten melanoma patients had a clinical response or stable 
disease, two dogs with no evidence of disease at the start of vaccination remained that way. 
Although the survival times are not statistically compared with a control group, the authors 
interpret their data as a suggestion that the vaccine prolongs survival time. Three cases of 
fibrosarcoma were also included. One patient had a partial response, another remained free of 
detectable disease and in the third patient the tumor progressed without response. The same 
vaccine is mentioned in a case report of a dog with a vertebral fibrosarcoma. After 
vertebrectomy and subsequent vaccination the dog was monitored for two years and no 
relapse occurred.
92
 Two dogs with osteosarcoma were treated with this vaccine, but no 
beneficial effects were observed.
91
 
 
A preliminary study with only three melanoma patients explored the use of autologous DCs 
that were transfected with an adenoviral vector encoding human glycoprotein 100 (gp100) as 
xenogeneic tumor antigen.
93
 The transfected DCs were injected back into the patient by the 
SC route. This was repeated three times monthly. Dogs had undergone surgery before 
vaccination and were treated with radiation therapy before and during the vaccination period. 
One of the three patients had a strong CTL response, which was associated with a long term 
clinical response.  
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Table 3: Preliminary trials with canine tumor vaccines without a control group 
CR = complete response, PR = partial response, SD = stable disease, tumor control rate = CR + PR + SD, NED = no 
evidence of disease, OSA = osteosarcoma, FSA = fibrosarcoma, MGT = mammary gland tumor, PNST = peripheral nerve 
sheath tumor, MST = median survival time 
 
In the study of Mito et al. four dogs with breast cancer and one dog with fibrosarcomas at two 
sites received an intratumoral injection of autologous DCs in combination with an 
intratumoral injection of recombinant canine IFN-gamma.
100
 The DCs were not loaded with 
antigen in vitro. It was considered that the DCs injected into the tumor took up antigen from 
tumor cells and were matured and activated in situ upon stimulation by IFN-gamma. The DC 
were given eight times at weekly intervals. The IFN-gamma injection happened together with 
the DCs and was repeated the second and the fifth day afterwards. One of the two tumors of 
the fibrosarcoma patient showed a partial response. Unfortunately, the dog died of 
disseminated intravascular coagulation due to massive necrosis of tumor tissue. Three of the 
four dogs with breast cancer showed a complete response and one a partial response. Again, 
one patient died as a consequence of massive necrosis of the tumor. An anti-tumor immune 
response of three responding patients was assessed with a radioactive peripheral blood 
mononuclear cells (PBMC) proliferation assay and was present in all three of them.   
Tumor 
type 
Vaccine 
type 
Number of 
patients 
Variable Frequency of responding 
patients; MST  
Reference  
OSA 
Melanoma 
FSA 
Tumor cell 
vaccine 
2 
10 
3 
CR, PR, SD, NED 0/2 
4/10 
2/3 
91
 
Melanoma  DC- vaccine 3 CR 1/3 
93
 
FSA 
MGT 
DC-vaccine 1 
4 
CR, PR 1/1 
4/4 
94
 
Melanoma  Tumor cell 
vaccine 
34 Tumor control rate 35.3% 
95
 
PNST Peptide 
vaccine 
9 Tumor control rate 5/9 
96
 
Lymphoma Tumor cell 
vaccine 
7 Survival attributable 
to vaccine 
7/7 
97
 
FSA 
OSA 
Tumor cell 
vaccine 
11 
5 
MST 
PR, NED 
1051 days 
3/5 
98
 
MGT DNA vaccine 7 PR 6/7 
99
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For the treatment of melanoma, the use of an allogeneic tumor cell vaccine was also explored. 
The tumor cells were transfected with human gp100, thereby exploiting the advantages of 
xenogeneic vaccination.
95
 Transfection of the cells occurred via gene gun particle-
bombardment. Thirty-four patients, with and without macroscopic tumor present at the time 
of first vaccination entered the trial. The vaccination schedule consisted of eight ID 
immunizations, four weekly followed by another four biweekly. The immune response was 
well characterized. Antibodies against human gp100 were detected in half of the tested 
patients. There was no correlation between the extent of gp100 antibodies and the clinical 
response. Cellular immune responses were evaluated with the DTH skin test and a CTLs 
assay using the allogeneic tumor cells of the vaccine as targets. The DTH test and the CTLs 
assay were positive in half of the tested samples. The DTH test correlated with the clinical 
response, however the CTLs assay did not. A tumor control rate (CR, PR, SD for minimum 
six weeks) of 35.3% is reported. Median survival time was 153 days, no statistical analysis 
with a control group or published data was performed. Dogs experiencing tumor control had a 
significantly longer MST than dogs having no response (337 versus 95 days), suggesting that 
this is a valid criterion for the evaluation of the efficacy of tumor vaccines. 
 
One protein vaccine has been evaluated in veterinary oncology. Recombinant human vascular 
endothelial growth factor (VEGF) together with liposome-DNA complexes as adjuvant was 
administered ID in nine patients with peripheral nerve sheath tumors.
101
 The vaccination 
scheme consisted of three biweekly vaccinations, followed by three monthly vaccinations. 
Three out of four dogs who received three or more vaccinations developed antibodies against 
human VEGF. None of the dogs had detectable antibodies against canine VEGF. The authors 
suggest that they were elicited but not detected due to rapid elimination after complexing with 
circulating canine VEGF. In two of these dogs there was indeed a significant reduction in 
circulating canine VEGF concentrations. The same was observed in two dogs without 
antibodies against human VEGF, which may suggest that also a cellular immune response is 
involved in the reduction of circulating canine VEGF. Three patients had a PR, two patients a 
SD. Reduction in circulating VEGF was correlated with tumor response.  
 
Morphogenesis together with Novartis Animal Health developed ImmuneFx™, a vaccine 
with tumor cells transfected with Emm55, a bacterial antigen.
102
 These cells have gained 
foreign characteristics for the immune system, and all of the antigens of the tumor cells are 
processed and presented as such. Veterinary physicians can send autologous tumor cells and 
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the company provides the vaccine in one to two weeks. The vaccine is administered 
intravenously four times weekly followed by monthly boosts. A published trial with seven 
lymphoma patients reported anti-tumor immune responses in every patient when assessed 
with a CTLs assay and an increased survival in the vaccinated dogs. However, we have to 
remark that they considered increased survival as days that the dog lived beyond the outer 
expectation limit of 42 days, with a correction if dogs were also treated with chemotherapy. 
The authors selected this expectation limit of 42 days based on data from the literature 
claiming that without treatment dogs with lymphoma die within four to six weeks. 
Consequently, in view of the low number of patients and the absence of a real control group 
in this study we can only consider this increase in survival as a promising result that should be 
confirmed in a randomized, placebo-controlled study. This is the only trial with lymphoma 
where complete remission was not an inclusion criterion. Additionally, in this study some 
patients also received chemotherapy concomitant with the vaccination.
103
 
 
As already discussed, the combination of surgery, tumor cell vaccination and thymidine 
kinase suicide gene therapy was very effective in melanoma patients. In a recent report 
Finocchiaro et al. evaluate the efficacy of this treatment in patients with fibrosarcoma and 
osteosarcoma.
98
 The study included eight fibrosarcoma patients. Five patients had no 
macroscopic tumor present at the start of the vaccination. A MST of 1051 days was 
documented, which was higher than the 236-532 days the authors found in the literature for 
fibrosarcoma. The conclusion that the vaccine improved the survival time was not based on a 
statistical comparison with a control group. The same protocol was used to treat five 
osteosarcoma patients. Tumors in four dogs were surgically removed before vaccination. In 
one dog this was not possible because the contralateral limb was amputated in the past for a 
previous osteosarcoma. The latter dog did exhibit a partial response, but was euthanized after 
three months because of poor quality of life. In two dogs no evidence of disease was present 
for over six months. One dog had a reappearance of the tumor within five weeks and was 
euthanized after six months. The fifth dog had signs of an affected lymph node after five 
months and was euthanized.  
 
A case report of a patient with astrocytoma treated with the combination of surgery, IFN-
gamma gene transfer and tumor cell lysate vaccine has been published.
104
 Five ID 
immunizations were given biweekly. The first contained autologous tumor cell lysate. 
Because of the slow growth of the autologous cells in culture an allogeneic lysate had to be 
General introduction 
24 
 
used for the subsequent vaccinations. The vaccine contained CpG oligonucleotides as 
adjuvant. The IFN-gamma gene transfer was performed using an adenoviral vector in the 
tumor tissue that remained after surgical tumor debulking. The dog experienced transiently 
focal neurological symptoms. An antibody response and a cellular response were identified. 
Cellular immunity was assessed by flow cytometric analysis of CD8 IFN-gamma positive T 
cells. After one year, the dog was still tumor free. 
 
A recent study evaluated genetic vaccination against p62 in seven dogs with mammary gland 
tumors.
99
 Vaccination schedule consisted of weekly IM injections of a plasmid encoding 
human p62, with the dose ranging from 0.75 to 2.5 mg and number of vaccinations from 3 to 
10. Although initially an increase in tumor volume was apparent, the vaccine resulted 
ultimately in a partial response in six out of seven patients, ranging from 23 to 78% decrease 
in tumor volume.  
 
Discussion 
Trial design: The wide range of vaccination protocols used in the different clinical trials is 
striking. This high variability of protocols was also noticed in studies that used the same type 
of tumor vaccine. The absence of a standardized protocol is related to the fact that the optimal 
administration route, dose and schedule for tumor vaccines are unknown at the moment. 
Apart from the vaccination protocol, also the selection of patients can affect the outcome. For 
example the outcome of a tumor vaccine may be better in patients that underwent tumor 
resection before vaccination. This wide range of vaccination protocols makes it very difficult 
to compare the efficiency of tumor vaccines. When a tested vaccine is ineffective, this may be 
due to a truly ineffective vaccine formulation, but also to suboptimal selection of the 
administration route, dose, schedule or patient population. The development of biomarkers 
identifying patients that could potentially benefit from cancer vaccination would decrease the 
number of false negative trials. The lack of a standardized trial design is a problem inherent to 
the field of tumor vaccination and is an equally important problem in human oncology.
90
 
Other concerns about the discussed vaccination studies are the low number of patients and the 
rare inclusion of a valid control group. Objections to a randomized trial are related to the 
increased sample size and ethical concerns. Randomized trials will allow more meaningful 
conclusions and will decrease the number of unnecessary trials. In the end, less patients, 
resources and time will have to be used. It may seem unethical to withhold promising 
treatments from patients. It is reasonable to argue that it is also unethical that a non-effective 
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treatment is given to many patients based upon a false positive trial.
59,60
 In conclusion, 
although single-armed trials remain appropriate in selected circumstances, trials that 
investigate clinical efficacy should be randomized trials.  
 
Tumor types: Melanoma and lymphoma are by far the most popular targets in veterinary 
cancer vaccination studies. Also in human medicine, these two forms of cancer were the first 
and most extensively studied candidates for cancer vaccination. Both tumors are known to be 
immunogenic and especially for melanoma extended knowledge exists about tumor 
antigens.
90
 In human oncology, virtually all tumor types have become targets for tumor 
vaccination.
105-115
  
 
Vaccine types: The majority of veterinary trials used tumor cell based vaccines. DC vaccines 
have up till now only been administered to a small number of canine patients. Due to the high 
cost price, this vaccine type will be difficult to introduce in veterinary medicine. To give an 
idea, the cost price of Provenge® in human oncology, which is a DC vaccine, is about 93 000 
dollars per course of treatment.
116
 Only two DNA vaccines were tested in veterinary 
oncology, but both with great success. Besides for canine melanoma, little is known about 
important immunogenic tumor antigens in veterinary oncology. This has hampered the 
development of other DNA vaccines. The recently developed TERT DNA vaccine can 
become an elegant solution for this problem. TERT is a non-specific tumor antigen, 
overexpressed in most canine tumors.
75-78
 This vaccine, already tested in canine patients with 
lymphoma, has potential to be effective in a broad range of tumor types. At present, the good 
results of DNA vaccination in animals, against tumors as well as infectious agents, cannot be 
achieved in human trials. This is however most likely a matter of optimizing the delivery 
method for human subjects, and not because this approach would not work in humans.
117
  
 
Immunological response: Tumor vaccination leads to an immune response in the majority of 
patients, with an appearance four to eight weeks after the first vaccination. This is also true 
for patients who simultaneously receive chemotherapy, confirming that this combination is 
not contraindicated. Some of the clinical trials investigated a correlation between the clinical 
response and the immune response.
71,81,84,93,95
 However, conflicting results have been 
published. Nevertheless, presence of an immune response reflects a mode of action and 
therefore kits that can detect a specific immune response can contribute greatly to the 
development of a new product. Also in human oncology immunological assays that can 
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predict the clinical response of tumor vaccines are urgently needed. More research to validate 
such immune assays is needed, comparable to human oncology where an international 
research project called ‘MIATA’ is started to resolve this problem.118 
 
Clinical response: Of the ten trials where a statistical survival analysis was performed, six 
could demonstrate a significant survival benefit for vaccinated dogs. However, since the 
majority of these trials are not randomized, for definite prove that tumor vaccination has 
potential as a complementary treatment modality for cancer, more randomized placebo 
controlled trials are necessary. With tumor vaccination being the sole therapy added to the 
standard treatment, the genetic vaccines for the treatment of lymphoma and melanoma give 
the best results.
66,70
 If we consider all trials, the tumor cell vaccine in combination with 
surgery and suicide gene therapy for the treatment of melanoma is superior.
64
 
 
Safety: Maybe the most consistent and trustworthy finding of all vaccination trials is the 
safety of tumor vaccines. In all the preclinical and clinical trials dogs were monitored closely, 
with no significant adverse effects in all but two trials. In the trial were DC vaccination was 
combined with IFN-gamma gene therapy there were two fatalities due to massive necrosis of 
the tumor.
100
 This can be prevented by surgically debulking the tumor before vaccination, 
thus this treatment still has clinical potential. The second reported adverse effects consisted of 
transient neurological symptoms in a patient with astrocytoma.
104
 In this dog a tumor cell 
lysate vaccine was combined with intracranial surgery and IFN-gamma gene therapy. The 
symptoms disappeared without treatment, so again they are not a reason to discontinue the use 
of this vaccine. In human medicine, tumor vaccination for the treatment of brain tumors has 
already been done in multiple trials and is considered safe.
115
    
 
Conclusion: In conclusion, veterinary tumor vaccination trials prove that tumor vaccination is 
safe and can be effective, even in combination with chemotherapy. Collaboration between 
human and veterinary medicine is of mutual interest and can lead to great results. For example 
the success of the canine melanoma vaccine, with 1500 canine patients treated in 2008, had 
led to the use of this vaccine in human clinical trials.
70,119,120
 It has to be stressed that all the 
effective vaccines are adjuvant therapies, either after or concomitant with surgery or 
chemotherapy. Hence, the total costs of a combination treatment can become very high. 
Therefore, in veterinary oncology tumor vaccination will, at least in the near future, be limited 
to motivated owners. Tumor vaccination trials suffer from a high likelihood of false positive 
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results due to lack of randomization and significant risk of false negative results  due to 
insufficient knowledge of optimal patient selection, administration route, dose and 
vaccination schedule. As long as this is not solved, evaluation of tumor vaccines will be 
suboptimal at best.    
 
3. Cytokine therapy 
Cytokines are a heterogeneous group of small signaling (glyco)proteins with more than 100 
known members. Despite their heterogeneity they also have some common characteristics. 
Cytokines are pleiotropic in every aspect; the same cytokine can be produced by a vast 
diversity of cell types, have an effect on many different target cells and have very different 
biological effects which can be autocrine, paracrine or endocrine.
121
 Cytokines are bioactive 
at very low concentrations and have a short half-life.
122
 Many cytokines play a crucial role in 
tumor immunology and are thus explored as anticancer agents.
121,123,124
 However, the 
biological characteristics of cytokines pose serious challenges for their therapeutic use. Their 
pleiotropic effects often lead to serious adverse effects, which is aggravated by the necessity 
of administering high doses because of their short half-life. However, in the last decade 
researchers have been able to diminish the toxicity of cytokines via molecular engineering of 
cytokines with prolonged half-life, enhanced specificity or localized activity. This enhanced 
the clinical applicability of cytokine therapy.
123
 Currently, IL-2, interferon-alpha (IFN-alpha) 
and tumor necrosis factor-alpha (TNF-alpha) are approved for clinical use in human 
oncology. All three are associated with serious adverse effects when given systemically.
124,125
 
For IL-2 and IFN-alpha, engineered formulations are now available and TNF-alpha is only 
administered via isolated limb perfusion.
123,125
 
 
IL-12 is the most potent anti-tumoral cytokine studied to date.
126
 However, because of severe 
toxicity with even fatalities in early clinical trials, clinical development was halted. Now, with 
new possibilities for delivery, IL-12 is again intensively studied in clinical trials. .
127
 In these 
trials IL-12 gene therapy is mostly used to express IL-12 in the tumor. IL-12 is a critical 
factor that can tip the balance towards immunity instead of tolerance.
128
  It is a very potent 
third level activation signal for T cells.
129
 IL-12 also induces clonal expansion and cytolytic 
function in activated CTLs as well as NK cells.
129-131
 Myeloid derived suppressor cells 
decrease their immune suppressive function in response to IL-12 and can be even converted to 
immune cells that help to establish an anti-tumor response.
126,132
 These strong immune 
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stimulatory effects are complemented by inhibition of tumor angiogenesis.
133
 In this PhD 
thesis we combined intratumoral IL-12 gene therapy with a DNA cancer vaccine. In this 
combination, IL-12 will synergize with tumor vaccination by providing an adequate 
intratumoral cytokine environment for the systemically generated CTLs to fully exercise their 
cytotoxic functions. Moreover, IL-12 will complement tumor vaccination by stimulating NK 
cells as additional effector cells next to CTLs.  
 
Some preliminary studies with cytokine therapy have been initiated in veterinary oncology. 
Intratumoral delivery of lipid complexed pDNA encoding GM-SCF or IL-2, in combination 
with a bacterial superantigen, was evaluated in dogs with melanoma.
134
 Intravenous 
administration of lipid complexed pDNA encoding IL-12 was evaluated in dogs with lung 
metastases after resection of osteosarcoma.
135
 IL-12 plasmid, delivered by electroporation, 
was administered to dogs with mast cell tumors, squamous cell carcinoma and 
melanoma.
136,137
 Moreover, intratumoral IL-12 gene therapy has been combined with 
electrochemotherapy in dogs.
138,139
 In cats with fibrosarcoma, intratumoral injection of 
recombinant interferon-gamma, intratumoral viral gene therapy with IL-2, intratumoral gene 
therapy with IL-2, IFN-gamma and GM-SCF by magnetofection and intratumoral adenoviral 
IL-12 gene therapy have been evaluated.
140-143
 In horses, intratumoral injection of IL-12 
plasmid for the treatment of melanoma, as well as intratumoral injection of recombinant IL-2 
in combination with cisplatin for the treatment of sarcoid, was explored.
144,145
 Although these 
trials demonstrate proof-of concepts of efficacy, safety and feasibility, the low number of 
patients and lack of a control group precludes any definite conclusions.  
 
4. Metronomic chemotherapy 
The regular administration of chemotherapeutics at low doses was called metronomic 
chemotherapy by Hanahan et al. in 2000 and is characterized by immune stimulatory and 
anti-angiogenic modes of action.
146
 Why these mechanisms of action are only evident with 
low and not high doses of chemotherapy can be explained by two reasons. Firstly, it can be a 
truly dose-dependent effect, when selective sensitivity of certain cell types to the cytotoxic 
action of the drug is the determining factor. This is for instance the case for the immune 
stimulatory action of metronomic cyclophosphamide by depleting Tregs. Regulatory T cells 
are more sensitive to cyclophosphamide than effector T cells. Low doses will only affect 
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Tregs and thus result in immune stimulation. Higher doses will also affect effector T cells 
resulting in immunosuppression.
147
 Other mechanisms of action rely on the different timing of 
metronomic versus traditional dosing. Also high doses of chemotherapy are antiangiogenic 
during treatment, but during the forced drug-free breaks because of toxicity a rebound 
proangiogenic effect negates the initial antiangiogenic effect of chemotherapy at high dose.
148
 
Because of the different mode of action, metronomic chemotherapy can be used in patients 
with tumors resistant to high dose of the same drug. As there are indications that metronomic 
chemotherapy can be equally effective as standard dose chemotherapy, but with a better 
quality of life, clinical trials directly comparing both treatment schedules are being conducted. 
Metronomic chemotherapy can also be combined with standard dose chemotherapy to avoid 
drug-free breaks or in combination with other treatment modalities for its synergistic 
biological effects.
149
 
 
The immune stimulatory actions of metronomic chemotherapy are diverse and dependent on 
the drug, comprehensively reviewed in the article of Hao et al.
150
 The immune effects of 
metronomic cyclophosphamide are the most extensively characterized and include but are not 
limited to the depletion of Tregs, maturation of DC, induction of MHC-I and NK2GD 
ligands.
150
 Of special interest for our combination therapy is the depletion of Tregs, 
considered major obstacles for immunotherapy.
151
 Drugs that have proven to decrease Tregs 
in rodent models and human patients and are easily orally administered are cyclophosphamide 
and temozolomide. The selective effect of metronomic cyclophosphamide towards Tregs is 
explained by reduced intracellular ATP levels in these cells, leading to decreased glutathione 
synthesis and thus reduced detoxification of cyclophosphamide.
147
 For temozolomide, the 
mechanism of selective toxicity towards Tregs is not yet elucidated.  
4.1. Metronomic cyclophosphamide in veterinary medicine 
Two trials investigated the effect of metronomic cyclophosphamide as an adjuvant therapy 
after surgery (table 4). The first clinical trial with metronomic chemotherapy in veterinary 
medicine consisted of nine dogs with stage II hemangiosarcoma that were treated with a 
combination treatment of metronomic cyclophosphamide (12.5-25 mg/m²) alternating with 
metronomic etoposide (50 mg/m²) and combined with continuous piroxicam administration 
(0.3 mg/kg) after splenectomy. This group was compared with three randomized control dogs, 
supplemented by 21 historical control dogs, treated with doxorubicin after splenectomy. 
Median survival time of dogs treated with metronomic chemotherapy was significantly higher 
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than control dogs (178 vs 133 days). Treatment was well tolerated, although two dogs 
developed hemorrhagic cystitis which led to discontinuation of the cyclophosphamide 
treatment.
152
 Another trial investigating the efficacy of metronomic cyclophosphamide in an 
adjuvant setting included incomplete resected soft tissue sarcomas. Thirty dogs were treated 
with cyclophosphamide at 10 mg/m² in combination with piroxicam at 0.3 mg/kg and 
compared to 55 contemporary, non-randomized control dogs without additional treatment.
153
 
Disease free interval was significantly higher in the treated dogs. Again, hemorrhagic cystitis 
was observed in three dogs, which necessitated euthanasia in one dog.  
 
Table 4: Clinical studies with metronomic chemotherapy in dogs 
1: all dosages are per day 
CPX=cyclophosphamide; MST=median survival time; DFI=disease free interval; CR=complete response; SD=stable disease; 
PR=partial response; NED=no evidence of disease; MVD=microvessel density; Tregs=regulatory T cells 
 
 
Tumor type Patients Control group Treatment protocol
1
 Outcome Reference 
Stage II splenic 
hemangiosarcoma 
9 3 randomized + 21 
historical 
doxorubicin 
treated dogs 
Surgery followed by CPX 
12.5-25 mg/m²+etoposide 50 
mg/m²+piroxicam 0.3 mg/kg 
MST 133 days 
vs 178 days 
152 
Incomplete resected 
soft tissue sarcoma 
30 55 non-
randomized dogs 
CPX 10 mg/m²+piroxicam 
0.3 mg/kg 
Median DFI 211 
vs minimal 410 
days 
153 
Various metastasized 
cancers 
15 / CPX 25 mg/m²+celexocib 2 
mg/kg 
1 CR, 5 SD 
(MST 3.39m) 
154 
Various metastasized 
cancers 
10 / CPX 12.5 mg/m2+piroxicam 
0.3 mg/kg 
1 CR, 1 PR, 2 
NED after 
surgery 
155 
Soft tissue sarcoma 11 / CPX 12.5 mg/m² or CPX 15 
mg/m² 
MVD and Tregs 
decreased 
(15mg/m²) 
156 
Various advanced 
stage cancers 
15 / Toceranib 2.75 mg/m²+CPX 
15mg/m² 
Tregs decreased, 
serum IFN-
gamma 
increased 
157 
Various cancers 81 / Lomustine 2.84 mg/m² 6%PR, 30%SD 
158 
Various cancers 36 / Chlorambucil 4 mg/m² 1 PR, 17 SD 
159 
Transitional cell 
carcinoma 
31 / Chlorambucil 4 mg/m² 1 PR, 20 SD 
(MST 221 days) 
160 
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Four studies describe the use of metronomic cyclophosphamide in advanced stages of disease 
(table 4). The first report documents clinical response of metronomic chemotherapy in 15 
dogs with metastasized cancer.
154
 Cyclophosphamide was given at 25 mg/m² and combined 
with celecoxib at 2 mg/kg. One dog with malignant melanoma experienced a CR, five other 
dogs had SD. Median overall survival was 3.39 months. No hemorrhagic cystitis or other 
toxicities were observed. Baseline serum levels of VEGF and interleukin-6 (IL-6) were 
measured. Responders (dogs with CR and SD) had lower baseline VEGF levels, suggesting 
that VEGF levels may serve as a predictor of efficacy. In the overall patient population, there 
was a strong correlation between baseline VEGF levels and poor prognosis. IL-6 was not 
correlated with therapy response or prognosis. A second study investigated the biological 
activity of metronomic cyclophosphamide in dogs with soft tissue sarcomas.
156
 Eleven dogs 
were either treated with 12.5 mg/m² or 15 mg/m² for four weeks and the effect on Tregs and 
microvessel density (MVD) were examined after two and four weeks. Only the dosage of 15 
mg/m² had a significant effect on the percentage of Tregs and MVD. At a dosage of 12.5 
mg/m², only the absolute number of Tregs was decreased. However, the authors state that the 
limited number of patients warrants careful conclusions about the dose dependent effect on 
Tregs. After four weeks of treatment, tumors were surgically removed and no further clinical 
follow-up was performed. The third study evaluated immune effects and safety of toceranib 
(2.75 mg/m²) given every other day and complemented after 14 days by daily 
cyclophosphamide (15 mg/m²) in 15 dogs with advanced disease, of which 12 had 
metastases.
157
 Treatment was well tolerated, with only grade 1 to 2 adverse effect, mainly 
during the first two weeks on toceranib treatment. Regulatory T cells were significantly 
decreased after toceranib treatment. After addition of cyclophosphamide, Tregs did not 
decrease further, however interferon-gamma levels in serum were only increased at time 
points when dogs received the combination treatment. This suggests either a further 
improvement in immune function after addition of cyclophosphamide or prolonged exposure 
to toceranib. In the fourth and last study; dogs treated with metronomic cyclophosphamide 
(12.5 mg/m
2
) and piroxicam (0.3 mg/kg) serve as a historical control group for the evaluation 
of a combination of this regimen with proton-pump inhibitors.
155
 For the group only receiving 
metronomic chemotherapy, ten dogs with various metastatic cancers are retrospectively 
described, with some of them treated by surgery before start of treatment. One dog 
experienced a CR, one dog a PR and two dogs showed no evidence of disease after surgical 
removal of the tumor.  
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4.2. Metronomic regimens of other drugs in veterinary medicine 
One study with metronomic lomustine (2.84 mg/m²) is published including a heterogeneous 
patient population of 81 dogs (table 4).
158
 Different tumor types were treated, with some 
patients receiving prior or concomitant surgery, standard chemotherapy or radiotherapy. In 22 
patients, therapy was discontinued due to toxicity (mainly gastrointestinal) and one dog died 
of treatment-related nephrotoxicity. Of dogs receiving only metronomic lomustine, 6% 
experienced a partial response and 30% stable disease. Also chlorambucil at 4 mg/m² is 
explored as metronomic chemotherapy in dogs (table 4).
159
 In 36 dogs with various cancers, 3 
dogs experienced a CR, one dog a PR (remission rate: 11%) and 17 dogs (47%) had SD. This 
led to a MST of 153 days. Treatment was very well tolerated, with adverse effects limited to 
grade 1 to 2 gastrointestinal effects in 4 patients. The same treatment regimen was applied in 
31 dogs with transitional cell carcinoma.
160
 One PR and SD in 67% of the patients was 
observed, leading to a MST of 221 days. 
 
5. Canine cancer patients as model for human oncology 
Cancer is an important disease in dogs, with a recent study in the UK identifying it as the 
most common cause of death.
161
 Therefore, exploring new treatment options in dogs is of 
great importance for veterinary medicine. However, these trials have also great value for 
human oncology, as cancer in dogs represents an excellent model for cancer in human 
patients.   
 
Tumors result from malignant transformation of a small number of the patient’s own cells and 
develop in close interaction with the tumor microenvironment and the immune system. In 
rodent models, tumors are either artificially induced or a result of inoculation of a great 
number of cultured tumor cells. Inbred rodents are not fully immune competent and in nude 
mice the adaptive immune system is evidently completely absent. Therefore, the complexity 
of spontaneously arising tumors in humans cannot be approximated with these models. This 
results in very low predictive power of rodent models, with a tremendous amount of negative 
phase I trials in human patients.
162,163
 
 
Spontaneously arising tumors in companion animals can be a very valuable intermediate 
model. In these pets, tumors develop in a syngeneic environment and in the presence of an 
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intact immune system. Although there are some concerns about inbred dog populations, it has 
been demonstrated that the genetic diversity in a population of dogs with a certain tumor type 
is similar to the diversity in a human population.
163
 Many tumors in dogs share biological, 
histological and clinical characteristics with their human counterparts. Moreover, responses to 
treatment are very similar. Genetic research has revealed nearly identical genetic changes in 
both species.
162,163
 This is especially true for lymphoma, osteosarcoma, melanoma and soft 
tissue sarcoma.
164,165
 Hemangiosarcoma is a highly metastatic, prevalent tumor that is very 
suitable as a model for anti-metastatic and anti-angiogenic therapies. Some tumor types, like 
osteosarcoma and brain tumors, are much more common in dogs than in humans, so it is more 
feasible to conduct clinical trials with sufficient statistical power.
164,165
 Progression of cancer 
in companion animals is slow enough to be able to compare responses to therapies and fast 
enough to obtain results within a reasonable period of time.
162,164
 In human medicine, only 
patients who are refractory to the standard treatment options can enter a phase I trial. In 
veterinary medicine no such restrictions exist, any patient can participate as long as this is 
based on an informed owner’s consent, approved by an ethical committee. Therefore, new 
medicines can be evaluated in early stages of disease and in the setting of minimal residual 
disease after e.g. surgery or chemotherapy.
164
 An additional advantage of dogs is their body 
size, that allows surgical interventions, medical imaging and tissue/blood sampling much like 
in human patients.
162,164
  
 
The present climate is very favorable for implementing clinical trials with dogs as treatment 
models for humans. The availability of species-specific research tools, which was an 
important impediment in the past, is increasing rapidly.
162,164,166
 Veterinary infrastructure 
today meets the standards of good clinical practice.
166
 Limited treatment options exist in 
veterinary oncology and dog owners want the best care possible for their pet. The benefit of 
their participation for human medicine is generally considered as a plus. For these reasons, 
compliance with treatment, control visits and autopsy are exceptional.
164
  
 
It can be concluded that dogs are excellent treatment models for human oncology in general. 
Evidently this applies even more to treatments dependent on the patient’s immune system. 
Many immunotherapy studies in dogs are conducted in close cooperation with human 
medicine.
66,74,81,84,85,93,98,100
 A good example of how this approach can benefit both veterinary 
and human medicine is the melanoma vaccine Oncept™. Clinical trials with this vaccine led 
to its licensing and widespread use in veterinary oncology and urged clinical trials with DNA 
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vaccines encoding murine/human tyrosinase in humans.
120
 Another example is a vaccine 
consisting of an adenoviral vector targeted to DCs, first studied in laboratory Beagles 
followed by a clinical trial in humans.
52,167
 Although not related to tumor vaccination, a last 
prime example of how canine trials can accelerate the development of new treatments for 
humans has been given by the work of McEwen et al., who tested a new immunotherapeutic 
treatment which was subsequently approved for the treatment of pediatric 
osteosarcoma.
73,168,169
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Scientific aims 
The general aim of this PhD thesis was the evaluation of a multimodal 
immunotherapeutic approach to treat cancer, with as ultimate future goal the evaluation of 
this treatment in companion dogs afflicted with cancer.  
 
The first objective was a proof-of-concept study in mice that the combination of tumor 
vaccination, interleukin-12 (IL-12) gene therapy and metronomic cyclophosphamide was 
safe and each component resulted in biological and clinical benefits (chapter 1). For this 
study, the B16-F10 melanoma model was used, as the individual components are well 
characterized in that model and thus needed no further optimization.  
 
After the confirmation that the proposed combination therapy indeed has potential 
because of safety and complementary mode of action, the individual components were 
further prepared for the evaluation of the combination therapy in dogs. In that context, a 
second aim was to characterize the effects of metronomic cyclophosphamide and 
temozolomide on regulatory T cells (Tregs) in a clinical trial with canine cancer patients 
(chapter 2). The major goal of this chapter was to investigate the potential value of this 
treatment for our immunotherapeutic combination approach. However, given the 
excellent applicability of metronomic chemotherapy as stand-alone therapy in veterinary 
medicine, some general considerations regarding the evaluation of this treatment modality 
outside the scope of immunotherapy are also given.  
 
A third aim was the development of a universal tumor vaccine. In chapter 1 a tyrosinase 
vaccine was used, which is evidently only applicable in melanoma patients, not very 
common in veterinary medicine. To be able to evaluate the combination treatment in a 
sufficient number of patients, a tumor vaccine potentially effective in many tumor types 
was deemed necessary. For this reason, vascular-endothelial growth factor receptor-2 
(VEGFR-2) was selected as antigen. Although different VEGFR-2 vaccines have been 
evaluated in the past, none of the formulations were feasible or available for evaluation in 
dogs. Therefore, the immunogenicity and safety of a new vaccine, consisting of a 
commercially available plasmid encoding human VEGFR-2, was tested in healthy mice 
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and laboratory dogs (chapter 3). Furthermore, the efficacy of this VEGFR-2 DNA 
vaccine was studied in two tumor mice models (chapter 4).  
 
The fourth and final aim consisted of enhancing the applicability of gene therapy in 
oncology in general, and of IL-12 gene therapy specifically. The approach used in chapter 
1 is limited to tumors that can be reached externally. Tumor specific delivery of IL-12 
after systemic infusion of transfected cells that preferentially home to tumor tissue could 
circumvent this issue. In chapter 5, the first steps towards evaluation of this form of gene 
therapy are set. A murine cell line with the theoretical potential to migrate towards tumor 
tissue was tested for tumor specific migration in vitro. Furthermore, methods to transfect 
these cells with reporter plasmids were evaluated. Lastly, transfection with IL-12 plasmid 
DNA was performed to quantify IL-12 production capacity and to gather preliminary in 
vitro data on the capability of this approach to modulate anti-tumor immune response. 
 RESEARCH STUDIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research studies 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 1  
 
 
 
 
 
 
 
 
Combination of interleukin-12 gene therapy, metronomic 
cyclophosphamide and DNA cancer vaccination directs all 
arms of the immune system towards tumor eradication 
 
 
 
 
This chapter is based on  
 
Denies S., Cicchelero L., Van Audenhove I., Sanders N.N. (2014). Combination of  
interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer  
vaccination directs all arms of the immune system towards tumor eradication. J Control  
Release 10;187:175-82. 
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1. Abstract  
In this work a combination therapy that acts upon the immune suppressive, the innate and 
specific arm of the immune system is proposed. This combination therapy, which consists out 
of intratumoral interleukin-12 (IL-12) gene therapy, human tyrosinase (hTyr) DNA 
vaccination and metronomic cyclophosphamide (CPX), was evaluated in a B16-F10 mouse 
model. Following groups were compared: (1) no treatment, (2) control vector, (3) 
intratumoral IL-12 gene therapy, (4) intratumoral IL-12 gene therapy + metronomic CPX, (5) 
intratumoral IL-12 gene therapy + metronomic CPX + hTyr DNA vaccination. Next to 
clinical efficacy and safety, we characterized acute effects of IL-12 and anti-tumor immune 
response after a second tumor challenge. All treatment groups showed increased survival and 
higher cure rates than control groups. Survival of non-cured mice was increased when 
metronomic CPX was combined with IL-12 gene therapy. Furthermore, mice that received 
metronomic CPX had significantly lower percentages of regulatory T cells (Tregs). Addition 
of the hTyr DNA vaccine increased cure rate and resulted in increased survival compared to 
other treatment groups. We also demonstrated that the manifest necrosis within days after IL-
12 gene therapy is at least partly due to IL-12 mediated activation of natural killer (NK) cells. 
All cured mice were resistant to a second challenge. A humoral memory response against the 
tumor cells was observed in all groups that received IL-12 gene therapy, while a cellular 
memory response was only observed in the vaccinated mice. In conclusion, every component 
of this combination treatment contributed a unique immunologic trait with associated clinical 
benefits. 
 
2. Introduction 
Active immunotherapy has earned its place in oncology research today, mainly due to its 
unique capacity to induce long-term protection, in the shape of a memory immune response. 
However, a specific antitumor response takes time to develop. Consequently, a sore point of 
many active specific immunotherapeutic agents is that they lack an acute effect, which 
renders them ineffective in controlling a rapidly growing tumor on their own. Therefore, it is 
often combined with non-immunological treatments that control gross tumor growth.
170
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However, targeting the innate immune system can be a valuable alternative, as this arm of the 
immune system is able to react almost immediately. A further advantage is that the innate 
immune system can play a beneficial role in influencing the adaptive immune response 
towards protective antitumor immunity.
171
 The combination of an adequate stimulation of 
both the innate and the adaptive immune response can therefore aid in the development of a 
robust long term antitumor immune response. This antitumor immune response is 
counteracted by immune-suppressive mechanisms, induced by the tumor thereby protecting 
itself against immune attack. A treatment to decrease these suppressive cells is indispensable 
for the success of any immunotherapeutic approach in the treatment against cancer.
172
 
Therefore, we believe that stimulation of the innate immune systems together with a cancer 
vaccination approach and an agent that tackles the immunosuppressive tumor environment 
may result in better responses.  
 
Of the various ways to modulate the innate immune system we have chosen in this study 
interleukin-12 (IL-12) for the following reasons. IL-12 is a cytokine that very strongly 
stimulates the innate immune system by acting as a growth factor for natural killer (NK) 
cells, inducing cytokine production in these cells and enhancing their cytotoxicity.
173
 NK 
cells can react very quickly upon stimulation, as they can exert their cytotoxicity without 
prior sensitization, antibody binding or protein presentation.
174
 Ensuring rapid tumor control, 
IL-12 meets the first prerequisite of our innate immune arm of the therapy. Moreover, IL-12 
favors cytotoxic T lymphocyte generation by inducing a Th1 response, functioning as a link 
between innate and adaptive immunity.
173
 Lastly, the immune effects of IL-12 are 
complemented by its capacity to decrease the suppressive function of myeloid derived 
suppressor cells (MDSCs) and by its antiangiogenic activity.
175,176
 Altogether, next to 
induction of acute effector functions, IL-12 therapy will create an ideal environment for the 
development of an effective specific antitumor immune response. This makes this cytokine 
exceptionally suitable to combine with specific immunotherapy. Although the therapeutic 
potential of IL-12 has been known for over a decade, its use has long been impeded by 
unacceptable toxicity when administered systemically.
133,177
 However, current technologies 
for local gene delivery have renewed interest in this cytokine. We have selected plasmid 
injection followed by electroporation for this experiment based on the impressive results 
reported with this technique.
178-180
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Tumor vaccination can be achieved by tumor cell vaccines, dendritic cell (DC) vaccines, 
genetic vaccines, protein or peptide vaccines. Tumor cell vaccines have the key advantage of 
including a wide variety of patient specific antigens. DC vaccines circumvent the difficulty of 
obtaining adequate tumor antigen presentation in vivo. Despite these advantages, labor 
intensive production and problems with quality control impede large-scale application of cell 
based vaccines.
35
 Genetic vaccination has the advantage to induce, next to a humoral immune 
response, a strong cellular immune response because the antigen is endogenously synthetized 
inside cells.
181
 Therefore, genetic vaccination was chosen over protein or peptide vaccination. 
Plasmid injection is safer than viral gene therapy and delivery with electroporation has the 
advantage of providing an inherent adjuvant effect.
182
 Hence, to obtain a specific antitumor 
response we delivered, via electroporation, a DNA vaccine encoding hTyr. A xenogeneic 
vaccination strategy was used as this can overcome immune tolerance to self-antigens, which 
comprise most tumor antigens.
183
 Moreover, this vaccination protocol is already approved by 
the USDA for clinical use in dogs with melanoma and phase I human clinical trials have 
recently been completed, making a fluent transition to further evaluation of this treatment in 
the clinical setting possible.
70,184,185
   
MDSCs and Tregs are induced by the tumor to obtain an immunologically permissive tumor 
microenvironment. MDSCs are a population of immature myeloid cells and are characterized 
by CD11b and Gr1 expression in mice. In humans, phenotypic markers are not yet 
conclusively established, although CD11b
+
CD33
+
HLA-DR
low
 cells are commonly classified 
as MDSCs. Strategies targeting these cells include MDSCs deactivation, inhibition of 
MDSCs formation, MDSCs depletion and forced differentiation in mature cells.
24,186
 IL-12 
belongs to the latter category, resulting not only in a decrease in MDSCs, but also an increase 
in antigen presenting cells.
176
 Regulatory T cells are CD4
+
CD25
+
FoxP3
+
 cells. Low doses of 
chemotherapy, tyrosinase kinase inhibitors and monoclonal antibodies to Tregs receptors can 
decrease the number or lower the suppressive capacities of Tregs.
187
 Metronomic 
cyclophosphamide (CPX), the most extensively studied method to suppress Tregs, is selected 
for this experiment, due to its excellent safety profile, ease of administration and low cost 
price. Low doses of CPX selectively kill Tregs because these cells have low levels of ATP, 
resulting in decreased glutathione synthesis, which is an important detoxification pathway for 
CPX.
147,188
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In summary, in this paper we investigated in a B16-F10 melanoma model whether 
metronomic CPX and DNA vaccination against hTyr could improve intratumoral IL-12 gene 
therapy. To answer these questions different treatment groups were included. To monitor the 
clinical efficacy of these treatments the tumor growth, the response rate and survival was 
determined. Additionally, the safety, the humoral and cellular immune responses as well as 
the role of NK cells in the acute anti-tumor effects of intratumoral IL-12 gene therapy were 
studied. Importantly, the immune response was measured after a second tumor challenge, 
reflecting a memory immune response and hence long term protection. The latter is very 
important as it distinguishes immunotherapy from all other oncology treatments. 
 
3. Materials and Methods 
Plasmids and tumor cells 
The B16-F10 tumor cell line was generously provided by Johan Grooten (Department of 
Biomedical Molecular Biology, Ghent University, Belgium). Transduction with luciferase 
was performed as described earlier.
189
 Briefly, retrovirus was produced in HEK293T cells by 
CaPO4 transfection, harvested after 48 and 72h, filtered and concentrated by 
ultracentrifugation. Transduction was performed in the presence of 8 µg/ml polybrene and 
efficiency was evaluated by bioluminescence. These cells were grown in Dulbecco’s 
modified Eagle’s medium, supplemented with 10% fetal calf serum, 100 mg/ml 
streptomycin, 100 IU/ml penicillin and 1 mmol/ml L-glutamine (Invitrogen, Carlsbad, USA). 
 
Murine IL-12 plasmid (pORF-mIL-12, indicated as IL-12 pDNA in this study) was purchased 
from Invivogen (Toulouse, France). A detailed description of the plasmid can be found on the 
website of the manufacturer.
190
 Human tyrosinase plasmid was generously provided by Alan 
N. Houghton and Jedd D. Wolchok (Sloan-Kettering Institute for Cancer Research, NY, 
USA) and has been described elsewhere.
191
 As control pDNA we used a plasmid encoding 
for green fluorescent protein. Purification of the plasmids was done with the EndoFree Giga 
kit, following the instructions of the manufacturer (Qiagen, Valencia, USA).  
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Study design 
For tumor inoculation, luciferase positive B16-F10 cells were harvested by trypsinization, 
washed twice with calcium and magnesium free Dulbecco’s phosphate buffered saline (PBS, 
Invitrogen) and 10
5
 tumor cells in PBS were injected subcutaneously in 8 weeks old 
C57BL/6JRj mice (Janvier Breeding Center, Le Genest St. Isle, France). The treatment 
scheme (Fig. 1) was started when the smallest diameter of the tumor reached 3-5 mm, which 
was 10-14 days after inoculation. We marked the first day of treatment as day 0. The mice 
were randomly divided in 5 groups of 12 mice and the following treatments were compared: 
(1) no treatment, (2) intratumoral electro-gene transfer (IT-EGT) of control pDNA, (3) IT-
EGT of IL-12 pDNA, (4) IT-EGT of IL-12 pDNA combined with low dose CPX 
(metronomic CPX), (5) IT-EGT of IL-12 pDNA combined with metronomic CPX and hTyr 
pDNA vaccination. IT-EGT of control pDNA and IL-12 pDNA was performed on day 0, day 
4 and day 7. The IT-EGT protocol consisted out of an intratumoral injection of 50 µg of 
pDNA in 40 µl PBS with a hypodermic needle. This was followed by electroporation with 
the BTX ECM 830 device (Harvard apparatus, Holliston, USA) using plate electrodes (3 
pulses of 75 V with a pulse duration of 40 ms and a 100 ms interval). Cyclophosphamide 
(Endoxan
®
; Baxter, Deerfield, USA) was administered via the drinking water from day 0 
until day 28. Continuous administration of 20 mg/kg/d of CPX was based on an average 
intake of 3 mL of drinking water per day by 20 g mice. The drinking water with CPX was 
changed twice weekly.
192
 On day 0 and day 14 hTyr pDNA (15 µg in 20 µl PBS) was 
injected intradermally and followed by electroporation with the BTX Agilepulse device 
(Harvard apparatus) using 4 mm gap needle electrodes (2 pulses of 450 V with a pulse 
duration of 0.05 ms and a 300 ms interval, followed by 8 pulses of 100 V with a pulse 
duration of 10 ms and a 300 ms interval).  
 
To assess the concentration of IL-12 in tumor and serum samples, and the percentage of 
Tregs we sacrificed 3 mice in each group five days after the last IT-EGT of IL-12 or control 
pDNA (i.e. at day 12). The remaining mice were followed for tumor growth and survival and 
were euthanized when humane endpoints were reached. These humane endpoints included 
tumor size (> 1cm
3
), significant weight loss (>20%) or self-mutilation. Cured mice, i.e. mice 
that were tumor-free for 100 days, were subjected to a new subcutaneous tumor challenge. 
Ten days after this challenge, three mice per group were euthanized for assessment of 
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immune parameters. The other mice were monitored for over one year. This experiment was 
approved by the ethical committee of the Faculty of Veterinary Medicine (Ghent University; 
EC-DI 2012-072) 
 
 
Fig. 1: Schematic representation of the experimental set-up: Treatment began when the smallest diameter of the 
tumor reached 3-5 mm, and consisted of three intratumoral IL-12 electro-gene treatments (EGT), two 
vaccinations with human tyrosinase plasmid (hTyrosinase) and metronomic cyclophosphamide (CPX). After 
100 days, cured mice were rechallenged. 
Determination of the concentration of IL-12 in tumor and serum 
Serum and tumor tissue from 3 mice per group were collected at day 12. Tumor tissue was 
lysed by homogenization with Tissue Disruptor in Tissue Extraction Reagent I (Invitrogen) 
supplemented with protease inhibitors (Roche, Basel, Switzerland). The solution was 
centrifuged in a Universal 320R centrifuge (Hettich, Tuttlingen, Germany) at 10000 rpm 
during five minutes, after which supernatant was stored at -80 °C until analysis. Blood was 
taken by cardiac puncture under terminal anesthesia and after centrifugation serum was 
collected and stored at -80 °C until analysis. IL-12 concentration in tumor and serum was 
measured with an ELISA-kit (Biolegend, San Diego, USA) following the manufacturer’s 
instructions.  
Flow cytometric staining of Tregs 
Splenocytes were isolated from 3 mice per group at day 12. One million cells in 100 µl FACS 
buffer (BD Biosciences, Erembodegem, Belgium) were stained for cell-surface antigens with 
FITC-conjugated anti-CD25 (Biolegend) and PerCp-conjugated anti-CD4 (Biolegend) 
antibodies. Fixation and permeabilization of the splenocytes preceded intracellular staining 
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with the PE-conjugated anti-Foxp3 antibody (FoxP3 staining kit, eBiosciences, San Diego, 
USA). The cells were analyzed with an Accuri C6 flow cytometer (BD Biosciences) and 
events in the lymphocyte gate were selected. Color compensation was done based on single 
staining, threshold for positive events were set based on fluorescence minus one (FMO) 
controls. The percentage Tregs was determined as the percentage of CD4
+
CD25
+
Foxp3
+
 cells 
within the CD4
+
 population. 
Tumor growth, survival and safety 
Tumor size was determined with a digital caliper. Mice were observed daily and weighed 
twice weekly to detect possible adverse effect of the treatment and recognition of humane 
endpoints. Survival analysis was performed using euthanasia when humane endpoints were 
reached as positive events. 
Challenge 
Mice that were tumor-free for 100 days were again challenged with 1x10
6
 B16-F10 cells 
subcutaneously. Injection of viable tumor cells was confirmed with in vivo bioluminescent 
imaging. Mice were injected intraperitoneally with 100 µl of D-luciferin (15 mg/ml, Goldbio 
Technology, St. Louis, USA) and in vivo imaging was performed after 10 minutes with an 
IVIS lumina II (Perkin-Elmer, Zaventem, Belgium). In vivo bioluminescent imaging was 
repeated every week to follow up tumor formation or tumor cell disappearance. 
Intracellular cytokine staining 
Ten days after rechallenge of the surviving mice, 3 mice were sacrificed and splenocytes 
were isolated and cultured in the presence of tyrosinase peptides. To assess both 
immunogenicity and cross-reactivity of the xenogeneic DNA vaccine, human as well as 
murine tyrosinase peptide mixes were used as stimuli (PepMix™ Mouse Tyrosinase and 
PepMix™ Human Tyrosinase; JPT, Berlin, Germany). After 2h of incubation, Brefeldin A 
(Biolegend) was added to block secretion of cytokines. After an additional 4h incubation, 
splenocytes were harvested, washed and resuspended in FACS buffer (BD Biosciences). 
Cell-surface staining with FITC-conjugated anti-CD8 antibody (Biolegend) was followed by 
fixation, permeabilization and intracellular staining with PE-conjugated anti-IL-4 (Biolegend) 
and APC-conjugated anti-interferon-gamma (IFN-gamma) (Biolegend) antibodies. The cells 
were analyzed with an Accuri C6 flow cytometer (BD Biosciences) and events in the 
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lymphocyte gate were selected, color compensation was done based on single staining, 
threshold for positive events was set based on FMO controls. Controls for specificity of the 
cytokine response were assessed by including non-stimulated splenocytes in the analysis. 
Detection of antibodies 
Serum was taken from 3 mice ten days after rechallenge of surviving mice. B16-F10 tumor 
cells were washed and resuspended in 50 µl of diluted mice serum (1/8 dilution in FACS 
buffer). Cells were incubated for one hour at 37 °C and 5% CO2. Subsequently the cells were 
washed and stained with APC-conjugated anti-mouse IgG antibodies (Biolegend) and the 
number of positive cells was analyzed via flow cytometry. Control for specificity of staining 
included B16-F10 cells that were not incubated with serum and stained with the secondary 
antibodies.  
In vitro effect of IL-12 on tumor cell growth and tumor cell lysis by immune cells  
B16-F10 tumor cells (10
6
 cells in 80 µl PBS) were in vitro electroporated, using a BTX ECM 
830 (Harvard apparatus), with 5 µg of IL-12 pDNA or control pDNA (2 pulses of 140 V, 5 
ms length and 100 ms pulse interval). Subsequently, 5x10
4
 viable electroporated cells were 
seeded in a black 96 well cell culture plate. Growth of cells electroporated with IL-12 pDNA 
versus control pDNA was compared using a previously described in vitro luciferase assay.
193
 
Briefly, 10 µl of D-luciferin (15 mg/ml) was added to each well and after 10 minutes 
incubation (37 °C, 95% relative humidity, 5% CO2) bioluminescent imaging was performed 
using an IVIS lumina II (Perkin-Elmer). Measurements were performed after 0, 24 and 48 
hours. 
To evaluate the effect of IL-12 on tumor cell lysis by immune cells we co-incubated IL-12 
electroporated B16-F10 cells and non-electroporated B16F-10 cells with purified NK cells 
and purified CD8
+
 splenocytes, harvested from five C57BL/6JRj mice. The effector/target 
ratio in these mixtures was 15:1. Purification of immune subsets was achieved by magnetic 
beads separation (Dynabeads, Invitrogen). Tumor cell death of non-electroporated and IL-12 
electroporated tumor cells by immune cells was determined by using respectively non-
electroporated and IL-12 electroporated tumor cells without immune cells as reference. 
Tumor cell death was determined by an in vitro luciferase assay, as described above.   
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Statistical analysis 
The statistical software package R was used. Because of the high cure rate observed in 
treatment groups and thus high proportion of censored cases, Kaplan Meier analysis of 
survival is not appropriate.
194
 An alternative approach, based on the mixed cure model, was 
used. For each time point the overall probability of survival for different groups was 
calculated as the proportion of mice alive at that time point. These probabilities across all 
time points were summed to come to a cumulative probability of overall survival for each 
group. A relative overall survival ratio of this cumulative probability was calculated for 
pairwise comparisons between treatment groups. Significance of this finding was calculated 
by 10.000 random permutations on the observed data. Analogue calculations were performed 
for a relative cure ratio and a relative non-cured survival ratio. Differences in immunological 
parameters were analyzed with one-way ANOVA with Bonferroni correction for pairwise 
comparisons. Differences between in vitro tumor cell death after incubation with splenocytes 
from the same mouse with and without IL-12 were compared with a paired t-test. 
 
4. Results 
Clinical response and cure rate 
Clinical response was followed in 9 mice in every group. Characterization of clinical 
response is subdivided by occurrence of complete responses and tumor growth in remaining 
tumor bearing mice (Fig. 2). We observed no complete responses in the control groups. In the 
IL-12 IT-EGT group and IL-12 IT-EGT + metronomic CPX group share a similar pattern of 
complete responses, i.e. rapid rise in number of complete responses, with no additional 
complete responses after 30 days (Fig. 2A). The fast response to IL-12 gene therapy is also 
illustrated in figure 2C. This leads to a cure rate for IL-12 IT-EGT of 67% and for IL-12 IT-
EGT+ CPX of 55%. Interestingly, a different pattern is visible in the vaccinated group, where 
additional complete responses were observed far after 30 days, suggesting that this is due to 
action of the vaccine and not of IL-12. Cure rate for this group reached 89%. Mice that 
received no treatment or intratumoral electroporation of a control plasmid are characterized 
by fast tumor growth (Fig. 2B). This is translated in a short mean survival (22.7 ± 1.4 days 
and 22.3 ± 1.3 days respectively) for these control mice. If we look at differences in tumor 
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growth of non-cured mice between treatment groups, tumor growth is markedly slower for 
the IL-12 IT-EGT + CPX group compared to IL-12 IT-EGT alone. As a consequence, mean 
survival for the non-cured mice in this combination group is higher compared to IL-12 IT 
EGT alone (73.75 ± 7.67 days versus 50 ± 8 days). Only one mouse in the vaccinated group 
died, after 75 days. 
 
Fig. 2: Number of mice with complete response (panel A) and tumor growth curve of tumor bearing mice (panel 
B) in function of time after treatment. Representative photos showing short term tumor shrinkage after 
intratumoral IL-12 pDNA electro-gene transfer are shown in panel C. Mice that were cured were not included in 
the tumor growth curves. Error bars represent standard error of the mean. Because of the low number of tumor 
bearing mice after 40 days in the group receiving IT-EGT with IL-12 pDNA, metronomic cyclophosphamide 
and human tyrosinase vaccination, tumor volume is displayed individually. The number of mice in each group 
was 9.  = no treatment;  = intratumoral electro-gene transfer (IT-EGT) with control vector ;  = IT-
EGT with IL-12 pDNA; = IT-EGT with IL-12 pDNA and metronomic cyclophosphamide; = IT-
EGT with IL-12 pDNA, metronomic cyclophosphamide and human tyrosinase vaccination. 
Relative overall survival ratios between groups (group in row/group in column) are listed in 
table 1. Thus, values significantly higher than 1 represent a higher chance of survival for 
mice in the group listed in rows compared to the group listed in columns. All treated mice 
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have a significant 3 to 4 time higher chance of survival compared to control groups. Between 
treatment groups, we see no difference between IL-12 IT-ETG and IL-12 IT-EGT + CPX. 
However, the vaccinated mice have a moderate higher chance of survival compared to the 
other treatment groups, i.e. 17% compared to IL-12 IT-EGT and 10% compared to IL-12 IT-
EGT+ CPX (relative overall survival ratio of 1.17 and 1.10 respectively). 
Table 1: Relative ratios of overall survival, cure and non-cured survival between different treatment groups 
 Control 
Control 
pDNA 
IL-12 pDNA 
IL-12 pDNA 
+ CPX 
Relative overall survival ratio     
IL-12 pDNA 3.57*** 3.46*** / / 
IL-12 pDNA + CPX 3.76*** 3.64*** 1.05  / 
IL-12 pDNA+ CPX + hTyr pDNA 4.13*** 4,00*** 1.17* 1.10* 
Relative cure ratio     
IL-12 pDNA NA NA / / 
IL-12 pDNA + CPX NA NA 0.83  / 
IL-12 pDNA+ CPX + hTyr pDNA NA NA 1.30  1.60* 
Relative non-cured survival ratio     
IL-12 pDNA 2.22*** 2.13*** / / 
IL-12 pDNA + CPX 3.13*** 3,01*** 1.41* / 
IL-12 pDNA+ CPX + hTyr pDNA 3.52*** 3.38*** 1.41  1  
Control = no treatment; Control pDNA = intratumoral electro-gene transfer (IT-EGT) with control vector; IL-12 pDNA = 
IT-EGT with IL-12 pDNA; IL-12 pDNA + CPX = IT-EGT with IL-12 pDNA and metronomic cyclophosphamide; IL-12 
pDNA + CPX + hTyr = IT-EGT with IL-12 pDNA, metronomic cyclophosphamide and human tyrosinase vaccination. (*** 
p<0.001, * p<0.05) 
For the calculation of relative overall survival ratio both the chance of cure and the chance of 
survival if not cured are considered (table 1). If we separate these factors to gain insight in 
the contribution of treatment components we can draw following conclusions. 
Cyclophosphamide does not increase cure rate, but increases chances of survival for non-
cured mice by 41% (relative non-cured survival ratio of 1.41). However, this is not sufficient 
to significantly enhance overall survival compared to IL-12 IT-EGT alone. When the vaccine 
is added to the treatment, a 60% increase in cure rate is observed (relative cure ratio of 1.6). 
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For vaccinated mice, the combined effect of increased cure rate and increased survival of 
non-cured mice sum up to the 17% higher chance of overall survival compared to IL-12 IT-
EGT alone. Increased cure rate results in a 10% higher chance of overall survival compared 
to IL-12 IT-EGT + CPX. 
Regulatory T cells and memory immune responses 
On day 12, the percentage of Tregs was determined. There was no difference in percentage of 
Tregs between control mice (6.57 ± 1.48%) and mice treated with IL-12 IT-EGT (5.93 ± 
0.75%). Mice that received metronomic CPX had significant reduced Tregs compared to 
mice that not received metronomic CPX (Fig. 3). In detail, the Treg percentages in mice that 
received IL-12 IT-EGT plus metronomic CPX or IL-12 IT-EGT plus metronomic CPX and 
hTyr vaccine were respectively 4.25 ± 0.47% (p=0.02) and 4.05 ± 0.13% (p=0.01). No 
differences in percentage of CD4
+
 cells were observed (data not shown).  
 
Fig. 3: Metronomic cyclophosphamide (CPX) significantly reduced the percentage of regulatory T cells. Twelve 
days after the start of the treatment the average percentage of regulatory T cells in the spleen of 3 mice per 
group was determined. Mice that received CPX had a significant reduction in the percentage of regulatory T 
cells compared to the control group and IL-12 gene therapy group. IL-12 gene therapy alone was not able to 
reduce Tregs. Control = no treatment; IL-12 pDNA = intratumoral electro-gene transfer (IT-EGT) with IL-12 
pDNA; IL-12 pDNA + CPX = IT-EGT with IL-12 pDNA and metronomic cyclophosphamide; IL-12 pDNA + 
CPX + hTyr = IT-EGT with IL-12 pDNA, metronomic cyclophosphamide and human tyrosinase vaccination. 
Error bars represent standard deviation. (* p<0.05) 
Chapter 1: Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer 
vaccination directs all arms of the immune system towards tumor eradication 
 
 
55 
 
Ten days after rechallenge, the percentage of IFN-gamma positive lymphocytes after 
incubation with murine tyrosinase peptides was determined. There was no difference in IFN-
gamma positive lymphocytes between the control groups (no treatment group: 0.03 ± 0.03%; 
control pDNA group: 0.03 ± 0.03%), the IL-12 IT-EGT group (0.05 ± 0.04%), and the IL-12 
IT-EGT plus metronomic CPX group (0.05 ± 0.02%). However, mice that received the hTyr 
pDNA vaccine had a statistically significant higher percentage of IFN-gamma positive 
lymphocytes (0.17 ± 0.04%) compared to the control groups (p<0.001) and the other IL-12 
IT-ETG groups (p<0.001). Similar percentages of IFN-gamma positive lymphocytes were 
observed after incubation of the splenocytes of hTyr vaccinated mice with human (0.16 ± 
0.05%) or murine tyrosinase peptides (0.17 ± 0.04%).  
 
Fig. 4: A humoral memory response is established after intratumoral electro-gene transfer of IL-12 pDNA. To 
determine the presence of antibodies against the tumor cells we incubated diluted sera of each mouse (3 mice 
per group) with a fixed amount of B16-F0 melanoma cells and determined via flow cytometry the percentage of 
tumor cells that became bound with IgG antibodies present in the mice’s serum. Control = no treatment; IL-12 
pDNA = intratumoral electro-gene transfer (IT-EGT) with IL-12 pDNA; IL-12 pDNA + CPX = IT-EGT with 
IL-12 pDNA and metronomic cyclophosphamide; IL-12 pDNA + CPX + hTyr = IT-EGT with IL-12 pDNA, 
metronomic cyclophosphamide and human tyrosinase vaccination. Error bars represent standard deviation. (*** 
p<0.001 compared to all other groups) 
Additionally, also a similar percentage of IFN-gamma producing T cells was present in the 
CD8 positive (0.10 ± 0.05%) and CD8 negative lymphocyte population (0.07 ± 0.06%) of 
mice that received the hTyr DNA vaccine. There were no differences in IL-4 response 
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between the different groups (data not shown). Ten days after the rechallenge also serum 
samples were taken to determine the presence of antibodies against the tumor cells. All 
treatment groups had, compared to the control groups, significantly higher levels of IgG 
antibody directed against B16-F10 cells (p<0.001). However, between the treatment groups, 
no significant differences could be detected (Fig. 4). 
Adverse effects and IL-12 concentration in tumor and serum 
No weight loss was observed during the study period in any group. We noticed that one 
mouse in the IL-12 IT-EGT plus metronomic CPX group and one mouse in the group that 
received IL-12 IT-EGT combined with metronomic CPX and hTyr pDNA vaccination 
showed lethargy and decreased interaction with the investigator. This occurred during the 
week of IL-12 treatments, and resolved spontaneously within two days. All mice in the 
vaccinated group exhibited alopecia in the weeks following second tumor challenge. Hair 
loss started in the area surrounding tumor inoculation and progressed in some mice, ranging 
from focal alopecia to almost generalized flank alopecia. This alopecia remained stable for 
over 12 months. None of the mice in the other treatment groups exhibited alopecia. 
The concentration of IL-12 in tumor lysate was significantly higher in the tumors 
electroporated with IL-12 pDNA than in the control groups (5.0 ± 1.2 pg/mg versus 0.07 ± 
0.05 pg/mg, p=0.04). The IL-12 concentration in serum was not detectable in most mice, 
except in two mice after IL-12 pDNA therapy, where it reached 35 pg/ml. These mice did not 
exhibit any signs of toxicity. Overall, there was no significant difference between IL-12 
pDNA treated mice and control mice in IL-12 serum concentration.  
Challenge of cured mice with a second injection of tumor cells 
All cured mice in the different treatment groups (6 in the IL-12 IT-EGT group, 5 in the IL-12 
IT-EGT plus metronomic CPX group, and 8 in the group that received IL-12 IT-EGT 
combined with metronomic CPX and hTyr pDNA vaccination) were rechallenged with tumor 
cells. Injection of viable tumor cells was confirmed via in vivo bioluminescent imaging. No 
macroscopic tumor developed, but a bioluminescent signal was visible for two to three 
weeks, after which no signal could be detected, with no difference between treatment groups. 
One year after the rechallenge all the mice were still alive and tumor free. 
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The origin of the acute effects after intratumoral IL-12 electro-gene transfer 
Intratumoral EGT with IL-12 pDNA caused tumor necrosis within 24h after the first 
treatment (Fig. 2). Because B16-F10 cells express the IL-12 receptor, a direct influence of IL-
12 on tumor growth in vitro was investigated. However, no difference in tumor growth 
between tumor cells electroporated with IL-12 pDNA or control pDNA was observed (data 
not shown). Another possible explanation for this rapid action of IL-12 in vivo is a 
stimulation of NK cells that subsequently attack tumor cells. There are conflicting in vivo 
studies in the literature concerning the role of NK cells in the antineoplastic action of IL-12 
195,196
. To check if NK cells are responsible for the rapid action of IL-12 we performed an in 
vitro experiment with co-incubation of immune cells and tumor cells electroporated with IL-
12 pDNA.  
 
Fig. 5: NK cell mediated tumor cell killing plays an important role in the acute effects of IL-12. Cytotoxic 
effects of purified NK cells and CD8
+
 T cells on non-transfected (dark grey) and IL-12 pDNA transfected tumor 
cells (light gray) are illustrated. Tumor cell death was measured 24h after co-incubation of the immune cells 
with the tumor cells (n=5). Error bars represent standard deviation. (* p<0.05) 
When immune cells were co-incubated with IL-12 transfected and non-transfected tumor 
cells, IL-12 significantly enhanced tumor cell cytotoxicity of purified NK cells (p=0.02). This 
was evident already after 24h and remained significant after 48h (data not shown). In 
contrast, IL-12 did not increase the cytotoxicity of CD8
+
 cells as co-incubation of IL-12-
transfected or non-transfected tumor cells with purified CD8
+
 cells did not result in 
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significant differences in cytotoxic effects on the tumor cells (Fig. 5). This suggests that in 
the acute phase, NK cells and not CD8
+
 cells are the dominant immune cells responding to 
IL-12.   
5. Discussion 
In this study we investigated whether metronomic CPX and DNA cancer vaccination could 
improve intratumoral IL-12 gene therapy. Interleukin-12 is the only agent capable of 
inducing complete tumor regression on its own.
197-199
 Therefore our principle research 
question was if metronomic chemotherapy and tumor vaccination can enhance the anti-tumor 
activity of IL-12 gene therapy and not vice versa. Overall survival was significantly enhanced 
in the vaccinated group compared to IL-12 IT-EGT with 17% and with 10% compared to IL-
12 IT-EGT + CPX, due to a 60% increase in cure rate. When compared to IL-12 IT-EGT 
alone, metronomic CPX significantly enhanced survival of non-cured mice with 40%, but did 
not increase cure rate. The effect of metronomic CPX alone was insufficient to significantly 
increase overall survival.  
Immune effects during or shortly after IL-12 gene therapy have already been documented, 
with conflicting results whether immune modulation is important for the clinical effect, and if 
it are NK cells or CD8
+
 cells that mainly react in response to IL-12 gene therapy.
195,196,200
 In 
our experiment, mice that were intratumorally electroporated with IL-12 pDNA exhibited 
local necrosis within one day after treatment, suggesting an important role for the innate 
immune system. We confirmed this hypothesis in an in vitro model, where NK cells were 
identified as the main effectors of IL-12 induced cytotoxicity. Because B16-F10 cells express 
the IL-12 receptor, a direct effect of IL-12 on tumor cell growth was investigated.
201
 No such 
direct effects were observed. In this work we have not investigated whether the anti-
angiogenic effects of IL-12 were responsible for the rapid onset of tumor necrosis. Although 
it has been indisputably demonstrated that anti-angiogenic mechanisms contribute 
significantly to the antineoplastic potency of IL-12, changes in neovascularization only start 
to occur three days after IL-12 gene therapy.
175
 In our study manifest necrosis was observed 
before this time. Therefore, in agreement with Kim et al., we believe that the rapid tumor 
necrosis after IL-12 gene therapy is mainly due to NK cell stimulation.
200
 The electroporation 
itself is not a causal factor, since necrosis was not observed in the control group subjected to 
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electroporation of a mock plasmid. Similar to other studies, IL-12 gene therapy had no effect 
on the percentage of Tregs.
202
 Depletion of Tregs only occurred in groups receiving 
metronomic CPX.  
 
All mice that were cured after IL-12 IT-EGT were resistant to a second tumor challenge. B 
cell memory was present in mice that received intratumoral IL-12 pDNA. Also Arulanandam 
et al. reported that IL-12 is able to stimulate the induction of B cell memory against viral 
disease.
203
 The massive exposure of tumor antigens after IL-12 mediated tumor necrosis 
probably assisted the development of a humoral memory immune response against the tumor 
cells. Previous reports on IL-12 gene therapy for cancer mainly focus on the effect of IL-12 
on the acute cellular immune response. Only in the last years the humoral immune response 
gained interest in cancer immunotherapy, mostly by the success of monoclonal antibodies.
204
 
Although the anti-tumor effects of endogenously evoked antibodies are not yet sufficiently 
characterized, there are some hints that they indeed may not be overlooked in cancer 
immunotherapy. For instance, in tumor vaccination studies humoral immune responses are 
frequently correlated with clinical efficacy and immunoglobulin kappa chain levels in tumors 
have proven to be an important prognostic factor in different human cancers.
205,206
 Moreover, 
it has been demonstrated that memory B cells isolated from melanoma patients produce 
antibodies that are able to kill tumor cells in vitro, at least partly by antibody dependent cell-
mediated cytotoxicity.
207
 More research is needed to determine if a memory B cell immune 
response is sufficient to protect against a second tumor challenge. Non-vaccinated mice that 
received intratumoral IL-12 gene therapy did not show a memory cellular immune response. 
It has been demonstrated that high IL-12 exposure strongly reduces both the quality and 
quantity of the memory T cell response.
208-210
 IL-12 stimulates the cellular immune response 
very strongly, however, doing so it promotes the differentiation into effector T cells at the 
expense of the formation of memory T cells. Interestingly, after the combination treatment 
with IL-12 gene therapy, metronomic CPX and DNA cancer vaccination, a robust cellular 
and humoral memory immune response was present. The alopecia only seen in vaccinated 
mice can be explained by this cellular immune response, since alopecia after tyrosinase 
immunotherapy is mediated by CD4
+
 and CD8
+
 lymphocytes.
211,212
 Thus, although IL-12 
gene therapy is not able to induce a cellular memory immune response as monotherapy, it 
does not impede its development in combination with tumor vaccination. A possible 
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explanation for this is that mice were not under influence of IL-12 during boost vaccination. 
The memory B cell immunity induced by IL-12 gene therapy may explain the resistance of 
the non-vaccinated mice against a second tumor injection. However, another explanation for 
resistance against tumor challenge in this experiment is the existence of a NK cell memory. 
IL-12 has proven to be indispensable for the generation of a NK cell memory, which is 
independent of B or T cells.
213,214
 Additionally, an antibody-dependent NK cell memory has 
recently been discovered.
215
 This is a very attractive explanation for resistance against tumor 
challenge in this experiment as IL-12 promotes both NK function and a humoral memory 
immune response. 
In the past intratumoral electroporation was only possible for tumors that were reachable 
from the outside. However, recent developments in electrode design have made it possible to 
electroporate internal tumors, with already early clinical experience with tumors in the liver, 
bone, brain and intestines.
216
 Another possibility to broaden the applicability of IL-12 gene 
therapy towards distant tumors is the use of tumor targeting strategies. For example, the use 
of cells that home to tumors as tumor targeting vehicles for IL-12 is an interesting approach 
to deliver IL-12 to internal tumors.
217
 Additionally, pDNAs that produce IL-12 equipped with 
a tumor targeting ligand have also been evaluated.
218
 To conclude, with the rapid 
advancement in electroporation and targeted delivery methods, we believe that intratumoral 
IL-12 (gene) therapy will be applicable in the near future for a broad range of tumor types.   
 
6. Conclusion 
In conclusion, every component of this combination treatment contributes a unique 
immunologic trait: stimulation of the innate immune system via IL-12 gene therapy, 
depletion of the suppressive Tregs through metronomic CPX, and specific stimulation of the 
cellular memory immune response via DNA cancer vaccine against tyrosinase. Rapid tumor 
shrinkage was observed in most mice after intratumoral IL-12 gene therapy. We 
demonstrated that this was most likely due to stimulation of NK cells. When metronomic 
CPX was combined with IL-12 gene therapy, survival in non-cured mice was enhanced and 
addition of the vaccine increased cure rate. This led to a significant increased overall survival 
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in vaccinated mice compared to the other treatment groups.  A memory B cell response was 
detected in surviving mice that received IL-12 gene therapy alone or in combination with 
metronomic CPX, while both a memory B and T cell response was only observed in the DNA 
vaccinated mice. After these encouraging results in mice, we hope to test such combination 
treatment in spontaneously arising tumors in dogs as a further step towards clinical 
validation. 
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1. Abstract 
Metronomic chemotherapy stimulates the immune response via depletion of regulatory T 
cells (Tregs) and suppresses angiogenesis by modulating the secretion of thrombospondin-1 
(TSP-1) and vascular endothelial growth factor (VEGF). In this study blood was collected 
from 10 healthy dogs and from 30 canine cancer patients before and two and four weeks after 
treatment with metronomic temozolomide (6.6 mg/m
2
), cyclophosphamide (12.5 mg/m
2
), or 
the combination of cyclophosphamide and temozolomide. The percentage of circulating 
CD25
+
Foxp3
+
CD4
+
 Tregs and the plasma levels of TSP-1 and VEGF were measured. There 
was a significant difference in the percentage of Tregs between cancer patients and healthy 
dogs. A significant decrease in Tregs was noted in patients treated with metronomic 
cyclophosphamide and the combination. Treatment with temozolomide had no effect on the 
percentage of Tregs. TSP-1 and VEGF levels were respectively significantly lower and 
higher in cancer patients than in healthy dogs, but they were not influenced by any of the 
studied metronomic treatment regimens. 
 
2. Introduction 
Metronomic chemotherapy is the frequent and continued administration of low doses of 
chemotherapeutics. Instead of targeting tumor cells directly, metronomic chemotherapy 
works by slowing the growth of new blood vessels and by selectively eliminating 
immunosuppressive immune cells.
219
 Regulatory T cells are an important class of 
immunosuppressive immune cells that play a major role in the suppression of an effective 
anti-tumor immune response in cancer patients. They suppress cytotoxic T cells as well as 
natural killer cell mediated cytotoxicity and also have an effect on B cells, CD4
+
 T cells and 
dendritic cells.
23
 Tregs can be depleted by metronomic cyclophosphamide or 
temozolomide.
220,221
 The selective effect of metronomic cyclophosphamide towards Tregs is 
explained by reduced intracellular ATP levels in these cells, leading to decreased glutathione 
synthesis and thus reduced detoxification of cyclophosphamide.
147
 Also for temozolomide, 
selective toxicity to Tregs is observed, but the mechanism is not yet elucidated.
221-223
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In human patients suffering from various cancers, intratumoral and circulating Tregs are 
elevated and this is often correlated with a poor prognosis.
224-227
 In some studies depletion of 
Tregs enhanced tumor-specific immune responses and increased the survival of humans 
afflicted with cancer.
220,228
 In canine cancer patients, higher percentages of Tregs compared 
to healthy control dogs and a decrease after treatment with metronomic cyclophosphamide 
have also been reported.
156,229-233
 Tregs are best characterized with the surface antigens CD25 
and CD4 and the intracellular antigen FoxP3.
234
 However, in canine cancer patients Tregs 
have been monitored using only CD4 and FoxP3 as Tregs markers, because a commercially 
anti-canine CD25 antibody was not available in the past. This is no longer an impediment and 
it is proven that also in dogs CD25 is an important marker of a regulatory phenotype.
235-237
 
 
The anti-angiogenic action of metronomic chemotherapy is mainly mediated by the 
upregulation of the anti-angiogenic protein thrombospondin-1 (TSP-1), as the effect of 
metronomic chemotherapy is abrogated in TSP-1 deficient mice.
197,238,239
 Moreover, it has 
been proven, in vitro and in mouse models, that different metronomic chemotherapy 
regimens induce TSP-1 production in tumor cells, endothelial cells and stromal cells.
197,239,240
 
Additionally, increased serum TSP-1 concentrations are found in human patients treated with 
metronomic chemotherapy.
241-244
 TSP-1 binds to the CD36 receptor, which is only present in 
specific cell types, of which activated endothelial cells are the most important. Binding of 
TSP-1 to the CD36 receptor on endothelial cells blocks their proliferation and induces 
apoptosis.
197,239
 TSP-1 also binds and sequesters VEGF, thereby also exerting an indirect 
anti-angiogenic effect.
245
 It has been demonstrated that metronomic chemotherapy also 
directly decreases VEGF secretion in tumor cells and decreased VEGF serum levels are in 
human patients associated with clinical response to metronomic chemotherapy.
243,246
  
 
The last decade cancer vaccination has gathered much attention in veterinary oncology.
247
 
However, tumor-induced immunosuppression is a major bottle neck for cancer vaccines, with 
Tregs playing an important role in this.
151
 Therefore, it might be interesting to combine 
metronomic chemotherapy with cancer vaccination. One study has investigated the effect of 
metronomic cyclophosphamide on Tregs in dogs at two doses. A dose of 15 mg/m
2
 decreased 
the percentage of Tregs in cancer patients but the lower dose of 12.5 mg/m
2
 gave 
inconclusive results, mainly because of the small sample size of 5 dogs in the latter group.
156
 
It has been reported that metronomic cyclophosphamide can cause sterile hemorrhagic 
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cystitis in dogs, which provides a rationale to use the lower dose if this could also result in a 
decrease in percentage of Tregs.
152,153
 Therefore, we reevaluated the effect of 
cyclophosphamide at 12.5 mg/m
2
 on Tregs. For the same reason, the evaluation of other low-
dosed chemotherapeutics that have similar effects as low-dose cyclophosphamide is 
interesting. It has been demonstrated in rodents and humans that metronomic temozolomide 
can decrease Tregs.
221-223
 An important advantage of metronomic temozolomide compared to 
other Treg depleting chemotherapeutics is that, like cyclophosphamide, it can be given orally, 
which facilitates its use in canine patients. In this study we evaluated for the first time 
whether metronomic temozolomide has comparable effects on Tregs in canine patients as 
metronomic cyclophosphamide. Lastly, also the combination of the two drugs was evaluated, 
as combinatory treatments can result in synergistic biological effects, requiring lower doses 
of each drug minimizing the risk of adverse effects.  Besides the effect of metronomic 
temozolomide and cyclophosphamide on Tregs we also measured whether they affect the 
plasma levels of the angiogenic marker TSP-1 and VEGF in canine cancer patients. 
 
3. Materials and methods 
Study population 
Ten healthy control dogs and 30 dogs with cancer were included in this study. Control dogs 
were determined to be healthy by conducting a thorough anamnesis and by physical 
examination. For dogs with cancer, all patients with a newly diagnosed malignant tumor, for 
which standard treatment options were not available or declined by owners, were eligible. 
Patients were diagnosed at the Faculty of Veterinary Medicine of Ghent University. This 
study was approved by the Ethical Committee of the Faculty of Veterinary Medicine of 
Ghent University, the Belgian national Deontological Committee and the Federal Agency for 
Medicines and Health Products. 
 
Treatment of cancer patients 
Dogs were sequentially allocated to one of the following treatment schedules; 
cyclophosphamide 12.5 mg/m² daily (Endoxan, Baxter, Lessines, Belgium), temozolomide
 
6.6 mg/m² daily (Temodal, Merck Sharpe & Dohme, Hertfordshire, UK) or 
cyclophosphamide 12.5 mg/m² plus temozolomide 6.6 mg/m² daily. The dosage of 
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cyclophosphamide was based on a previous study with metronomic cyclophosphamide in 
dogs.
156
 For temozolomide, it was demonstrated that 1/15 of the cytotoxic dose had a 
selective effect on Tregs in rodents.
222
  No phase I studies with temozolomide are performed 
in dogs but a study reports 100 mg/m² given in a cytotoxic regimen that demonstrated clinical 
efficacy.
248
 Therefore the metronomic dosage was calculated to be 6.6 mg/m²/day. 
Reformulation of the drugs was done in collaboration with the Faculty of Pharmaceutical 
Sciences of Ghent University. Concomitant non-steroidal anti-inflammatory drugs (NSAIDs) 
were permitted when necessary for pain relief, no other antineoplastic agents were given 
during the study. As all dogs were in advanced stages of disease and treatment was given in a 
palliative setting, treatment was continued for as long as the patient lived. As this study was 
designed to investigate immunological and angiogenic biomarkers during metronomic 
chemotherapy and not clinical efficacy, no standard follow up of tumor progression was 
included.  
 
Determination of Tregs 
Blood was collected from control dogs and from patients in EDTA tubes one day before 
treatment and 2 and 4 weeks after the start of metronomic chemotherapy. Blood samples 
were analyzed the same day. In detail, peripheral blood mononuclear cells (PBMC) were 
isolated by centrifugation with Ficoll-Paque 1.007 g/ml
 
(GE healthcare Europe, Diegem, 
Belgium). Subsequently, one million PBMC in a volume of 100 µl phosphate buffered saline 
were stained with APC-conjugated anti-dog CD4 and FITC-conjugated anti-dog CD25 
antibodies (eBioscience, USA, San Diego). Surface staining was done at 4 °C for 30 minutes. 
Intracellular staining for FoxP3 was done as described previously, with a cross-reactive 
murine PE-conjugated anti-FoxP3 antibody using the fixation/permeabilization and 
permeabilization buffer provided by the company.
230
 Briefly, cells were washed to remove 
unbound surface antibodies and subsequently resuspended in fixation/permeabilization buffer 
and incubated overnight at 4 °C. The next day, cells were washed twice with 
permeabilization buffer and incubated with the FoxP3 antibody at a concentration of 1 µg per 
1x10
6
 cells for 30 minutes at 4 °C. Fluorescence minus one tubes were analyzed as controls 
to determine thresholds and single staining tubes to perform color compensation. Flow 
cytometric analysis was done with a BD Accuri C6 flow cytometer and Cflow software (BD, 
Erembodegem, Belgium). Analysis was performed on the permeabilized lymphocyte 
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population based on forward and side scatter characteristics. The percentage of Tregs was 
calculated as CD25
+
FoxP3
+
CD4
+ 
cells in the overall CD4
+
 T cell population.  
 
Determination of angiogenic serum markers 
Blood was collected from control dogs and from patients one day before treatment and 2 and 
4 weeks after initiation of metronomic chemotherapy. After centrifugation with Ficoll-Paque 
1.007 mg/ml the plasma fraction was collected and stored at -20 ° C. The concentration of 
angiogenic markers in these plasma fractions was measured with commercial canine VEGF 
and TSP-1 ELISA kits following manufacturer’s instructions (R&D systems, Minneapolis, 
USA; Biotang, Lexington, USA). 
 
Statistical analyses 
Statistical analysis was done with SPSS software (IBM, Belgium, Brussels). Correlations 
were calculated with the Pearson correlation coefficient. Differences in baseline values 
between control dogs and dogs with cancer for Tregs and the angiogenic markers were 
compared with the independent student t-test and the Mann-Whitney U test respectively. 
Differences in baseline values between mesenchymal versus epithelial tumors were also 
investigated, as well as between dogs with and without metastatic disease. Changes in 
percentage Tregs and angiogenic markers during treatment were analyzed with a repeated 
measures ANOVA.  Flow cytometric data are reported as mean ± standard deviation (SD), 
and concentration of VEGF and TSP-1 as median and range (minimum-maximum). 
Significance level was set at alpha = 0.05. 
 
4. Results 
Population characteristics 
Thirty dogs with cancer were enrolled between 2012 and 2014 at the small animal clinic of 
the Faculty of Veterinary Medicine of Ghent University. The patient population consisted of 
10% mongrels and 90% purebred dogs. The mean age and standard deviation of the dogs was 
8.8 ± 2.6 years. Tumor types are listed in table 1. Nineteen dogs (63%) had confirmed 
metastases, of which 3 dogs underwent complete resection of the primary tumor before start 
of treatment (2 hemangiosarcoma patients and 1 renal carcinoma patient). Two patients (1 
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hemangiosarcoma patient and 1 renal carcinoma patient) underwent incomplete resection of 
the primary tumor without gross metastases present at the time of surgery. Ten healthy aged-
matched control dogs (7.6 ± 3.4 years) were also included. 
 
       Table 1: Patient population characteristics 
       CPX TMZ CPX+TMZ 
Breed 
         Purebred 
         Mongrel 
 
8 
2 
 
8 
2 
 
10 
0 
Sex 
         Male 
         Female 
 
5 
5 
 
7 
3 
 
7 
3 
Age (years) 9.0±2.2  8.5±3.1 8.7±2.3  
Tumor types 
         Heart base tumor 
         Round cell tumor 
         Liver carcinoma 
         Soft tissue sarcoma 
         Histiocytic sarcoma 
         Hemangiosarcoma 
         Osteosarcoma 
         Malignant pilomatricoma 
         Unknown  
         Mammary carcinoma 
         Nasal adenocarcinoma 
         Mesothelioma 
         Renal carcinoma 
         Sinus carcinoma 
         Lymphoma 
         Tonsillar carcinoma 
         Thyroid carcinoma 
 
1 
 
 
1 
1 
2 
 
1 
1 
 
 
1 
1 
1 
 
 
 
 
1 
 
1 
2 
1 
 
1 
 
 
1 
1 
 
 
 
 
1 
1 
 
 
1 
1 
1 
 
2 
 
 
 
1 
1 
 
1 
1 
1 
 
 
Metastases 
        Present 
        Absent 
 
6 
4 
 
5 
5 
 
8 
2 
                                         TMZ=temozolomide, CPX=cyclophosphamide 
 
 
Levels of regulatory T cells, VEGF and TSP-1 differ between healthy dogs and dogs with 
cancer  
Regulatory T cells were quantified as the percentage of CD25 and FoxP3 positive T cells in 
CD4 positive PBMC obtained from healthy dogs and dogs with cancer. In dogs with cancer a 
Chapter 2: Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in 
canine cancer patients 
71 
 
significant higher percentage of Tregs was present than in healthy dogs (4.2 ± 2.1% versus 
2.5 ± 0.7%, p<0.001). Although the mean Tregs percentages are significantly different 
between the two groups, it is clear that not all cancer patients had elevated percentages of 
Tregs (Fig. 1). There is no association between the percentage of Tregs and the tumor type 
(epithelial/mesenchymal), the presence of metastases or the use of NSAIDS (data not shown). 
 
 
Fig. 1: The percentages of regulatory T cells in PBMC obtained from dogs with cancer patients (n=30) and 
healthy dogs (n=10). Pluses represent individual dogs, lines represent group mean. 
 
Besides the percentage of Tregs also the plasma concentrations of two angiogenic factors, i.e. 
VEGF and TSP-1, were compared between dogs with cancer and healthy dogs. In dogs with 
cancer the concentration of VEGF was significantly higher than in healthy dogs (Fig. 2; 77 
pg/ml (range: 56-466) versus 61 pg/ml (range: 31-84), p=0.03). TSP-1 concentration was 
significantly lower in cancer patients compared to healthy dogs (Fig. 2, 84 pg/ml (range: 26-
387) versus 475 pg/ml (range: 284-1945), p=0.001). Patients with metastases had 
significantly higher VEGF concentrations than patients without metastases (82 pg/ml (range: 
65-466) versus 71 pg/ml (range: 56-80), p=0.002), whereas for TSP-1 there was no 
significant difference. The concentration of both angiogenic markers did not differ between 
patients with epithelial versus mesenchymal tumors and was not associated with the use of 
NSAIDs.    
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Fig. 2: Boxplots of plasma VEGF and TSP-1 concentrations in healthy dogs (n=10, light gray) and dogs with 
cancer (n=30, dark gray). VEGF=vascular endothelial growth factor; TSP-1=thrombospondin-1. (*p<0.05, 
**p<0.01) 
 
Metronomic cyclophosphamide but not temozolomide decreases regulatory T cells, neither 
influence angiogenic markers 
A significant decrease in CD25
+
Foxp3
+
CD4
+ 
Tregs was noted in patients treated for two 
weeks with metronomic cyclophosphamide (5.2 ± 2.2% versus 3.8 ± 1.7%, p=0.02) and 
metronomic cyclophosphamide plus temozolomide (3.7 ± 2.0% versus 2.8 ± 1.0%, p=0.03) 
(Fig. 3). After four weeks of treatment the percentages of Tregs did not decrease further 
throughout the treatment period, resulting in a similar Treg percentage after four weeks 
compared to two weeks. Treatment with metronomic temozolomide had no effect on the 
percentage of Tregs during the study period (p=0.3). None of the treatment protocols had an 
effect on the percentages of CD4
+
 cells, demonstrating selective toxicity for Tregs. The 
concentration of VEGF and TSP-1 did not change during any treatment protocol (data not 
shown).  
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Fig. 3: Effect of the different metronomic chemotherapy protocols on the percentage of regulatory T cells 
(Tregs) in dogs with cancer. The Tregs were measured one day before the start of the metronomic chemotherapy 
(baseline) and respectively 2 and 4 weeks after metronomic chemotherapy. Data are represented as means and 
error bars represent standard errors. CPX=dogs that received metronomic cyclophosphamide (n=10); 
TMZ=dogs that received metronomic temozolomide (n=10); CPX+TMZ=dogs that received simultaneously 
metronomic cyclophosphamide and temozolomide (n =10). (*p<0.05) 
 
Evaluation of CD25 expression in CD4
+
FoxP3
+
 cells 
Because an anti-canine CD25 antibody was not available in the past, previous studies in dogs 
have characterized Tregs solely based on CD4 and FoxP3 expression.
156,229-233,249
 To relate 
our findings to these studies, the relationship between CD4
+
FoxP3
+
 cells and CD25 
expression was investigated. True Tregs (defined as CD25
+
FoxP3
+
CD4
+
cells) were on 
average only 31% of FoxP3
+
CD4
+
cells (Fig. 4A). However, if the proportion of CD25 
negative FoxP3
+
 CD4
+
 cells is relatively stable compared to the CD25
+
 fraction, changes in 
FoxP3
+
 CD4
+
 cells can still primarily reflect changes in the CD25
+
 fraction. To investigate 
this, the correlation between measurements with and without the CD25 marker was 
calculated. The correlation coefficient between the percentage of FoxP3
+
CD4
+
 cells and 
CD25 positive FoxP3
+
CD4
+
 cells was 0.61 (p<0.001), corresponding with a coefficient of 
determination (R
2
) of 0.37 (Fig. 4C). This means that only 37% of the variation in 
FoxP3
+
CD4
+
 cells is explained by variation in CD25 positive FoxP3
+
CD4
+
 cells, while 88% 
is explained by variation in CD25 negative FoxP3
+
CD4
+
 (correlation coefficient of 0.94, 
p<0.001, Fig. 4B). The percentages of CD25
-
FoxP3
+
CD4
+
 cells were also compared between 
healthy dogs and dogs with cancer (Fig. 4D). Interestingly, a significant difference in CD25
-
FoxP3
+
CD4
+
 was found between healthy dogs and dogs with cancer (p=0.01). However, 
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CD25
-
FoxP3
+
CD4
+
 cells were not influenced by our metronomic cyclophosphamide regimen 
(data not shown). 
 
 
Fig 4: Expression of CD25 in FoxP3
+
CD4
+
 lymphocytes. (A) CD25
+
 cells are only a minority of the 
FoxP3
+
CD4
+
 cells; (B) and (C) FoxP3
+
CD4
+ 
variation is mostly explained by variation in CD25
- 
cells, and not 
CD25
+
 cells; (D) CD25
-
FoxP3
+
CD4
+
 cells differ significantly between healthy control dogs (n=10) and dogs 
with cancer (n=30). Bars represent mean and error bars standard errors. (*p<0.05)  
 
5. Discussion 
This study confirmed for the first time with an anti-canine CD25 antibody a significant 
difference in the percentage of CD25
+
Foxp3
+
CD4
+
Tregs in the peripheral blood of canine 
cancer patients compared to healthy dogs. Although mean Treg percentages were 
significantly higher in dogs with cancer compared to the healthy dogs, considerable variation 
exists in cancer patients with a proportion of patients having Tregs percentages similar as 
those of healthy dogs. This might seem unexpected in a population of dogs with advanced 
disease, as it is accepted that a tumor has to induce immune tolerance for progression and 
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inducing Tregs is a major way to accomplish this. However, there are several possible 
explanations for this. Firstly, local proliferation or selective migration can cause elevated 
intratumoral Tregs concentration without elevated circulating Tregs.
229
 Moreover, not only 
the number of Tregs, but also their functionality may be increased in cancer patients.
250
 
Lastly, tumors have a vast repertoire of escaping immunity outside Tregs, so it is possible 
that individual tumors accomplish the same goal in different ways, a feature characteristic for 
many tumor traits. Some examples include tumor antigen loss, downregulation of MHC 
molecules and resistance to cytotoxic pathways.
5
 In contrast with previous studies that did 
not use the anti-CD25 antibody, we could not discover an association between the percentage 
of Tregs and the tumor type nor the presence of metastasis.
232,233
 Limited patient numbers in 
the referenced studies as well as in the current study may explain this discrepancy.  
 
Metronomic cyclophosphamide at 12.5 mg/m² decreased the percentage of these Tregs in 
cancer patients. This is in agreement with previous studies in human patients.
220
 Although 
Burton et al. could not detect a significant difference in the percentage of FoxP3
+
CD4
+
 cells 
after treatment with 12.5 mg/m
2
 in dogs with cancer, the authors stated that that was probably 
due to insufficient power, as absolute number of these cells were decreased and only five 
dogs were included.
156
 As Tregs are considered the main obstacle for successful immune 
therapy, our metronomic cyclophosphamide regimen can thus be an adequate supportive 
treatment for immunotherapy in dogs.
151
 Metronomic temozolomide at 6.6 mg/m² had no 
effect on the percentage of Tregs. This may be explained by the dosage, as only one dose 
based on extrapolation of an experiment on rats was evaluated.
222
 In that experiment, 
depletion was already evident after one week. A recent study in human cancer patients also 
reports a decrease in percentage Tregs as soon as one week after treatment with low dose 
temozolomide.
221
 However, in this study of Ridolfi et al. the dose (75 mg/m
2
) was only 2.5 
times lower than the conventional cytotoxic dose and only given for two weeks. Therefore, 
this study did not use a truly metronomic regimen. Consequently, grade II adverse effects 
occurred frequently and dosage had to be reduced in some patients. From preclinical studies 
for the approval of temozolomide for human use, it is evident that dogs are more sensitive for 
this drug, with human therapeutic doses of 200 mg/m
2
 within the lethal range for dogs.
251
 
Nevertheless, since our dose was much lower than the one reported in the human study, a 
dose escalation study in dogs for metronomic temozolomide might identify a dose with 
selective toxicity to Tregs.   
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Baseline plasma VEGF levels were significantly higher in cancer patients than in healthy 
control dogs. Moreover, baseline plasma VEGF levels were also higher in cancer patients 
when metastases were present. This corresponds with previous findings in human and canine 
patients.
252-255
 The TSP-1 concentration in dogs with cancer was markedly lower than in 
healthy dogs. This has also been reported in human cancer patients.
256
 To our knowledge, this 
is the first time that plasma TSP-1 concentrations have been measured in canine cancer 
patients. The distinct difference observed in this study warrants further investigation of the 
use of TSP-1 as a tumor marker. It would be interesting to evaluate if TSP-1 measurements 
could aid in early detection of disease. As all patients in this study had advanced stages of 
disease, this could not be evaluated. An additional control group consisting of dogs with 
various other diseases could provide more information about the specificity of this potential 
marker. Despite the pathological levels of TSP-1 and VEGF at baseline, no difference after 
treatment with metronomic cyclophosphamide and/or temozolomide could be observed. This 
is in agreement with Burton et al., who also failed to detect an effect on tumor microvessel 
density after treatment with cyclophosphamide at 12.5 mg/m
2
.
156
 Immune modulating effects 
occur indeed at lower dosages of metronomic chemotherapy than anti-angiogenic effects.
219
 
The efficiency of metronomic chemotherapy is mainly dependent on anti-angiogenic 
activity.
240
 The determination of metronomic dosage in veterinary, but also human medicine, 
has been empirical so far.
257
 For cyclophosphamide, doses between 10 and 25 mg/m
2
 for 
dogs are reported, with no evidence based rationale to select an optimal dose at this 
moment.
152-155,157
 This can be partly explained by the vast number of patients required to 
conduct a comparative study based on clinical efficacy.
258
 For different chemotherapeutic 
agents, it has been proven that their metronomic mode of action involves modulation of 
secretion of VEGF and TSP-1 and it has been demonstrated that the concentration of these 
factors in the circulation can be affected by metronomic chemotherapy in human 
patients.
238,241-244,246
 Therefore, these factors can be valuable pharmacodynamic markers for 
dose optimization studies. This study demonstrates that circulating concentrations of these 
markers are different for dogs with cancer compared to healthy dogs, providing a window to 
show therapeutic modulation. Evaluation of these biomarkers in canine cancer patients 
treated with higher doses of metronomic chemotherapy would thus be highly interesting.  
 
Cyclophosphamide currently is the drug of choice for metronomic treatment in veterinary as 
well as in human medicine.
257
 Although low doses of cyclophosphamide are considered safe, 
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sterile hemorrhagic cystitis, a common side effect in patients that receive high doses of this 
drug, has also been observed in about 10% of canine patients that received metronomic 
cyclophosphamide for long periods.
152,153
 Also in our study, one dog developed 
cyclophosphamide induced cystitis, with other causes ruled out by urinalysis, urine culture 
and ultrasound. Considering the relative high frequency of this side effect, alternatives for 
metronomic cyclophosphamide should be evaluated in veterinary oncology. Therefore, in this 
study, we studied for the first time metronomic temozolomide (6.6 mg/m
2
 daily) in dogs with 
cancer. However, since no biological effect of temozolomide could be demonstrated, 
additional studies with higher doses are advocated. 
 
Most of previous studies investigating Tregs in dogs used only CD4 and FoxP3 for Treg 
identification.
156,157,230-233,249
 In four studies an anti-human CD25 antibody is used, which 
cross reacts with canine CD25 but with too low affinity to ensure sufficient 
sensitivity.
236,237,259,260
 To our knowledge, this is the first study analyzing Tregs with the anti-
canine CD25 antibody, developed by Abrams and coworkers, in dogs with cancer.
235
 It has 
already been established that in healthy dogs a significant proportion of non-regulatory CD25 
negative FoxP3
+
CD4
+
cells exists and thus that the proportion of FoxP3
+
CD4
+
cells is an 
overestimation of the proportion of true Tregs.
237
 This is confirmed by our data in cancer 
patients. FoxP3
+
CD4
+
 T cells without suppressive capacity have been identified earlier, in 
humans as well as in dogs.
259,261
 It has been reported that these CD25 negative cells constitute 
a peripheral inactive reservoir, capable of converting to fully functional CD25
+
 Tregs. CD25 
expression is thus an activation marker for Tregs, similar as for conventional CD4 cells.
262
 To 
our knowledge, this is the first time that in addition to increased CD25
+
FoxP3
+
CD4
+
, 
increased CD25
-
FoxP3
+
CD4
+
 cells are reported in cancer patients. In other physiological and 
pathological conditions, also a parallel increase in CD25
+
 and CD25
-
 FoxP3
+
CD4
+
 is 
reported.
263,264
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Immunogenicity and safety of xenogeneic vascular 
endothelial growth factor receptor-2 DNA vaccination in 
mice and dogs 
 
 
 
 
 
This chapter is based on Denies S., Cicchelero L., Polis I., Sanders N.N. Immunogenicity and 
safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice 
and dogs. Under revision by Oncotarget. 
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1. Abstract 
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an attractive target in the 
treatment of cancer due to its crucial role in angiogenesis. In this study a DNA vaccine 
coding for human VEGFR-2 was evaluated in healthy mice and dogs as a xenogeneic 
vaccination approach. In mice, three doses (5, 15 and 25 µg) and vaccination schedules 
(prime, prime-boost, prime-boost-boost) were evaluated. The vaccine was administered by 
intradermal injection followed by electroporation under general anesthesia. Cellular immune 
responses were measured by intracellular staining of interferon-gamma (IFN-gamma) and a 
cytotoxicity assay. Serum antibodies were determined by ELISA. Safety was assessed by 
measuring regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) and by 
performing a wound healing assay. The VEFGR-2 DNA vaccine was subsequently evaluated 
in healthy dogs, which were vaccinated three times with 100 µg with a two week interval. 
The vaccine was administered by intradermal injection followed by electroporation under 
sedation and local anesthesia. Cellular immune responses in dogs were measured by 
intracellular IFN-gamma staining and antibodies by a flow cytometric assay. In mice, 
maximal cellular immune responses were already observed after two vaccinations with 5 µg. 
Humoral immune responses continued to increase with higher dose and number of 
vaccinations. No abnormities in the levels of Tregs, MDSCs or wound healing were 
observed. In dogs, the vaccine was also capable of eliciting a cellular and humoral immune 
response, but only after three vaccinations. No adverse effects were observed, but tolerability 
of the electroporation protocol in dogs was poor with sedation and local anesthesia. As the 
immunogenicity and safety of this xenogeneic VEGFR-2 DNA vaccine is demonstrated in 
dogs and mice, this will facilitate its evaluation in tumor bearing animals, ranging from 
preliminary rodent models to dogs with spontaneous tumors. 
 
2. Introduction 
It is well-known that the immune system is capable to recognize tumor cells and to establish 
a specific long-term antitumor response. Therefore, vaccination against tumor antigens holds 
great promises for the treatment of cancer.
5
 However, due to complex interactions between 
tumor cells and the immune system and the problem of tolerance, the translation of the 
theoretical potential of tumor vaccines into an effective clinical response has been difficult.
265
  
Chapter 3:  
Immunogenicity and safety of xenogeneic VEGFR-2 DNA vaccination in mice and dogs. 
 
82 
 
In healthy individuals, VEGFR-2 is expressed on virtually all endothelial cells as well as on 
certain other cell types including retinal progenitor cells, megakaryocytes and pancreatic duct 
cells. In cancer patients, VEGFR-2 is strongly overexpressed on endothelial cells.
266
 VEGFR-
2 can thus be classified as a ubiquitous tumor antigen. The potential of raising an effective 
immune response against these tumor antigens without causing autoimmunity can be 
explained by the level of overexpression in tumors, reaching the threshold for T cell 
recognition and thus breaking immune tolerance.
27
 As it is difficult to raise a strong immune 
response against self-antigens, xenogeneic vaccination, which involves the use of an antigen 
of a different species, has been proven to result in more potent immune responses.
267
 
 
VEGFR-2 as vaccine target has some important advantages. Tumor cells have grown under 
the selective pressure of the immune system. Evading immune control is one of the hallmarks 
of tumors, with down regulation of MHC-1 molecules and evasion of cytotoxic effects of 
immune cells as two common examples.
5
 These immune evasive strategies acquired during 
tumor growth make tumor cells difficult targets for vaccine strategies. Moreover, because of 
their genetic instability, tumor antigens in tumor cells are prone to mutations, which leads to 
escape mutants that further decrease the efficacy of tumor vaccines.
5
 In contrast, endothelial 
cells of tumoral blood vessels have not acquired immune evasive strategies and are 
genetically stable.
268
 They are thus more vulnerable to vaccination strategies. Targeting 
tumor vasculature instead of tumor cells directly has proven its value, for instance by the 
success of bevacizumab.
266
 
 
Although targeting VEGFR-2 is primarily an anti-angiogenic treatment, certain tumors also 
express VEGFR-2, serving as an autocrine growth factor for these cells.
269
 In these tumor 
types VEGFR-2 vaccination can also induce a direct antitumor effect. Moreover, VEGFR-2 
is expressed on Tregs and MDSCs.
270,271
 Targeting these cells via VEGFR-2 vaccination can 
have a self-reinforcing effect, as these cells suppress anti-tumor immune responses.
5
  
 
VEGF/VEGFR-2 targeting has been explored extensively with different treatment modalities, 
with some of them approved for clinical use.
268
 In preclinical studies vaccination against 
VEGFR-2 has also been explored.
272
 Vaccination has some important advantages. It is more 
specific than small molecule inhibitors and compared to monoclonal antibodies the 
polyclonal antibody response evoked by vaccination may have a higher antigen neutralizing 
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capacity. Both monoclonal antibodies and small molecule inhibitors have to be administered 
frequently, which makes vaccination a much more cost efficient and patient friendly 
therapy.
268
 Different vaccine platforms exist. DNA vaccination has the advantage that the 
antigen is synthetized intracellularly, leading to a robust cellular immune response.
273
 
Moreover, DNA vaccines often make use of plasmids that contain immune stimulating 
unmethylated CpG motives.
274
 Electroporation mediated delivery of DNA vaccines can 
further support the development of an immune response because the limited tissue damage 
caused by electroporation also serves as an adjuvant.
275
 Delivery of DNA vaccines via 
electroporation has also the advantage that the vaccine manufacture is more economical, 
uniform and suitable for large scale production than when viral or chemical carriers are used 
for the delivery.
276,277
  
 
In this study we evaluated in healthy mice and dogs the safety and immunogenicity of a 
xenogeneic VEGFR-2 DNA vaccine. The DNA vaccine was administered as a naked plasmid 
in combination with needle array electroporation.  
 
3. Materials and Methods 
Tumor cell lines and VEGFR-2 plasmid 
The B16-F10 tumor cell line was generously provided by Johan Grooten (Department of 
Biomedical Molecular Biology, Ghent University, Belgium) and was stably transduced with 
luciferase as described earlier.
278
 Briefly, retroviral vectors encoding luciferase were 
produced in HEK293T cells by calcium phosphate transfection. Virions were harvested after 
48 and 72h, filtered and concentrated by ultracentrifugation. Transduction the B16-F10 cells 
was performed in the presence of 8 µg/ml polybrene and transfection efficiency was 
evaluated by bioluminescence. The canine hemangiosarcoma (HSA) cell line was generously 
provided by Douglas Thamm (College of Veterinary Medicine and Biomedical Sciences, 
Colorado State University, USA). These cells were grown in Dulbecco’s modified Eagle’s 
medium, supplemented with 10% fetal calf serum, 100 mg/ml streptomycin, 100 IU/ml 
penicillin and 1 mmol/ml L-glutamine (Invitrogen, Carlsbad, USA). The plasmid encoding 
human VEGFR-2 was purchased from Invivogen (Toulouse, France). A full description of 
the plasmid can be found on the website of the manufacturer.
279
Purification of the plasmids 
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was done with the EndoFree Giga kit, following the instructions of the manufacturer (Qiagen, 
Valencia, CA, USA).  
DNA vaccine doses and vaccination schedules in mice 
Healthy C57BL/6JRj mice of 8 weeks old were used for this optimization study (Janvier 
Breeding Center, Le Genest St. Isle, France). Three doses (5 µg, 15 µg and 25 µg) and three 
vaccination schedules (prime, prime-boost, prime-boost-boost) were evaluated with 4 mice 
for each condition (Fig. 1). A group of untreated mice served as control (n=4). The VEGFR-2 
plasmid was injected intradermally in 20 µl calcium and magnesium free phosphate buffered 
saline (PBS; Invitrogen) followed by electroporation with the BTX Agilepulse device 
(Harvard apparatus, Holliston, USA) using 4 mm gap needle electrodes. The following 
electroporation protocol was used: 2 pulses of 450 V with a pulse duration of 0.05 ms and a 
300 ms interval, followed by 8 pulses of 100 V with a pulse duration of 10 ms and a 300 ms 
interval. Mice were anesthetized with isoflurane (2%) during this procedure. The interval 
between the vaccinations was 2 weeks and mice were euthanized 2 weeks after the last 
vaccination. This experiment was approved by the ethical committee of the Faculty of 
Veterinary Medicine (Ghent University; EC2013/77) 2013_40 
 
Figure 1: Vaccination schedule in mice. Mice were vaccinated with two weeks interval, two weeks after each 
vaccination four mice were sacrificed to measure cellular and humoral immune response. This vaccination 
schedule was used to evaluate three different doses of the VEGFR-2 DNA vaccine (5, 15 and 25 µg). 
 
Assessing cellular immune response in vaccinated mice 
Splenocytes were isolated two weeks after the last vaccination. To assess the cytotoxic 
response to cells expressing the target, splenocytes were co-incubated with bioluminescent 
B16-F10 melanoma cells that were in vitro electroporated with a plasmid encoding human 
VEGFR-2. Electroporation was performed in 2mm cuvettes with the BTX ECM 830 device 
(Harvard apparatus, Holliston, USA). Two pulses of 140 V with a pulse duration of 5 ms and 
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100 ms interval were used. As a control for specificity to the VEGFR-2 target, B16-F10 
melanoma cells that were mock electroporated were also included. Absence of natural 
VEGFR-2 expression on the B16-F10 cells and induction of expression after electroporation 
were assessed by flow cytometry with a rabbit antibody that binds mouse VEGFR-2 and an 
Alexafluor-688 conjugated secondary goat anti-rabbit antibody (Abcam, Cambrige, UK). To 
measure the tumor killing capacity of lymphocytes from vaccinated and non-vaccinated mice 
we incubated 2x10
5
 splenocytes with 1x10
4
 B16-F10 cells. After 24 hours the bioluminescent 
signal, which is related to the number of living cells, was measured with an IVIS lumina II 
(Perkin-Elmer, Zaventem, Belgium). 
 
Additionally, the IFN-gamma response was also measured. In more detail, 1x10
6
 splenocytes 
were stimulated overnight with 2 µg of murine VEGFR-2 protein (Bio-Connect, Te Huissen, 
The Netherlands). Subsequently, the protein transport inhibitor brefeldin A was added and 
after 4 hours the cells were incubated overnight in fixation buffer (ImTec Diagnostics, 
Antwerp, Belgium). The following day the cells were permeabilized and the intracellular 
staining of IFN-gamma was performed with an APC-conjugated anti-IFN-gamma antibody 
(Imtec Diagnostics). The cells were analyzed with an Accuri C6 flow cytometer (BD 
Biosciences, Erembodegem, Belgium) and events in the permeabilized lymphocyte gate were 
selected for analysis. Controls for specificity of the cytokine response were assessed by 
including non-stimulated splenocytes in the analysis.  
 
Assessment humoral immune response in vaccinated mice 
Blood was collected 2 weeks after the last vaccination of each vaccination schedule by 
cardiac puncture under terminal anesthesia. Blood was centrifuged (10 min, 3000 g, 
Eppendorf centrifuge) and serum was collected and stored at -80 °C until analysis. Microtiter 
plates were coated overnight with 1 µg murine VEGFR-2 protein in coating buffer and 
loaded with serial dilutions of serum in ELISA assay diluent for 2 hours (Imtec Diagnostics). 
After washing, a HRP-conjugated anti-mouse IgG antibody was added, followed by 
development with TMB substrate and measuring absorbance with a microplate reader at 
450nm (ImTec Diagnostics). The titer was determined as the limiting dilution with a signal 
exceeding mean plus twice the standard deviation of the signal from control samples (non-
vaccinated mice).  
 
Chapter 3:  
Immunogenicity and safety of xenogeneic VEGFR-2 DNA vaccination in mice and dogs. 
 
86 
 
Assessment of Tregs and MDSCs levels  
As VEGFR-2 expression is reported on Tregs and MDSCs, the effect of vaccination on 
normal levels of these cells was assessed as a measure of safety. Splenocytes were isolated 
when mice were sacrificed and the percentage of Tregs and MDSCs were measured by flow 
cytometry. Regulatory T cells were stained with a FITC-conjugated anti-CD25 antibody, an 
APC-conjugated CD4 antibody and a PE-conjugated anti-FoxP3 antibody after fixation and 
permeabilization with commercial buffers (Ebioscience, Vienna, Austria). MDSCs were 
stained with a FITC-conjugated anti-CD11b antibody and a PE-conjugated anti-Gr1 antibody 
(Ebioscience). The cells were analyzed with an Accuri C6 flow cytometer and events in the 
lymphocyte gate were selected for analysis. Color compensation was based on fluorescence 
minus one (FMO) controls.  
 
Assessment of wound healing in vaccinated mice 
To further assess safety of VEGFR-2 vaccination, a wound healing assay was performed. 
Two circular full-thickness dermal wounds were created between the shoulder blades with a 2 
mm punch biopter one week after the last vaccination. These wounds were allowed to heal 
spontaneously and the days until macroscopic closure of the wound were determined, as 
described earlier.
280
  
 
Vaccination of dogs 
Six laboratory Beagle dogs were vaccinated three times with 100 µg of human VEGFR-2 
plasmid dissolved in 100 µl magnesium and calcium free PBS. The vaccine was injected 
intradermally on the flank followed by electroporation with the BTX Agilepulse device. 
Following electroporation protocol was used: 2 pulses of 450 V with a pulse duration of 0.05 
ms and a 0.2 ms interval, followed by 8 pulses of 100 V with a pulse duration of 10 ms and a 
20 ms interval using 4 mm gap needle electrodes. Dogs were sedated by intravenous injection 
of 0.2mg/kg butorphanol (Dolorex, Intervet, Boxmeer, Nederland). Local anesthesia was 
obtained by subcutaneous injection of 0.5 ml of lidocaïne 2% (Xylocaïne, Recipharm Monts, 
Monts, France) around the vaccination site. This experiment was approved by the ethical 
committee of the Faculty of Veterinary Medicine (Ghent University; EC2013/40). 
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Assessment of cellular immune response in vaccinated dogs 
Blood was collected before each vaccination and two weeks after each vaccination. Blood 
was collected in EDTA tubes and peripheral blood mononuclear cells (PBMC) were isolated 
by centrifugation with Ficoll-Paque 1.007 g/ml (Invitrogen). The canine HSA cell line was 
used to assess a cytotoxic response against VEGFR-2 expressing cells. Expression of 
VEGFR-2 by these cells was confirmed with an anti-VEGFR-2 antibody and a secondary 
Alexa fluor 688-conjugated goat anti-rabbit antibody (both from Abcam). Subsequently, the 
canine HSA cells were in vitro transfected with eGFP via electroporation with the BTX 
device. A cytotoxicity assay was performed by incubating 2x10
5
 PBMC with 1x10
4
 eGFP 
transfected HSA cells and 24 hours later the number of eGFP expressing cells was analyzed 
by flow cytometry as a measure of PBMC mediated killing of VEGFR-2 positive cells. 
PBMC obtained before vaccination served as controls. 
 
Additionally, the IFN-gamma response was measured after overnight incubation of 1x10
6
 
PBMC with 2 µg human VEGFR-2 protein, as a recombinant canine VEGFR-2 protein is not 
available (Acro Biosystems, London, UK). Subsequently, brefeldin A was added followed 
after 4 hours by overnight incubation in fixation buffer (Ebioscience).The next day, PBMC 
were stained with a FITC-conjugated anti-IFN-gamma antibody after permeabilization with a 
commercial buffer (Life Technologies, Ghent, Belgium). The cells were analyzed with an 
Accuri C6 flow cytometer and events in the permeabilized lymphocyte gate were selected for 
analysis. Controls for specificity of the cytokine response were assessed by including non-
stimulated PBMC in the analysis. 
 
Assessment of the humoral immune response in vaccinated dogs 
Plasma was collected two weeks after each vaccination. HSA tumor cells were washed and 
resuspended in 50 µl of diluted plasma (1/8 dilution in FACS buffer, Imtec Diagnostics). 
Cells were incubated for one hour at 37 °C and 5% CO2. Subsequently the cells were washed 
and stained with APC-conjugated anti-dog IgG antibodies (Imtec Diagnostics) and the 
number of positive cells was analyzed via flow cytometry. Control for specificity of staining 
included HSA cells that were not incubated with plasma and stained with the secondary 
antibodies. 
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Assessment of tolerability and safety of the vaccination in dogs 
As this is the first time that the Agilepulse was used for electroporation of dogs, an important 
outcome measurement was also the tolerability to the electroporation. Acute stress and pain 
signals during the electroporation as well as the aspect and sensitivity of the vaccination site 
the days after electroporation were monitored. A thorough physical examination including 
Doppler blood pressure monitoring was performed the week after each vaccination to assess 
safety of the vaccine.  
 
Statistical analyses 
Data were analyzed with the SPSS software version 19 (IBM, Brussels, Belgium). The effect 
of DNA vaccine dose and vaccination schedule on the cytotoxicity and IFN-gamma secretion 
of murine splenocytes were analyzed with a general linear model. The effect of DNA vaccine 
dose and vaccination schedule on antibody titers in serum of mice were analyzed with an 
exact linear by linear association test. The effect of vaccination on IFN-gamma secretion of 
canine PBMC was analyzed with a repeated measures ANOVA. The effect of vaccination on 
antibody bound HSA cells were analyzed with the non-parametric Friedman test. For post 
hoc tests, correction for multiple comparisons was performed with the Tukey method. Data 
are represented as mean ± standard deviation, unless otherwise specified.  
 
4. Results 
Effect of vaccine dose and vaccination schedule on the immune response in mice   
Cellular immune response in mice  
To study the influence of the VEGFR-2 DNA dose and vaccination schedule on the induction 
of tumor antigen specific cytotoxic T lymphocytes, we incubated splenocytes with tumor 
cells expressing human VEGFR-2 at an effector:target ratio of 20:1. Splenocytes from 
vaccinated mice demonstrated significant higher cytotoxicity than those from control mice 
(p=0.015) without a significant effect of the DNA vaccine dose (Fig. 2). When we tested the 
effect of the different vaccination schedules on the cytotoxic T-lymphocytes we found that 
one boost is superior to none (p=0.002). Overall, there was no significant difference between 
three and two vaccinations, although for 5 µg a trend towards better response after three 
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vaccinations is visible. After co-incubation with splenocytes from mice vaccinated at least 
two times there were on average 52 ± 14% surviving target cells, compared to 89 ± 13% 
when co-incubated with splenocytes from non-vaccinated mice.   
 
Fig. 2: Cytotoxic activity of splenocytes isolated from non-vaccinated and vaccinated mice that received one 
(prime), two (prime + boost), or three (prime + boost + boost) VEGFR-2 DNA vaccinations. Three different 
DNA vaccine doses (5, 15 or 25 µg) were tested. Two weeks after the last vaccination splenocytes were 
collected and their capacity to lyse VEGFR-2 expressing target cells was measured. Control indicates non-
vaccinated mice. Bars represent mean, error bars standard error of the mean (n=4). 
 
Analysis of IFN-gamma secretion led to the same conclusions (Fig. 3). After overnight 
incubation with a murine VEGFR-2 protein there were on average 14 ± 5% IFN-gamma 
positive lymphocytes in the splenocytes of mice that received at least two vaccinations, 
compared to 1 ± 1% in splenocytes from non-vaccinated mice. 
 
                                         Table 1: Effect of dose and schedule on antibody titers 
 Prime Prime + boost Prime + boost + boost 
5 µg <4 <4 <4 
15 µg <4 4 100 
25 µg <4 400 800 
All four mice within each group had the same antibody titer. 
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Humoral immune response in mice  
The impact of the VEGFR-2 DNA dose and vaccination schedule on the induction of 
antibodies is summarized in table 1. Both DNA vaccine dose and vaccination schedule had a 
significant impact on antibody titer (p<0.001 and p=0.003 respectively). Antibody responses 
were undetectable in mice vaccinated with the lowest dose (5 µg) and for all doses after only 
one vaccination. The highest antibody titers were present in serum from mice vaccinated 
three times with 25 µg, reaching an antibody titer of 800 in this group.  
 
 
Fig. 3: Interferon-gamma response of splenocytes isolated from non-vaccinated and vaccinated mice that 
received one (prime), two (prime + boost), or three (prime + boost + boost) VEGFR-2 DNA vaccinations. Three 
different DNA vaccine doses (5, 15 or 25 µg) were tested. Two weeks after the last vaccination splenocytes 
were collected and stimulated with murine VEGFR-2 protein. Following stimulation the percentage of IFN-
gamma positive splenocytes was measured by flow cytometry after intracellular cytokine staining. Control 
indicates non-vaccinated mice.  Bars represent mean, error bars standard error of the mean (n=4). 
 
Safety in mice 
Vaccination with DNA encoding human VEGFR-2 had no effect on normal levels of Tregs 
(2.38 ± 0.49 in non-vaccinated mice versus 2.57 ± 0.51% in vaccinated mice) or MDSCs in 
the spleen of healthy mice (1.68 ± 0.35% in non-vaccinated mice versus 1.70 ± 0.32% in 
vaccinated mice). There was also no effect on the mean time until wound closure (5 ± 1 days 
for both vaccinated and non-vaccinated mice).  
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Immunogenicity in dogs 
Cellular immune response in dogs  
Before the start of the vaccination and two weeks after each vaccination PBMC were 
collected from the dogs and stimulated with human VEGFR-2. Subsequently, the percentage 
of IFN-gamma positive PMBC was measured by flow cytometry after intracellular staining. 
After the first and second vaccination we could not detect a significant IFN-gamma response 
compared to baseline (data not shown). However, after the third vaccination (i.e. second 
boost) the percentage of IFN-gamma positive lymphocytes were significantly increased with 
an average of 9 ± 0.05% of IFN-gamma positive lymphocytes compared to 4 ± 0.02% at 
baseline (p=0.04) (Fig. 4).   
 
 
Fig. 4: Interferon-gamma response of lymphocytes isolated from dogs before vaccination and after a second 
boost with the VEGFR-2 DNA vaccine. Two weeks after the second boost lymphocytes were collected and 
stimulated with human VEGFR-2. Following stimulating the percentage of IFN-gamma positive lymphocytes 
was measured by flow cytometry after intracellular cytokine staining. Bars represent mean, error bars standard 
error of the mean. (*p<0.05) 
 
We also tried to measure the cytotoxic T cell response after VEGFR-2 DNA vaccination of 
dogs by co-incubating PBMC with a canine HSA cell line. However, at baseline (i.e. before 
vaccination) there was already a considerable cytotoxic response of isolated PBMC towards 
the canine HSA cell line, with only 26 ± 9% HSA cells surviving the co-incubation. No 
increase in this cytotoxic response was observed after the last vaccination (data not shown). 
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This demonstrates that the allogeneic nature of the target cells already triggered a significant 
cytotoxic response from naïve PBMC, as previously reported for human PBMC.
281
 It is 
hypothesized that this response is already at maximal capacity at baseline explaining no 
increase after vaccination. 
 
Humoral Immune response in dogs 
In vaccinated dogs antibody levels against VEGFR-2 had significantly increased (relative to 
baseline levels) after the third vaccination (p=0.03). When looking at individual dogs, four 
out of six dogs had a clear increase in antibodies after the second boost (Fig. 5).  
 
 
Fig. 5: (A) Flow cytometric plots illustrating the evaluation of antibody response by the amount of 
VEGFR-2 expressing target cells bound with antibodies present in serum via a secondary anti-dog 
IgG antibody (upper: at baseline, lower: after the last vaccination of the same dog).( B): time course 
of the antibody response for individual dogs, arrows indicate vaccination moments and each colored 
line represents an individual dog. HSA=hemangiosarcoma. 
 
Tolerability in dogs 
The delivery of the very short electric pulses caused in all dogs a startle response 
characterized by withdraw movements, vocalization and stress-induced anal sac excretion. 
This only occurred during electroporation, which lasted less than one second. Immediately 
after electroporation, dogs exhibited normal behavior and no reaction when manipulating the 
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electroporation site could be elicited. With the Agilepulse device, actual resistance of the 
tissue during electroporation is measured and saved. Hence it could be checked whether the 
electrodes remained in place during the withdraw movements. Based on these resistance data 
we could conclude that the withdraw movements did not affect any of the electroporations. 
This is most likely because the total duration of pulses is less than a second. Twenty-four 
hours after electroporation, the electroporation site was red and swollen, which evolved over 
two weeks to an epidermal crust. All physical parameters (heart rate, respiration rate, 
temperature, blood pressure) remained stable during the vaccination period.  
 
5. Discussion 
This study demonstrates that a human VEGFR-2 DNA vaccine, administered in combination 
with electroporation, is capable of inducing a cellular and humoral immune response in mice 
and dogs. The dose escalation study in mice demonstrated that it was easier to elicit a cellular 
immune response than a humoral immune response. This is in agreement with other studies 
with DNA vaccines and can be explained by the limited amounts of proteins released after 
DNA vaccination, which is insufficient for a robust antibody response.
282
 A very small 
amount of antigen when presented within an antigen presenting cell, either directly by 
transfection or indirectly via cross-presentation, is sufficient to prime strong cytotoxic T cell 
responses.
282
 In our mice study a cellular immune response was already observed after prime-
boost vaccination with 5 µg pDNA, while higher DNA vaccine doses and at least two 
vaccinations were needed to elicit a humoral immune response. VEGFR-2 is a 
transmembrane protein, and thus accessible for both arms of the immune system.
266
 Indeed, it 
has been reported that both a humoral and a cellular response against VEGFR-2 can convey 
anti-tumor effects.
283
 Further evaluation of the efficacy of our VEGFR-2 DNA vaccine in 
tumor bearing mice should thus be done with at least 25 µg and three vaccinations. 
Vaccination against VEGFR-2 did not affect wound healing or normal levels of Tregs or 
MDSCs in healthy mice, two important factors that could warn for side-effects impeding 
clinical use. Both Tregs and MDSCs significantly upregulate their VEGFR-2 expression in 
response to tumor secreted cytokines.
270,271
 It is thus possible that in tumor bearing hosts, 
VEGFR-2 vaccination has a differential effect on the percentage of Tregs and MDSCs 
compared to healthy individuals.  
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Dose extrapolation of DNA vaccines from mice to humans or other animals is difficult. A 
linear extrapolation based on body weight is often used to calculate the dose in other species. 
From such calculations it is frequently concluded that the doses are too high to be feasible in 
humans. However, this reasoning is not correct. Firstly, correct allometric translation of drug 
doses should be done based on body surface area, which results in drug doses 0.08 times less 
than when based on simple conversion based on body weight.
284
 Secondly, allometric scaling 
of vaccine doses is not relevant, as this is based on pharmacokinetic characteristics that do 
not influence the interactions between antigen and immune cells after local injection.
285
 Many 
other species specific factors do influence vaccine efficiency, that are too complex to allow 
for a scaling formula. Therefore, the DNA vaccine dose for dogs in this study (100 µg) was 
not based on a conversion from the results in mice, but on studies that tested xenogeneic anti-
cancer DNA vaccines in dogs delivered with electroporation.
56,286
 The xenogeneic VEGFR-2 
DNA vaccine was successful in inducing a cellular and humoral immune response in dogs. A 
cellular immune response was evident by interferon-gamma secretion after incubation with 
human VEGFR-2 protein. The immune response against human VEGFR-2 required more 
boosts in dogs compared to mice, with a clear response only after three vaccinations. The 
higher degree of homology between human and canine VEGR-2 (93%) compared to murine 
VEGFR-2 (86%) may explain the higher immunogenicity of our vaccine in mice. However, it 
has been shown that one xenogeneic peptipe epitope is equally efficient in breaking tolerance 
as the full length xenogeneic protein, suggesting that the degree of heterology is not 
critical.
287
 Additionally, also in other studies with xenogeneic DNA vaccines in dogs, 
immune responses are only evident after multiple boosts, suggesting this might be required in 
dogs independent of the vaccine composition 
56,286
.  
 
The normal levels of Tregs and MDSCs, wound healing in healthy mice and physiological 
parameters (heart rate, respiration rate, temperature and blood pressure) in healthy dogs are 
not influenced by the vaccine. This indicates that no acute side effects occur after 
administration of our VEGFR-2 DNA vaccine. The tolerability of the electroporation on 
butorphanol sedated dogs in combination with local anesthesia is poor. As humans treated 
with the same protocol report good tolerability of electroporation and given the nature of 
reactions of the dogs, responses are believed to come from startling more than pain.
288,289
 
Based on the reaction of the dogs one may consider to use higher levels of sedation or even 
anesthesia during electroporation. Because of the very short duration of the entire procedure 
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and based on evaluation of experienced veterinarians supervising the experiment this is not 
ethically imposed, considering discomfort caused by additional manipulations and recovery 
associated with deep sedation or anesthesia. However, since the safety of the operators is also 
an aspect that has to be taken into account, higher levels of sedation are in our opinion 
advised. The inflammation and limited tissue damage observed on the vaccination site 
illustrates the adjuvant effect of electroporation and did not impact the dogs’ welfare in any 
way.   
 
Different DNA vaccines targeting VEGFR-2 have been evaluated in the past. This wide 
interest in VEGFR-2 vaccination demonstrates the potential of this approach. The majority of 
studies with VEGFR-2 DNA vaccines used a viral, bacterial or chemical vector to facilitate 
the delivery.
280,283,290-296
 However, uniform large scale production is difficult with chemical 
and biological vectors, making clinical use outside a research context challenging.
276,277
 
Moreover, biological vectors also raise safety concerns.
40
 Vaccination with naked plasmid is 
evaluated in three research papers.
297-299
 Transfection efficiency of naked plasmid however is 
very low, making this approach far from optimal. However, when naked plasmid is delivered 
by the aid of a physical gene delivery method it is possible to combine the advantage of 
industrial suitable vaccine manufacturing with high transfection efficiency.
300
 Moreover, 
physical gene delivery methods lack vector related toxicity issues. Electroporation mediated 
delivery of a VEGFR-2 DNA vaccine has only been evaluated once in a preclinical setting.
301
 
However, the vaccine in this study was developed to include only B cell epitopes, excluding 
cellular immune responses, whereas our vaccine was able to elicit both humoral and cellular 
immune responses.   
 
As the immunogenicity and safety of this xenogeneic VEGFR-2 DNA vaccine is 
demonstrated in dogs and mice, the next step is the evaluation of its efficacy in animals with 
cancer. Spontaneously arising tumors in dogs can be a very valuable intermediate model, 
potentially limiting the now tremendous amount of negative phase I trials in human patients 
because of the low predictive power of rodent models.
302
 Many tumors in dogs share 
biological, histological and clinical characteristics with their human counterparts and 
responses to treatment are very similar. Genetic research has revealed that tumors in humans 
and dogs undergo nearly identical genetic changes. An additional advantage of dogs is their 
body size, allowing surgical interventions, medical imaging and tissue/blood sampling much 
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like in human patient.
303
 Several tumor vaccines have first been evaluated in canine patients, 
followed by a clinical trial in humans.
62,185,304,305
 The evaluation of tumor vaccines in clinical 
trials with dogs can also lead to licensing of the vaccine for veterinary use. For example, the 
licensing of Oncept, a xenogeneic DNA vaccine encoding human tyrosinase for the treatment 
of melanoma in dogs has led to its widespread use in veterinary oncology.
306
 Similar to 
humans VEGFR-2 overexpression is confirmed in numerous canine cancer types.
307-315
 In 
conclusion, our data and the many reports on VEGFR-2 will facilitate the evaluation of our 
xenogeneic VEGFR-2 DNA vaccine in animals with cancer, ranging from preliminary rodent 
models to highly translational models of dogs with spontaneous tumors.    
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1. Abstract 
In this study a xenogeneic DNA vaccine encoding for human vascular endothelial growth 
factor receptor-2 (hVEGFR-2) was evaluated in two murine tumor models, the B16-F10 
melanoma and the EO771 breast carcinoma model. The hVEGFR-2 DNA vaccine was 
administered by intradermal injection followed by electroporation. The immunogenicity and 
the biological efficacy of the vaccine was tested in (1) a prophylactic setting, (2) a therapeutic 
setting and (3) a therapeutic setting combined with surgical removal of the primary tumor. In 
the prophylactic and therapeutic setting, 14 vaccinated and 14 control mice were included per 
tumor model. Ten mice were followed for tumor growth and survival and 4 mice per group 
were sacrificed for biological read-outs. The systemic cellular immune response was 
measured by a bioluminescence based cytotoxicity assay with VEGFR-2 expressing target 
cells. Humoral immune responses were quantified by ELISA. Ex vivo bioluminescence 
imaging of organs was used to detect (micro)metastases. For the experiment where 
vaccination was combined with surgery, ten vaccinated and ten control mice were included 
per tumor model, and all ten were sacrificed three weeks after removal of the primary tumor 
for ex vivo bioluminescent quantification of (micro)metastases. A cellular and humoral 
immune response was present in prophylactically and therapeutically vaccinated mice, in 
both tumor models. Nevertheless, survival in prophylactically vaccinated mice was only 
moderately increased, and no beneficial effect on survival in therapeutically vaccinated mice 
could be demonstrated. Unexpectedly, the vaccine caused an increased quantity of early 
micrometastases in the liver. Lung metastases were not increased by the vaccine. These early 
liver micrometastes did however not grow into macroscopic metastases in either control or 
vaccinated mice when allowed to develop further after surgical removal of the primary 
tumor.  
 
2. Introduction 
It is well-known that the immune system is capable to recognize tumor cells and to establish 
a specific long term anti-tumor response.
5
 Therefore, vaccination against tumor antigens 
holds great promises in the treatment for cancer. However, it has been difficult to translate 
the theoretical potential of tumor vaccines in clinical efficacy due to the capacity of tumor 
cells to create an immunosuppressive environment and to downregulate the expression of 
Chapter 4: Xenogeneic VEGFR-2 vaccination in tumor bearing mice. 
 
100 
 
tumor antigens.
265
 Therefore, VEGFR-2 as vaccine target has some important advantages. 
Instead of the tumor cells, which are sculptured by the selective pressure of the immune 
system, VEGFR-2 vaccines target tumor associated endothelial cells, which have not 
acquired immune evasive strategies and are not prone to the development of escape 
mutants.
5,268
 Additionally, it is known that certain tumor cells also express VEGFR-2. 
Therefore, the anti-angiogenic effect of VEGFR-2 based vaccines can be complemented by a 
direct anti-tumor action in these tumors.
269
 Moreover, certain tumor associated regulatory T 
cells and myeloid derived suppressor cells express VEGFR-2, possibly enabling a self-
enforcing mechanism of VEGFR-2 based vaccines, as depletion of these cells improves the 
efficacy of cancer vaccine.
5,270,271,316
  
 
VEGF/VEGFR-2 targeting has been explored extensively with different treatment modalities, 
with some of them approved for clinical use.
268
 In preclinical studies vaccination against 
VEGFR-2 has also been explored.
317
 In these studies dendritic cells, DNA or proteins based 
VEGFR-2 vaccines have been tested. The advantage of DNA vaccines for tumor vaccination 
is that the antigens are synthetized intracellularly, leading to a robust cellular immune 
response.
273
 The majority of studies with VEGFR-2 DNA vaccines used viral, bacterial or 
chemical carriers.
280,283,291-293,295,318-321
 However, reproducible large scale production is 
difficult with chemical and biological carriers, making clinical use outside a research context 
challenging.
276,277
 Moreover, biological carriers also raise safety concerns.
40
 Vaccination with 
naked (i.e. unformulated) plasmid DNA (pDNA) encoding VEGFR-2 has been evaluated in a 
few publications.
297-299
 However, the transfection efficiency of naked pDNA is very low, 
making this approach far from optimal. By using physical delivery methods, e.g. 
electroporation, it is possible to combine the manufacturing advantages of unformulated 
DNA vaccines with high transfection efficiency.
300
 Moreover, physical delivery methods do 
also not have carrier related toxicity issues. Therefore, in this study, we evaluated for the first 
time the vaccination efficacy after electroporation of a naked pDNA vaccine encoding human 
VEGFR-2 (hVEGFR-2). Human VEGFR-2 is used as antigen, as xenogeneic vaccination can 
help to overcome immune tolerance.
267
 Additionally, the development of metastases in 
different organs is monitored by bioluminescence imaging of excised organs, which allows 
the detection of micrometastases. This is necessary as it has been demonstrated, in a 
preclinical and clinical setting, that targeting VEGFR-2, by monoclonal antibodies as well as 
receptor inhibitors, can induce metastases.
322-324
 In experiments with vaccination against 
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VEGFR-2, the effect of VEGFR-2 vaccination on metastases has been insufficiently 
examined.  
 
3. Materials and Methods 
Tumor cell lines, VEGFR-2 plasmid and mice 
The B16-F10
325
 and the EO771
326
 tumor cell lines were generously provided by respectively 
Johan Grooten (Department of Biomedical Molecular Biology, Ghent University, Belgium) 
and Jo Van Ginderachter (Cellular and Molecular Immunology, VIB, Free University of 
Brussels). Both cell lines were transduced with luciferase as described earlier.
278
 Briefly, 
retroviruses were produced in HEK293T cells by calcium phosphate transfection, harvested 
after 48 and 72h, filtered and concentrated by ultracentrifugation. Transduction was 
performed in the presence of 8 µg/ml polybrene and efficiency was evaluated by 
bioluminescence. Both cell lines were grown in Dulbecco’s modified Eagle’s medium, 
supplemented with 10% fetal calf serum, 100 mg/ml streptomycin, 100 IU/ml penicillin and 1 
mmol/ml L-glutamine (Invitrogen, Carlsbad, CA, USA). For tumor inoculation, the cells 
were harvested by trypsinization and washed twice with calcium and magnesium free 
Dulbecco’s phosphate buffered saline (PBS, Invitrogen).  Human VEGFR-2 plasmid was 
purchased form Invivogen (Toulouse, France). A full description of the plasmid can be found 
on the website of the manufacturer.
279
 Purification of the plasmids was done with the 
EndoFree Giga kit, following the instructions of the manufacturer (Qiagen, Valencia, CA, 
USA). For all experiments, C57BL/6JRj mice of 8 weeks were used (Janvier Breeding 
Center, Le Genest St. Isle, France). 
 
Study design 
The experiments were approved by the ethical committee of the Faculty of Veterinary 
Medicine (Ghent University; EC-DI 2014-45). 
 
For prophylactic vaccination, 56 mice were randomly allocated into four groups of 14 mice. 
The first and third group were challenged with respectively B16-F10 and EO771 cells 
without prior vaccination (control groups, table 1). The second and fourth group were 
vaccinated and subsequently challenged with respectively B16-F10 or EO771 cells (Fig. 1 
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and table 1). The vaccination schedule consisted of three intradermal injections near the tail 
base of 25 µg human VEGFR-2 pDNA in calcium and magnesium free PBS followed by 
electroporation with the BTX Agilepulse device (Harvard apparatus, Holliston, MA, USA) 
using 4 mm gap needle electrodes. The following electroporation protocol was used: 2 pulses 
of 450 V with a pulse duration of 0.05 ms and a 300 ms interval, followed by 8 pulses of 100 
V with a pulse duration of 10 ms and a 300 ms interval. The interval between the 
vaccinations was two weeks. One week after the final vaccination, the mice from group one 
and three were subcutaneously inoculated in the right flank with 2x10
5
 B16-F10 cells, while 
the mice from group two and four were inoculated with 5x10
5
 EO771 cells. Once weekly, 
tumor volume was measured with a digital caliper (formula: 1/2(Length × Width
2
). 
Additionally, the bioluminescence signal of the primary tumor was also measured 10 minutes 
after intraperitoneal injection of 100 µl of D-luciferin (15 mg/ml, Goldbio Technology, St. 
Louis, USA) with an IVIS lumina II (Perkin-Elmer, Zaventem, Belgium). Four mice of each 
group were randomly selected to be sacrificed three weeks after tumor inoculation, to isolate 
blood and immune cells from the spleen and to detect via ex vivo bioluminescence imaging 
(micro)metastases in the excised livers and lungs. The remaining mice (10 per group) were 
followed for tumor growth and survival and were euthanized when humane endpoints were 
reached. These humane endpoints included tumor size (> 1cm3), weight loss (>20%) or self-
mutilation. 
 
 
Fig. 1: Design of the prophylactic vaccination study (groups 1 to 4 in table 1). This experiment was performed 
in both the B16-F10 melanoma and EO771 breast carcinoma model. Sample size between parentheses represent 
mice numbers in vaccinated groups (left) and control group (right). BLI=bioluminescence imaging.   
 
For therapeutic vaccination, 28 mice were inoculated in the flank with 2x10
5
 B16-F10 cells 
and another group of 28 mice with 5x10
5
 E0771 cells. As soon as tumors became palpable 
(circa 15 mm
3
), mice were randomly allocated to serve as non-vaccinated control (n=14, 
group 5 and 7, table 1) or to receive the vaccination schedule (n = 14, group 6 and 8, table 1 
and Fig. 2) described above. Due to rapid tumor growth, vaccination interval was adjusted to 
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one week. Tumor volume and bioluminescent signal of the primary tumor was measured 
weekly as described above. Four mice of each group were sacrificed one week after the last 
vaccination to measure immune responses and to screen for (micro)metastases in the livers 
and lungs via ex vivo bioluminescence imaging. However, because most mice in the control 
and vaccinated groups reached humane endpoints before this time, the mice that were 
sacrificed were not randomly selected as initially planned, but were instead the mice that 
were still alive at that time. Tumor growth and survival were analyzed for all 14 mice until 
the time of sacrifice, with mice sacrificed for the biological read-out censored.  
 
 
Fig. 2: Design of the therapeutic vaccination study (groups 5 to 8 in table 1). This experiment was performed in 
both the B16-F10 melanoma and EO771 breast carcinoma model. Sample size between parentheses represent 
mice numbers in vaccinated groups (left) and control group (right). BLI=bioluminescence imaging,*this time 
point varied individually per mouse depending on first appearance of a palpable tumor.   
 
To study over a longer time period the effect of VEGFR-2 DNA vaccination on metastasis 
we surgically removed the tumor (Fig. 3). In more detail, 20 mice were inoculated with either 
B16-F10 or E0771 cells as described above. When tumors became palpable, mice were 
randomly allocated to serve as surgery-only control (n=10, group 9 and 11, table 1) or 
surgery-vaccination group (n=10, group 10 and 12, table 1). At this time point vaccination 
was started in the latter group and consisted out of three intradermal vaccinations with a time 
interval of one week (see above). Three weeks after inoculation, primary tumors (600-1000 
mm
3
) were surgically removed. Three weeks later, mice were sacrificed for the detection of 
macrometastases (visual inspection) and ex vivo bioluminescent imaging of organs (liver, 
spleen and lungs).  
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Fig. 3: Design of the surgery-vaccination study (groups 9 to 12 in table 1). This experiment was performed in 
both the B16-F10 melanoma and EO771 breast carcinoma model. Sample size between parentheses represent 
mice numbers in vaccinated groups (left) and control group (right). BLI=bioluminescence imaging,*this time 
point varied individually per moues depending on first appearance of a palpable tumor. 
 
Follow-up of the immune response 
In chapter 3 we have characterized the immune response after vaccination of healthy mice 
and dogs with hVEGFR-2 pDNA. In this study the most important assays were repeated. 
Splenocytes were isolated when mice were sacrificed. To assess cytotoxic response to cells 
expressing the target (i.e. VEGFR-2), splenocytes were coincubated with bioluminescent 
B16-F10 cells that had been in vitro electroporated with the VEGFR-2 pDNA (BTX ECM 
830 electroporator, Harvard apparatus, Holliston, USA; 2 pulses of 140 V with a pulse 
duration of 5 ms and a 100 ms interval). As a control for specificity to the hVEGFR-2 target, 
B16-F10 melanoma cells that were mock electroporated were also included. Absence of 
natural VEGFR-2 expression on the bioluminescent B16-F10 cells and induction of 
expression after electroporation were assessed by flow cytometry with an anti-VEGFR-2 
antibody combined with an Alexafluor-688 conjugated secondary goat anti-rabbit antibody 
(Abcam, Cambrige, UK). A cytotoxicity assay was performed by incubating 2x10
5
 
splenocytes with 1x10
4
 B16-F10 cells. After 24 hours the bioluminescent signal, which is 
related to the number of living cells, was measured with an IVIS lumina II (Perkin-Elmer, 
Zaventem, Belgium).  
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                               Table 1: Overview of all experimental groups included in this study. 
Group Treatment Inoculation Follow-up 
1 None 
B16-F10 Immune response 
& ex vivo BLI (n=4) 
+ survival (n=10) 
2 hVEGFR-2 (P) 
3 None 
EO771 
4 hVEGFR-2 (P) 
5 None 
B16-F10 Immune response, 
ex vivo BLI 
& survival (n=14) 
6 hVEGFR-2 (T) 
7 None 
EO771 
8 hVEGFR-2 (T) 
9 Surgery 
B16-F10 
Ex vivo BLI (n=10) 
10 Surgery+hVEGFR-2 (T) 
11 Surgery 
EO771 
12 Surgery+hVEGFR-2 (T) 
                               hVEGFR-2: human vascular endothelial growth factor-2 vaccination; 
                 P=prophylactic, T=therapeutic; BLI=bioluminescence imaging 
 
Blood was taken by cardiac puncture under terminal anesthesia when mice were sacrificed 
and after centrifugation serum was collected and stored at -80 °C until analysis. To assess 
humoral immune response, microtiter plates were coated with 1 µg murine VEGFR-2 protein, 
blocked with blocking buffer and loaded with serial dilutions of serum (Bio-Connect, Te 
Huissen, The Netherlands). After washing, a HRP-conjugated anti-mouse IgG antibody was 
added, followed by development with TMB substrate and measuring absorbance with a 
microplate reader at 450 nm (ImTec Diagnostics, Antwerp, Belgium). The titer was 
determined as the limited dilution with a signal exceeding mean plus two times the standard 
deviation of the signal from control samples (non-vaccinated mice).  
 
Statistical analysis 
Data were analyzed with the SPSS software version 19 (IBM, Brussels, Belgium). The effect 
of vaccination on the cytotoxicity and IFN-gamma secretion of murine splenocytes were 
analyzed with a student t-test. The effect of vaccination on antibody titers were analyzed with 
an exact linear by linear association test. For post hoc tests, correction for multiple 
comparisons was performed with the Tukey method. Survival between treatment groups were 
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compared with Kaplan-Meier analysis. Bioluminescence data was compared with a one-way 
ANOVA after log transformation.  
4. Results 
Immune response 
There was a significant (p=0.001) cytotoxic T lymphocyte (CTLs) response in 
prophylactically vaccinated mice (Group 2 and 4) compared to control mice (Group 1 and 3). 
In more detail, 4 weeks after the last vaccination (i.e. three weeks after tumor inoculation) 
lymphocytes from the B16-F10 and EO771 challenged mice killed, on average, 44% more 
VEGFR-2 positive target cells than lymphocytes from non-vaccinated mice (Fig. 4A). 
Additionally, vaccinated mice also developed a significant humoral response, with antibody 
titers in the vaccinated groups ranging from 1:400 to 1:1600, whereas in the control groups 
no antibody response could be detected (p<0.001, table 2). 
 
 
Fig. 4: Splenocytes of prophylactically (4A) or therapeutically (4B) vaccinated (groups 2, 4 and 6, 8 from table 
1) and control mice (groups 1, 3 and 5, 7 from table 1) were coincubated with VEGFR-2 expressing target cells. 
After 24h, a significant cytotoxic response of splenocytes from vaccinated mice is evident. (black: B16-F10 
bearing mice, grey: EO771 bearing mice) (**p<0.01) 
 
A similar systemic immune response was present in the therapeutically vaccinated mice. One 
week after the last vaccination (i.e. four weeks after tumor inoculation) splenocytes from the 
B16-F10 and EO771 bearing mice (Groups 6 and 8) killed, on average, 40 % more VEGFR-2 
positive targets than lymphocytes from non-vaccinated mice (Groups 5 and 7, Fig. 4B). 
Antibody responses in the therapeutically vaccinated mice were also higher than in control 
mice (p<0.001, table 2). No difference in immune response between tumor models or 
between vaccination schedules (prophylactic/therapeutic) were evident.  
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         Table 2: Number of mice in each group per antibody titer 
Treatment group 
Antibody titer 
400 800 1600 
Group 2 1 3 - 
Group 4 - 2 2 
Group 6  3 1 - 
Group 8 1 1 2 
      Groups: see table 1.  Non-vaccinated mice are not shown 
      in the table as all control mice had no detectable antibody levels. 
 
Effect of prophylactic vaccination on tumor growth and survival 
The VEGFR-2 DNA vaccine was able to slow down the growth of B16-F10 and EO771 
tumors when mice were vaccinated before they were inoculated with the tumor cells (Fig.  5 
and 6). The bioluminescence signal of the tumor followed a similar trend as the tumor 
volume (data not shown). This decrease in tumor growth led to a modest increase in survival 
of the vaccinated mice (Fig. 5 and 6). In detail, vaccination was able to significantly increase 
median survival of B16-F10 challenged mice from 25 days to 30 days, and of EO771 
challenged mice from 38 days to 48 days (Fig. 2, p=0.004 and p=0.002 respectively). 
However, prophylactic vaccination was not protective as all vaccinated mice developed a 
tumor.  
 
 
 
Fig. 5: Individual tumor growth curves (left) and survival curves (right) for prophylactically vaccinated (group 
2) and control mice (group 1) inoculated with B16-F10. 
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Fig. 6: Individual tumor growth curves (left) and survival curves (right) for prophylactically vaccinated (group 
4) and control mice (group 3) inoculated with EO771.  
 
Effect of therapeutic vaccination on tumor growth and survival 
The VEGFR-2 DNA vaccine was subsequently tested in mice that already had a tumor. The 
volumes of the B16-F10 and EO771 tumors did not significantly decrease after vaccination 
with the VEGFR-2 DNA vaccine and survival was not affected by vaccination (Fig. 7 and 8). 
Only a proportion of mice survived long enough to receive the complete rounds of 
vaccinations.  
 
 
Fig. 7: Individual tumor growth curves (left) and survival curves (right) for therapeutically vaccinated (group 6) 
and control mice (group 5) inoculated with B16-F10. 
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Fig. 8: Individual tumor growth curves (left) and survival curves (right) for therapeutically vaccinated (group 8) 
and control mice (group 7) inoculated with EO771. 
 
At day 27, i.e. 6 days after the last vaccination, clear differences between the 
bioluminescence patterns of the tumors of vaccinated and non-vaccinated were noticed (Fig. 
9). Indeed, the ratio of the tumor bioluminescence to the tumor volume was significantly 
lower for vaccinated then control mice, suggesting less viable tumor mass in the vaccinated 
mice (p=0.01, Fig. 10). It is important to note that these measurements are not from randomly 
selected mice per group, but only from mice in each group that survived up until this time 
point (4 control mice and 5 vaccinated mice for B16-F10 and 4 control mice and 8 vaccinated 
mice for EO771). At earlier time points there was no difference in bioluminescence signal 
between vaccinated and non-vaccinated mice (data not shown).  
 
 
 
Fig. 9: Bioluminescence signals of the tumors of the therapeutically vaccinated mice. (A) Representative in vivo 
bioluminescence image of a control (left) and vaccinated (right) B16-F10 tumor mouse 4 weeks after tumor 
inoculation (i.e. 1week after the last vaccination) (B) Bar chart of the ratio of the tumor bioluminescent to the 
tumor volume one week after the third therapeutic vaccination. (**p<0.01) 
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Metastases  
Development of metastases in B16-F10 tumor mice 
Prophylactic and therapeutic vaccination had the same effect on the development of 
metastases. Four weeks after the last prophylactic vaccination (i.e. 3 weeks after tumor 
inoculation) only microscopic metastases were detected in the liver of vaccinated and control 
mice (Fig. 10). The metastases were visible as multiple bioluminescent spots. Remarkably, 
the total bioluminescence signal of these spots was significant higher in the vaccinated than 
in the non-vaccinated mice (Fig. 10). Similarly, mice with established tumors before 
vaccination (i.e. therapeutic vaccination) had one week after the last vaccination (i.e. 4 weeks 
after tumor inoculation) only microscopic metastases in the liver. Interestingly, the 
bioluminescence signal of the metastases in these therapeutically vaccinated mice was again 
significantly higher than the bioluminescence signal of the metastases of the control mice 
(Fig. 10). No metastases in the lungs could be detected.  
 
 
Fig. 10: B16-F10 liver metastases in control, prophylactic and therapeutic vaccinated mice. (A) Representative 
bioluminescence image of the liver of a control (left) and vaccinated mouse (right). (B) Bar chart showing the 
bioluminescent signal in livers of control mice and prophylactic and therapeutic vaccinated mice. (*p<0.05)  
 
Development of metastases in EO771 tumor mice 
Four weeks after the last prophylactic vaccination (i.e. three weeks after tumor inoculation) 
only micrometastases were detected in the liver and lung of prophylactic vaccinated and 
control mice. The metastases were visible as bioluminescent spots. Again, the average total 
bioluminescence signal of these spots was significantly higher in the vaccinated than in the 
non-vaccinated mice (Fig. 11). Likewise, therapeutic vaccinated mice had, one week after the 
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last vaccination (i.e. 4 weeks after tumor inoculation), only microscopic metastases in the 
liver and lung and also in this tumor model the bioluminescence signal of these metastases in 
the liver of vaccinated mice was significantly higher than the bioluminescence signal of the 
liver metastases of the control mice (Fig. 11). On the other hand, the bioluminescence signal 
of the lung metastases in the vaccinated mice was not significantly different from the 
bioluminescence signal of the lung metastases in the control mice (Fig 11). 
 
 
Fig. 11: EO771 lung and liver metastases in control, prophylactic and therapeutic vaccinated mice. (A) 
Representative bioluminescence image of the lung and liver of a control (upper row) and a vaccinated mouse 
(lower row). (B) Bar chart showing the bioluminescent signal in the lungs and livers of control mice and 
prophylactically (upper) and therapeutically (lower) vaccinated mice. (**p<0.01) 
 
Long term effect of vaccination on metastases  
When metastases were allowed to develop further for three weeks after surgical removal of 
the primary tumor (6 weeks after inoculation), we found in both tumor models small 
macroscopic metastatic nodules in the lungs of therapeutic vaccinated mice as well as control 
mice (Fig. 12).  
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Fig. 12: Representative images demonstrating the size of macroscopic tumor nodules in the lungs from animals 
three weeks after surgical removal of the primary tumor (left: EO771/right: B16-F10). There was no difference 
between control and vaccinated animals. 
 
On visual inspection as well as by bioluminescence measurements there was no difference 
between control mice and vaccinated mice (data not shown). In the liver the metastases 
remained microscopic in both tumor models. In control mice, the total bioluminescence 
signal of these liver metastases (6 weeks after inoculation) was increased in comparison with 
earlier time point (3 and 4 weeks after inoculation). In vaccinated mice, there was no further 
increase in bioluminescent signal of the liver micrometastases compared to earlier time 
points. As a consequence the bioluminescence signals of the metastases in the livers and 
lungs were, three weeks after removal of the primary tumor, not significant different between 
vaccinated and control mice. This was true for both tumor models. 
 
5. Discussion 
In this study, VEGFR-2 vaccination was evaluated in three different settings in two tumor 
models (B16-F10 and EO771). The three settings we tested were: (1) prophylactic 
vaccination, (2) therapeutic vaccination and (3) therapeutic vaccination in combination with 
surgery. In a prophylactic setting, survival of vaccinated mice was modestly increased. In a 
therapeutic setting, only a small proportion of mice survived long enough to receive the 
complete rounds of vaccinations, as both B16-F10 and EO771 are very aggressive tumor 
models. The time necessary to develop an anti-tumor immune response and associated 
clinical benefit is also an issue in clinical immunotherapy.
265
 Although tumor size was 
comparable between control and vaccinated animals after therapeutic vaccination, the ratio of 
bioluminescent signal per tumor volume was significantly different. This confirms that 
classical volumetric tumor measurements are not ideal to detect a treatment effect of anti-
VEGF/VEGFR-2 agents.
327
 Our fining corresponds with other reports of loss of viable tumor 
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mass without significant alterations in tumor size measurements after treatment with anti-
VEGF/VEGFR agents.
327
 Although it is difficult to compare between studies, as often tumor 
type and vaccination scheme are different, our effect on primary tumor growth and survival 
seems less than that for other VEGFR-2 vaccine formulations. This coincides with a more 
limited humoral immune response in our study compared with others, whereas cellular 
immune responses are comparable. This link between humoral immune response and clinical 
efficacy for VEGFR-2 vaccination is confirmed by the study of Xu and others.
298
 In this 
study mice were also vaccinated with naked plasmid, but without electroporation, and they 
observed a low humoral response associated with only a limited effect on tumor growth. 
After conjugation with the C3d molecular adjuvant, humoral responses were markedly 
increased and this corresponded with a much more pronounced effect on tumor growth. 
Limited humoral immune responses after DNA vaccination are due to the fact that only very 
small amounts of proteins are secreted.
282
 Improving humoral immunity of our vaccine, 
without losing the advantage of a safe and easy to manufacture formulation, could be 
attempted by increasing DNA dose, combining it with a protein vaccine or incorporating 
molecular adjuvants.
298,328,329
    
 
DNA vaccination with human VEGFR-2 had a clear effect on metastasis. At an early time 
point (i.e. 3-4 weeks after tumor inoculation) liver micrometastases were significant higher in 
both tumor models after prophylactic and therapeutic vaccination. In contrast, the 
micrometastases in the lungs of EO771 mice were not significantly different between 
prophylactic/therapeutic vaccinated and non-vaccinated mice.  Based on these observations it 
seems that the seeding of circulating tumor cells (CTCs) in the liver is easier in vaccinated 
mice than in control mice. Probably VEGFR-2 vaccination caused hypoxia in the primary 
tumor, which is in agreement with a lower bioluminescence signal of the primary tumor in 
the vaccinated mice. Hence, CTCs of VEGFR-2 vaccinated mice are probably more adapted 
to a hypoxic environment than the CTCs of non-vaccinated mice and this allows them to 
proliferate sooner after dissemination in the liver, which is known to be a relative hypoxic 
organ.
330
 On the other hand, the lungs have high basal levels of oxygen perfusion. In such an 
oxygen rich environment CTCs of vaccinated mice which are adapted to a hypoxic milieu, do 
not have an advantage over CTCs of non-vaccinated for colonization.
330
 This may explain the 
differential effect of VEGFR2 vaccination on lung and liver metastases. It has been 
demonstrated in the past that hypoxia in the primary tumor caused by anti-angiogenic 
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treatment can influence multiple crucial steps in the metastatic process.
327,331
 Additionally, an 
association between hypoxic markers in the primary tumor and liver metastases has been 
demonstrated earlier.
332
 We report, to our knowledge, for the first time that VEGFR-2 
vaccination promotes early liver metastases. In the past, the effect of VEGFR-2 vaccination 
on spontaneous arising metastases has been investigated in three studies. However, only 
metastases in the lungs and not the livers were examined in these studies.
280,292,333,334
 The 
other studies that investigated the effect of VEGFR-2 vaccination on metastasis used an 
experimental metastasis model that consisted of the injection of tumor cells in the tail 
vein.
291,294,295,318,320,335,336
 With such metastatic models it is not possible to evaluate the effect 
of treatments that modulate the metastatic capacity of CTCs originating from a primary 
tumor.  
 
When metastases were allowed to develop further after surgical removal of the primary 
tumor, both EO711 and B16-F10 tumor bearing mice developed macroscopic lung 
metastases, while the liver metastases stayed microscopic. Interestingly, the micrometastases 
in the liver of control animals increased to the same level as those in vaccinated mice, whose 
metastases had not increased compared to earlier time points. This indicates that for B16-F10 
and EO771 cells the liver is not an adequate metastatic site for the development of 
macroscopic metastases, which is in agreement with previous findings.
337,338
 The higher 
metastatic capacity of tumor cells from VEGFR-2 vaccinated mice thus only applies for 
initial colonization of the liver, but not for macroscopic tumor growth. Indeed, forming 
micrometastases is a result of the capacity to survive in the foreign environment of the distant 
organ, whereas forming macroscopic metastases is another process depending on many other 
factors.
339
 So, on the long term no overall increase in liver metastases between VEGFR-2 
vaccinated and control mice is observed. Furthermore, no difference in the development of 
lung metastases between control and vaccinated animals was observed, in contrast to 
previous studies that found decreased lung metastases in VEGFR-2 vaccinated mice.
280,333,334
 
Next to different tumor types used in the other studies compared to ours, another possible 
explanation is the time of read-out. Metastatic tumor nodules in our experiment were 
considerably smaller than those reported in other studies. It is possible that the effect of 
VEGFR-2 vaccination on metastases becomes more pronounced with increasing metastatic 
tumor size, as the dependence on neovascularization will increase accordingly.  
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6. Conclusion 
In summary, the VEGFR-2 DNA vaccine resulted in a limited effect on primary tumor 
growth, which may be enhanced by adjusting the vaccination schedule to induce a more 
potent humoral immune response. Interestingly, for the first time, we have shown VEGFR-2 
vaccination to affect metastatic behavior, in two different tumor models. This consisted of 
accelerated occurrence of liver micrometastases. As for both tumor models the liver is not an 
adequate site for the development of macrometastases, the clinical consequences of this 
phenomenon cannot be evaluated. Therefore, it would be highly interesting to investigate this 
in tumor models with the liver as preferential site of metastasis. Moreover, further research 
regarding the mechanisms behind this process could identify anti-metastatic complementary 
treatments, which may significantly improve efficacy of VEGFR-2 vaccination as well as 
other anti-angiogenic treatment. 
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1. Abstract 
Recent research has demonstrated that cell-mediated gene therapy can be an interesting 
method to obtain local intratumoral expression of therapeutic proteins. In cell-mediated 
cancer gene therapy, cells that naturally home to tumor tissue are in vitro transfected with the 
protein of interest followed by systemic infusion of the cells. Myeloid derived suppressor 
cells (MDSCs) home strongly to tumor tissue. In this work we explored the possibility to use 
MDSCs, derived from a murine cell line, as a cellular vehicle to transport anti-cancer agents 
like interleukin-12 (IL-12) to tumors. A drawback of using MDSCs as cellular vehicles for 
tumor targeted delivery is that they cause immunosuppression. Therefore, IL-12, a very 
potent anti-tumor cytokine, was used because it can reprogram the immunosuppressive 
MDSCs into immune stimulating immune cells. We demonstrated in vitro that the cell line 
derived MDSCs strongly migrate towards tumor cells. The transfectability of these cells with 
electroporation and lipofectamine 2000 was evaluated with reporter plasmids. DNA 
electroporation was not an adequate method as it caused massive cell death. This was not due 
to electroporation-induced cell damage, but due to the intracellular presence of plasmids. In 
contrast, cell death was not significant after transfection with lipofectamine 2000. However, 
transfection efficiency remained modest (40%) and transgene expression was almost 
completely lost after 72h. Nevertheless, we demonstrated, with an IL-12 encoding plasmid, 
that this relatively low percentage of transfected MDSCs could produce biologically relevant 
IL-12 amounts. Additionally, the produced IL-12 caused an upregulation of CD80, which is a 
confirmation that IL-12 decreases the immune suppressive capacities of MDSCs. However, 
in a preliminary in vitro cytotoxicity assay we found that IL-12 transfection reduced, but not 
completely eliminated the immunosuppressive capacity of the MDSCs. In conclusion, our 
data show that the MDSC cell line can be transfected with lipofectamine 2000. Additionally, 
the MDSC cell line has the tumor migratory capacity to be used as a cellular vehicle for 
cancer gene therapy. However, the immunosuppressive effects of these cells will be an 
important challenge for their use. In that context, an efficient transfection protocol, leading to 
a higher percentage of IL-12 transfected MDSCs and a higher concentration of IL-12 is 
critical.  
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2. Introduction 
Myeloid derived suppressor cells (MDSCs) are immature myeloid cells that are strongly 
immunosuppressive and pro-angiogenic. They are induced by tumor derived cytokines and 
accumulate into the tumor micro-environment to protect tumor cells from immune 
destruction and promote angiogenesis. As these are crucial mechanisms for tumor 
progression, MDSCs have been identified as important targets in the treatment against 
cancer.
340
 However, their ability to migrate to tumor tissue can also be exploited by using 
these cells as vehicles to deliver anti-tumor agents specifically to tumor cells.
341
 This 
includes, but is not limited to, cell-mediated gene therapy.
342
 Gene therapy has gained much 
attention as a treatment modality against cancer. Amongst other applications, cytokine 
therapy by gene transfer is highly interesting, considering the short half-life and potential 
toxicity of most cytokines impeding systemic use. Gene therapy can provide a constant 
source of local cytokine production within the tumor, eliminating the need for frequent 
administration of high amounts of protein to obtain similar effects.
343
 However, many gene 
therapy approaches rely on local applications, either by practical constraints due to the 
method of gene transfer (physical methods) or by the lack of specificity after systemic 
injection (chemical or viral methods).
344
  
 
Mesenchymal stem cells (MSCs) are currently the most common cell type that is explored for 
intratumoral delivery of drugs.
345
 However, MSCs also have tumor-stimulating properties. In 
addition, the large size of MSCs poses problems with passing the capillary bed in the lungs 
after systemic administration.
346
 MDSCs are much smaller and as immune cells more fit to 
efficiently migrate through the body. Tumor infiltrative T cells or genetically modified T 
cells are other cell types used for tumor-specific delivery.
347
 They have the advantage of 
being anti-tumoral in contrast to MDSCs and MSCs. However, as part of their immune-
evasive strategies, tumors do not secrete cytokines to attract T cells and T cells that do 
extravasate will have to deal with a microenvironment that is very hostile for T cells. MDSCs 
are strongly attracted by tumor cells and the tumor microenvironment supports their survival 
and expansion. Indeed, the excellent tumor specific accumulation of transferred MDSCs 
compared to other immune cells has been recently demonstrated.
341
 A recent study with 
freshly isolated syngeneic MDSCs as carriers for an oncolytic virus proves that the overall 
outcome of MDSCs-mediated therapy can be tumoricidal.
341
 Additionally, it has been 
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demonstrated that MDSCs can be reprogrammed in in immune stimulating immune cells by 
interleukin-12 (IL-12).
126,132
 Therefore, it is possible that for the delivery of IL-12, the pro-
tumor characteristics of MDSCs are of less importance, if they lose this trait under influence 
of the IL-12 they produce.  
 
IL-12 is also a very potent anti-tumor cytokine that stimulates T cells and natural killer (NK) 
cells to attack tumor cells. However, IL-12 results in major toxicity when delivered 
systemically.
133
 Therefore, intratumoral administration of viral or non-viral vectors that 
encode IL-12 has been used in many pre-clinical and clinical studies.
180
 However, a 
disadvantage of intratumoral IL-12 gene transfer is that it is difficult to apply to internal 
tumors and metastases whose exact location is not always known. Therefore, specific 
targeting of IL-12 to these hard-to-reach tumors after systemic administration would be a 
breakthrough. 
 
In the past a murine MDSC cell line has been established.
348
 Using a cell line instead of 
freshly isolated MDSCs greatly facilitates preclinical evaluation as it requires fewer animals 
and generates more reproducible data. In this study, we investigated if this previously 
described MDSC cell line can be transfected with reporter plasmids by physical and chemical 
methods. These methods have the advantage over viral gene transfer to be more versatile, 
thus allowing for quick evaluation of different therapeutic molecules. Transfection with IL-
12 was performed to quantify IL-12 production capacity of this approach and to investigate 
the effect of IL-12 transfection on the immunosuppressive capacity of the MDSCs. Lastly, we 
investigated by an in vitro assay if this MDSC cell line has retained its capacity to migrate in 
response to tumor secreted cytokines.  
 
3. Materials and Methods 
Cell lines and plasmids 
The MDSC cell line was generously provided by Vincenzo Bronte (Department of Oncology 
and Surgical Sciences, Padova, Italy). These cells were grown in Dulbecco’s modified 
Eagle’s medium, supplemented with 10% fetal calf serum, 100 mg/ml streptomycin, 100 
IU/ml penicillin and 1 mmol/ml L-glutamine (Invitrogen, Carlsbad, USA). pGL4 luciferase 
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plasmid (Promega, Massachussets, USA) and eGFP-C1 plasmid (generously provided by K. 
Remaut, laboratory for general biochemistry and physical pharmacy, Ghent University, 
Belgium) were used as reporter plasmids. For IL-12 transfections, murine pORF-mIL-12 
plasmid was used (Invivogen, Toulouse, France). All plasmids were purified with Qiagen 
Endofree Giga purification kit following instructions of the manufacturer (Qiagen, Valencia, 
USA).  
 
Electroporation  
In vitro electroporation was performed with the ECM830 device (BTX Harvardt apparatus, 
Holliston, Massachusetts, USA). After initial optimization (range 100-500 V), the optimal 
electroporation protocol consisted of 2 pulses of 140 V and 5 ms length with an interval of 
100 ms. One million cells were transfected in 2 mm cuvettes with 5 µg pGL4 plasmid in 80 
µl calcium and magnesium free phosphate buffered saline (PBS, Invitrogen). Also cells that 
underwent electroporation without plasmid were included. After electroporation, cells were 
transferred to a 96 well plate and bioluminescent signal was measured with an optical 
imaging system after 4h, 24h, 48h and 72h (IVIS Lumina II, Perkin-Elmer, Zaventem, 
Belgium). Viability of the cells was evaluated 24h after electroporation with AlamarBlue 
(Invitrogen) and by microscopic evaluation. Electroporation and biological read-outs were 
performed at least in duplicate per experiment and repeated once in an independent 
experiment.  
 
Lipofection 
Lipofection was performed with lipofectamine 2000 (LF2000, Invitrogen) with optimization 
following the instructions of the manufacturer. Following ratios of volume (µl) LF2000 to 
weight (µg) of plasmid DNA (pDNA) were evaluated: 1:1, 1:1.25, 1:1.7, 1:2.5. Cells were 
seeded 24h before lipofection in a 96 well plate at two densities, 5x10
3
 and 1x10
4
 cells in 100 
µl. Lipofection was done with 100 ng pGL4 plasmid per well in serum containing medium 
without antibiotics. All transfections performed to find the optimal protocol were performed 
in duplicate per experiment and repeated once in an independent experiment. Viability was 
evaluated by flow-cytometric determination of cell numbers within healthy FSC-SSC profile 
that were negative for 7-AAD (Ebioscience, Vienna, Austria). Additionally, 24h after 
transfection cell viability was also qualitatively evaluated by microscopic evaluation. Flow 
cytometry was done with an Accuri C6 flow cytometer (BD, Biosciences, Erembodegem, 
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Belgium). With the most optimal transfection condition (LF2000:pDNA ratio 1:1.25, and 
seeding density of 5x10
3
 MDSCs/96 well) we studied the evolution of the luciferase 
expression by measuring the bioluminescence 24h, 48h and 72h after transfection. The 
number of transfected MDSCs was determined by flow cytometry after transfection with an 
eGFP plasmid. All transfections were performed in triplicate. 
 
IL-12 transfection and effect on costimulatory molecules 
MDSCs were transfected with IL-12 plasmid using the optimal protocol identified for 
LF2000. After 24h, medium was collected and stored at -20 °C. The concentration of IL-12 
in the medium was determined with an ELISA following the instructions of the manufacturer 
(ImTec Diagnostics, Belgium, Antwerp). To study the effect of IL-12 plasmid transfection on 
the expression of costimulatory molecules by MDSCs we stained the MDSCs 24h after 
transfection with the pGL4 plasmid (control) or the IL-12 plasmid with FITC-conjugated 
anti-CD40, APC-conjugated anti-CD80 and PE-conjugated anti-CD86 antibodies 
(Ebioscience). The cells were subsequently analyzed with an Accuri C6 flow cytometer. 
Color compensation was set based on fluorescence minus one controls.  Transfections and 
read-outs were performed in triplicates and positive results confirmed by an independent 
experiment with four replicates.  
 
Effect of IL-12 transfection on the immunosuppressive capacity of MDSCs  
To study the effect of IL-12 transfected MDSCs on the tumor cell killing capacity of 
lymphocytes we added non-transfected MDSCs and IL-12 transfected MDSCs to co-cultures 
of luciferase positive B16-F10 cells 
278
 and freshly isolated splenocytes from healthy 12 week 
old C57BL/6 mice (Janvier Breeding Center, Le Genest St. Isle, France). Co-cultures of B16-
F10 cells with freshly isolated splenocytes and B16-F10 alone served as additional controls. 
The ability of splenocytes to interfere with B16-F10 growth was measured by comparing the 
bioluminescent signal from the co-incubation conditions to the bioluminescent signal from 
B16-F10 alone. Splenocytes were co-cultered with tumor cells in a 20:1 ratio and MDSCs 
were added in a 1:10 ratio with tumor cells. After 24h, the bioluminescent signal was 
measured with an optical imaging system (IVIS Lumina II). Four replicates were included, 
each with splenocytes from separate mice.  
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In vitro migration assay 
To investigate if the cell line derived MDSCs have retained their ability to migrate in 
response to tumoral cytokines, an in vitro migration assay was performed with 24 well 8µm 
transwells (VWR, Leuven, Belgium). B16-F10 cells were stained with CFSE (ImTec 
Diagnostics) and 1x10
4
 cells seeded in the bottom compartment of the transwells. In control 
wells, serum containing medium without any cells was added in the bottom compartment. 
After 24h, 2x10
5
 MDSCs in serum free medium were added on the upper compartment. After 
4h, nonadherent and adherent cells in the lower compartment were collected by centrifuging 
the medium and by trypsinization following instructions of the manufacturer (VWR). CFSE 
negative cells representing the migrated MDSCs were counted by flow cytometry. Specific 
migration towards tumor cells was calculated by the ratio of migrated MDSCs in 
compartments with tumor cells to migrated MDSCs in compartments with medium. The 
assay was performed in triplicate.  
 
Statistical analysis 
Data were analyzed with the SPSS software version 19 (IBM, Brussels, Belgium). Results of 
the AlamarBlue assay and the immune assay were analyzed with Kruskal-Wallis test. Flow 
cytometric data and results of the migration assay were analyzed with a student t-test.  
 
4. Results 
Electroporation mediated transfection of MDSCs 
Electroporation of MDSCs with a luciferase plasmid resulted in a clear bioluminescent signal 
after 4h, demonstrating efficient uptake of the plasmid. However, after 24h, a tremendous 
decrease in signal was observed, leading to loss of signal after 72h (Fig. 1). This is explained 
by significant (p=0.02) loss of viability of transfected cells 24h after electroporation (Fig. 2). 
The viability, assessed by AlamarBlue, of MDSCs electroporated with plasmid was only 54% 
compared with untreated cells and on microscopic evaluation electroporated cells showed 
signs of apoptosis. This cell death was not caused by electroporation-induced cell damage, as 
such a massive cell death was not observed in cells electroporated without plasmid. Indeed, 
MDSCs that were electroporated without plasmid had on average  90% viability compared to 
untreated cells and did not show abnormalities on microscopic evaluation (Fig. 2).   
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Lipofectamine mediated transfection of MDSCs 
As electroporation is not an adequate method for transfecting MDSCs, transfection with 
LF2000 was evaluated. Optimization of the transfection protocol of LF2000 was done with a 
luciferase plasmid and by measuring the bioluminescent signal 24h after transfection. The 
best results were obtained at LF2000:pDNA ratio of 1:1.25 (volume:weight ratio; (µl:µg)) 
and a seeding density of 5x10
3
 MDSCs per 96 well (Fig. 3). After 24h the viability of the 
transfected MDSCs was, compared to untreated MDSCs, on average 85% (95% CI 63-94%). 
 
 
Fig. 1: Transfection of MDSCs with electroporation. MDSCs were electroporated with 100 ng pGL4 plasmid 
and the bioluminescent signal was followed as a function of time. (n=2 and repeated once in an independent 
experiment) 
 
The bioluminescence signal of a fixed number of cells decreases after 48h to less than half of 
its signal 24h after transfection. However, the total signal after 48h, bioluminescence signal 
per cell multiplied by the total amount of cells after 48h, is not significantly different from 
the total signal after 24h. This indicates that the drop in bioluminescence signal per cell is 
mainly due to a dilution of the luciferase, and hence also of the plasmids, during cell division. 
Consequently, after 48h degradation of plasmids is not responsible for the drop of the 
bioluminescence signal in each cell. However, between 48h and 72h, the bioluminescence 
signal per cell decreases faster than that the cells increase in number and hence the total 
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bioluminescence signal also decreases significantly compared to 24h and 48h after 
transfection. Plasmid degradation or transgene silencing becomes thus much more important 
after 48h (Fig. 4). Cells were also transfected with eGFP to quantify the proportion of 
positive cells 24h after transfection. On average, 43 ± 3% of the cells were positive. Further 
kinetic studies with the eGFP plasmid were not performed, as the long half-life of eGFP 
(24h) complicates interpretation.  
 
 
Fig. 2: Relative viability of MDSCs 24h after electroporation with and without pGL4 plasmid compared to 
untreated cells measured by AlamarBlue (left) and by microscopic evaluation (right). EP = electroporation (n = 
4 and repeated in an independent experiment, * p <0.05) 
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Fig. 3: Bioluminescent signal 24h after lipofectamine 2000 mediated transfection of MDSCs with a luciferase 
encoding plasmid. Different lipofectamine:pDNA ratios (x-axis) and two cell densities were evaluated. (n=2 and 
repeated in an independent experiment) 
 
 
 
Fig. 4: Bioluminescent signal of MDSCs after lipofectamine 2000 mediated transfection of MDSCs with a 
luciferase encoding plasmid. (A) Bioluminescence signal per 5x10
3
 cells 24h, 48h and 72h after transfection. 
(B) Total bioluminescence signal 24h, 48h and 72h after transfection. (n=3 and repeated in an independent 
experiment) 
  
Lipofectamine 2000 mediated transfection of MDSCs with a IL-12 encoding plasmid 
To have an idea about the IL-12 production capacity of IL-12 transfected MDSCs we 
determined the amount of IL-12 produced after transfection of the MDSCs with an IL-12 
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encoding plasmid. Twenty-four hours after transfection 18 ± 3 ng of IL-12 per one million 
MDSCs was produced in the medium. MDSCs that were not transfected or transfected with a 
luciferase encoding plasmid did not secrete detectable amounts of IL-12.  
 
 
Fig. 5: CD80 expression on non-transfected MDSCs and on MDSCs transfected with an IL-12 encoding 
plasmid. CD80 expression was measured 24h after transfection. Transfections were performed with 
lipofectamine 2000. (n=4 and repeated in an independent experiment, ***p<0.001)  
 
Twenty-four hours after transfection we also determined the expression of the activation 
markers CD40, CD80 and CD86 on the surface of the MDSCs. Lipofection of the MDSCs 
with a plasmid encoding luciferase (control) or IL-12 did not significantly change the 
expression of CD40 and CD86. However, the expression of CD80 was significantly 
upregulated after lipofection of the IL-12 encoding plasmid (p<0.001, Fig. 5). This was not 
observed after lipofection of a luciferase encoding plasmid.  
 
Effect of IL-12 transfected MDSCs on the tumor killing capacity of lymphocytes 
The effect of IL-12 transfected MDSCs on the tumor killing capacity of lymphocytes was 
studied by coincubating either non-transfected or IL-12 transfected MDSCs with freshly 
isolated splenocytes and bioluminescent B16-F10 tumor cells. In the absence of MDSCs 
splenocytes reduce the median growth of B16-F10 tumor cells with 40% (p=0.04) compared 
to B16-F10 tumor cells without splenocytes (Fig. 6). In the presence of non-transfected 
MDSCs splenocytes were no longer able to reduce the growth of the B16-F10 cells with a 
median growth inhibition of -4% (Fig. 6). Interestingly, the splenocytes almost completely 
regained their ability to suppress tumor cell growth when IL-12 transfected MDSCs are 
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added to the splenocytes and B16-F10 cells which resulted in a median growth inhibition of 
23% (p=0.07, Fig. 6).  
 
Fig. 6: Relative growth of B16-F10 tumor cells in the presence of splenocytes from 4 different mice (separate 
lines) with and without the presence of non-transfected and IL-12 transfected MDSCs. S=splenocytes.  
 
In vitro migration 
An in vitro migration assay (Fig. 8) was performed to determine whether the cell line derived 
MDSCs still have the capacity to migrate in response to tumoral cytokines. This assay 
demonstrated that MDSCs migrate on average three times more to the bottom compartment 
when B16-F10 cells are present in the bottom compartment instead of culture medium (Fig. 
8, p=0.03). 
 
 
Fig. 8: Migration of MDSCs in a transwell system with only medium or B16-F10 cells with medium in the 
bottom compartment. The migration of the MDSCs when only medium was present in the bottom compartment 
was set as 100%. (n=3, *p<0.05) 
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5. Discussion 
A good cellular vehicle for cancer gene therapy should fulfill two important criteria. A first 
prerequisite is that the cells should efficiently migrate towards tumor cells. A second 
requirement is that the cells can be efficiently transfected without major cytotoxic effects. In 
this study we determined whether a MDSC cell line meets these requirements. Using an in 
vitro migration assay we demonstrated that these MDSCs migrate under the influence of 
tumor secreted factors, which confirms the potential of these cells as vehicles for tumor 
targeted delivery. Nevertheless, in vivo migration studies are necessary to confirm this 
finding. Subsequently, the possibilities to transfect this MDSC cell line with a luciferase 
reporter plasmid was studied. Electroporation was found not to be an adequate transfection 
method for these MDSCs due to the induction of cell death. Cell death was only observed 
when cells where electroporated with a plasmid, and not after mock electroporation (i.e. 
without plasmid). It can thus be concluded that the cell death is not due to the physical stress 
of electroporation, but due to the intracellular delivery of the plasmid. Most likely apoptosis 
or pyroptosis was induced by immune recognition of the foreign plasmid by intracellular 
pattern recognition receptors (PRRs) like e.g. DNA-dependent activator of interferon 
regulatory factors.
349
 Recognition of pDNA by intracellular PRRs has been described and 
well characterized in other myeloid cell lines.
350,351
 In contrast, transfection with LF2000 did 
not result in significant death of the MDSCs. This discrepancy with electroporation has also 
been observed by others and could be explained by the massive cytoplasmic influx of naked 
plasmid during electroporation and hence massive activation of the PRRs.
351
 Nevertheless, 
the immune related effects after plasmid electroporation are not necessarily coupled with 
transfection efficiency, so it is possible that by further optimizing the protocol, especially the 
pulse length, an efficient electroporation protocol can be found.
352
  
 
Lipofectamine 2000 mediated transfection of the MDSCs with an eGFP plasmid resulted in 
43% eGFP positive cells. Transgene expression per cell decreased significantly after 48 hours 
but the total expression by the total population of transfected cells remained similar, 
suggesting initially a dilution by cell division. After 72 hours also the total expression 
decreased significantly, suggesting plasmid degradation or transgene silencing. Increased rate 
of plasmid degradation over time can be explained by the initial very high amounts of 
plasmid DNA per cell, vastly exceeding the capacity of endonucleases present in each 
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individual cell. As the plasmid becomes more diluted, more endonucleases per plasmid copy 
will become available, and degradation will occur more rapidly. Also transgene silencing 
could explain the loss of signal after 72 hours. Indeed, transgene silencing can occur 
immediately after transfection but also after a certain period of adequate expression.
353
  
 
To be effective as a cellular vehicle for tumor targeted delivery the pDNA transfected 
MDSCs in this work should migrate within 48h after transfection towards the tumor. 
Additionally, the temporarily expression of the therapeutic molecule, like e.g. IL-12, has to 
be sufficient for inducing a biological effect. Preliminary in vivo data demonstrated that the 
cell line derived MDSCs indeed migrate to tumor tissue within 48h (data not shown).Twenty-
four hours after transfection the MDSCs had produced 18 ng of IL-12. In the literature it has 
been demonstrated that IL-12 transfected cells, which produce similar amounts of IL-12, can 
convey anti-tumor effects in mice and humans.
354,355
 The IL-12 production capacity of 
MDSCs after transfection with LF2000 should thus be sufficient. However, there is no data 
on how long this production capacity should be maintained to result in anti-tumor effects.   
 
The MDSC cell line reacted itself on the IL-12 it produces by upregulating CD80. Depending 
on the other receptors present on immune effector cells, CD80 can either act as a 
costimulatory (CD28 receptor) or inhibitory (CTLA-4 receptor) signal.
356
 The functional 
effect of this upregulation can thus not be predicted. It is however known that MDSCs in a 
tumor microenvironment also upregulate CD80 expression upon IL-12 treatment and this is 
associated with a decrease in their immunosuppressive function.
126,132
 This is encouraging, 
because using IL-12 as a therapeutic protein has thus the potential to decrease the 
immunosuppressiveness of MDSCs. Nevertheless, in an in vitro killing assay we found that 
IL-12 transfection reduced, but not completely eliminated the immunosuppressive capacity of 
the MDSCs. Better anti-tumor effects could be potentially obtained by introducing a selection 
marker in the IL-12 plasmid, as only 43% of the MDSCs were currently transfected. Only 
selecting IL-12 transfected MDSCs will result in the same IL-12 concentration with less 
MDSCs, potentially tipping the balance more in the direction of anti-tumor effects of IL-12 
than towards the pro-tumor effects of MDSCs. 
 
 
 132 
 
  
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General discussion 
134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General discussion 
 
1. Overview  
An in depth discussion and relation to the literature of the specific results is included in the 
different chapters. Here, a more general discussion of the treatment modalities used in this 
thesis is presented.  
 
Gene therapy 
A large part of this thesis is relying on gene therapy to convey therapeutic effects. For IL-12 
gene therapy, the rationale is a constant local source of IL-12 production, necessary because 
of its systemic toxicity and short half-life. For genetic tumor vaccination, the expression of 
the antigen by the cells after gene therapy mimics best the actual situation of target cells 
expressing the antigen.  
 
Despite these advantages, one might question the clinical potential of gene therapy as until 
now only one approach based on gene therapy (unrelated to cancer) is approved for clinical 
use by the European Medicines Agency (EMA), and none by the FDA.
357
  The entire field of 
gene therapy has been severely hindered by the occurrence of serious adverse effects in the 
first clinical trials. In 1999, a patient died after a massive immune response against the viral 
vector, which prompted the FDA to re-evaluate the regulation of gene therapy trials.
358
 Later, 
a second major setback happened, when the initial success of total cure of an otherwise fatal 
immunodeficiency disorder was overshadowed by the development of a leukaemia-like 
disorder in two patients as a result of insertional mutagenesis.
359
   
 
However, these serious adverse effects are vector-related and are not a risk for plasmid based 
gene therapy, the method selected in this thesis.
360
 In the clinical trial database of the Journal 
of Gene Medicine (Wiley Database), 2210 clinical trials with gene therapy are listed, with 
64% of them in oncology and 79 already in phase III trials. Most common gene types under 
consideration are antigens (20%) and cytokines (16%).
361
 These data clearly indicate the 
potential of gene therapy in the treatment of cancer in general, and more specifically for 
vaccination and cytokine therapy as well as its suitability to proceed into clinical evaluation. 
 
Alternatives for gene therapy do exist, both for sustained local production of IL-12 and 
cancer vaccination approaches.
362-364
 However, gene therapy often compares advantageous 
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compared to the alternatives because of low production cost and high stability of plasmid 
DNA.
360
  
 
Vaccination against self-antigens 
In this thesis we vaccinated against self-antigens. The principle of vaccination against self-
antigens raises two important questions; can it be effective and if so can it be safe. 
Autoreactive T cells are a normal component of the peripheral T cell repertoire. In contrary to 
early believes, T cells are to a certain extent cross-reactive and deletion of all autoreactive T 
cells would compromise the recognition of non-self-antigens.  Instead, deletion is based on 
avidity, the concentration of antigen necessary for the induction of T cell activation and 
effector functions. T cells with high avidity (low threshold) for self-antigens are deleted, but 
cells with low avidity for self-antigens are allowed in the periphery. They will not be 
activated by physiological levels of self-antigen expression but can have at the same time a 
high avidity for non-self-antigens, thereby contributing to immunity against pathogens.
365
 In 
conclusion, the presence of autoreactive T cells proves that vaccination against self-antigens 
is theoretically possible and the control of avidity provides a window of doing so without 
causing overt autoimmunity.  
 
The targets for vaccination against self-antigens are thus low avidity T cells. These cells are 
very difficult to activate with the native antigen, even at high antigen concentration.
366
 
However, the discovery of altered peptide ligands was a major breakthrough in the 
manipulation of these low avidity T cells. Epitopes that only differ from the native self-
epitopes by one or a few amino acids influence the stability of MHC-peptide-TCR binding 
and can lead to efficient fully functional activation of low avidity T cells. Once activated, 
these low avidity T cells can exert their cytolytic functions against target cells expressing 
high levels of the native antigen.
366,367
 During activation, avidity of T cells is increased, 
requiring less antigen for exerting effector functions.
368
 The extent of this avidity increase 
depends on the structure of the altered peptide ligand and this can exceed the safety threshold 
for autoimmunity. However, peripheral tolerance mechanisms are in place to delete these 
high avidity T cells after activation.
369
 Similarly, the increase of avidity in memory T cells is 
controlled in the case of self-antigens by peripheral tolerance mechanisms.
370,371
 Therefore, 
with altered peptide ligands, it is possible to activate low avidity T cells that will only 
recognize cells overexpressing the antigen above physiological levels, providing a clear 
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therapeutic window for vaccination against self-antigens. One way to provide altered peptide 
ligands is to use xenogeneic vaccination, the strategy used in this thesis.
287
  
 
This mode of action has a clear implication for therapeutic use: only patients that have a 
strong overexpression of the antigen can benefit from such vaccination strategy. For VEGFR-
2, this has been demonstrated in a wide variety of tumor types.
372
 Ideally, patient selection 
occurs on an individual basis, for instance by non-invasive imaging of VEGFR-2 expression 
by PET.
373
 For VEGFR-2, the safety margin between normal and tumoral expression appears 
to be quite wide, as even the adoptive transfer of CAR T cells recognizing VEGFR-2, having 
higher avidity than naturally evoked T cells, seems to be safe in rodents and is currently 
tested in humans (NCT01218867).
374
 
 
Despite the theoretical foundation of a safety margin as discussed above, one has to keep in 
mind that vaccination can have a life-long effect that is difficult to control afterwards. 
Moreover, the safety of vaccines against self-antigens relies on intact tolerance mechanisms 
that are yet incompletely understood.
365
 For now, only one tumor vaccine directed to self-
antigen is approved for clinical use. The bottleneck in the approval of tumor vaccines is 
currently mainly limited efficacy, and not toxicity.
375
 Time will tell if, when tumor vaccines 
become more efficacious, the risk for autoimmunity will become an important limitation in 
the regulatory approval of such vaccines. Progress in induction of antigen-specific tolerance 
might diminish this risk in the near future, providing a safety mechanism when unforeseen 
autoimmune reactions occur.
376
  
 
An alternative to obtain tumor reactive CD8 cells is the adoptive transfer of (genetically 
modified) T cells (TIL therapy, TCR modified T cells and CAR T cells).
377
  Very impressive 
results have been published, but it is also associated with severe toxicity, either by the 
lymphodepletion and high dose IL-2 therapy necessary for TIL-therapy or on-target toxicity 
because of the unnatural affinity of genetically modified T cells, which resulted in death of 
patients in three trials.
377
 Moreover, adoptive transfer is technically challenging, whereas 
vaccination is a simple procedure.  
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Anti-angiogenesis 
The VEGFR-2 vaccine evaluated in this thesis relies on an anti-angiogenic mechanism of 
action. The rationale for anti-angiogenic treatment has been postulated in the early 1970’s 
and is still sound: tumors need blood supply to grow beyond 2mm, hence targeting tumoral 
blood vessels will result in anti-tumor activity. Although different anti-angiogenic drugs have 
been approved for clinical use (e.g. bevacizumab (an anti-VEGF monoclonal antibody) and 
sunitinib (a small molecule inhibitor)), results are rather disappointing. Survival benefit is 
measured in the range of months, with durable responses very rare.
378
 The reason is the 
occurrence of resistance, because of many redundant pathways in the regulation of 
angiogenesis.
379
  
 
However, in contrast to traditional anti-angiogenic drugs that inhibit a pathway, VEGFR-2 
vaccination will ideally result in destruction of the endothelial cells. It is conceivable that this 
will have profound implications for the occurrence of resistance. In our models however, 
vaccination against VEGFR-2 did not have a significant impact on tumor growth. A possible 
explanation is the known limited efficacy of tumor vaccines as monotherapy, due to the local 
immunosuppressive tumor microenvironment. If the vaccine can be rendered more 
efficacious, a direct comparison with traditional anti-angiogenic drugs regarding the 
development of resistance would be highly interesting, possibly revealing a unique advantage 
of active immunization as anti-angiogenic treatment.  
 
Another limitation of anti-angiogenic treatment is that total eradication of tumor cells is not 
possible. In the best case, if anti-angiogenic treatment is completely effective, small dormant 
tumor islands, capable of surviving without blood vessel supply, will persist and regrow 
when anti-angiogenic treatment is discontinued.
380
  Again, active immunization may offer a 
unique advantage, as memory immune cells can convey life-long control forcing tumor cells 
to stay dormant.  
 
Importantly, influencing angiogenesis can have an effect on invasion and metastasis 
pathways, which we also observed with our vaccine.
327
 As HIF-1a is a major mediator of the 
response of tumor cells to hypoxia, combining anti-angiogenic treatment with an HIF-1a 
inhibitor (e.g. topotecan) may disrupt this association.
381
 In this context, an interesting tool in 
the development of anti-angiogenic therapeutic interventions is mathematical modelling by 
computational biology.
382
 With the vast knowledge of signalling pathways implicated in 
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angiogenesis and interactions of these pathways with other biological processes, such effects 
can hopefully in the future be predicted early on instead of being dependent on observations 
in preclinical experiments.  
 
Apart from VEGFR-2 vaccination, also IL-12 and metronomic cyclophosphamide have anti-
angiogenic activity. Combining these treatments could also work synergistically in that 
context, on top of their synergistic immunological effects. This is especially interesting, 
considering that the key to improving anti-angiogenic treatment is thought to be combination 
therapy acting on multiple pathways thereby limiting escape strategies.
379
  
 
In conclusion, although anti-angiogenesis in general or our VEGFR-2 vaccine has not yet 
been able to meet its potential, we still believe firmly in the concept of anti-angiogenic 
treatment and especially by active immunization. However, combination of our vaccine with 
agents that tackle the immunosuppressive tumor environment, increase the immunogenicity 
of the vaccine and abolish hypoxia mediated deleterious effects is deemed necessary for 
successful anti-tumor activity.  
Immune modulation by selective depletion of immune subsets 
In this thesis, regulatory T cells were targeted by metronomic cyclophosphamide. Selective 
toxicity of chemotherapeutica for certain cell types might seem unexpected but several 
mechanisms have been elucidated. The selectivity of low dose cyclophosphamide for Tregs is 
explained by reduced detoxification of cyclophosphamide, because Tregs contain low ATP 
levels.
147
 Another example includes selective toxicity of 5-fluorouracil (5-FU), a thymidylate 
synthase inhibitor, for MDSCs. MDSCs are much more sensitive to 5-FU because they 
expression much lower levels of thymidylate synthase than other cells.
383
  As both MDSC 
and regulatory T cells are major regulators of tumor induced immune suppression, strategies 
to revert immune suppression should at least address both cell types. However, many immune 
subsets can have an immune-regulatory phenotype, including NK cells, dendritic cells, B 
cells and macrophages.
384-387
 Moreover, also non-immune stromal cell suppress immune 
responses in cancer.
388
  
 
Therefore, it might be more meaningful to interfere more downstream on T cells rather than 
targeting a specific immunosuppressive cell type. Immune checkpoint inhibitors use this 
strategy by blocking inhibitory pathways on T cells and have shown impressive efficacy.
389
 
However, more downstream interference also will have a more profound impact, 
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circumventing many natural control mechanisms. Indeed, autoimmune manifestations after 
immune checkpoint therapy are common.
390
 Especially with combination therapies, its safety 
will have to be carefully determined. 
 
Immunotherapy 
Last but not least, although the recent successes of immunotherapy are considered a major 
breakthrough in cancer treatment, one might wonder if this is not premature, considering the 
low number of responding patients. However, for the first time in decades of intensive 
research, immunotherapy gives hope that a cure of cancer may be possible after all. Although 
significant progress has been made with chemotherapy and targeted therapies, durable 
response also after cessation of treatment remains very rare.
391,392
 The occurrence of enduring 
responses and even complete responses in cancers that were incurable in the past makes 
immuno-oncology an important emerging field, deserving the attention it has been receiving 
in recent years.
392
  
 
Only a low number of patients respond to cancer immunotherapy. So the question remains 
how to improve the proportion of responding patients. An important factor could be the 
combination of different immunotherapeutic agents, the foundation of this thesis. For 
instance, the success of immune checkpoint inhibitors is related to the mutation rate of 
tumors, representing immunogenic tumors.
393
 It is indeed logical that immune checkpoint 
inhibitors only have an effect if activated anti-tumoral T cells are naturally present. For 
inherently non-immunogenic tumors, this can be achieved by combining with a vaccination 
approach. Similarly, with vaccination you might elicit activated T cells, but if this is not 
combined with a strategy to revert immune suppression, these activated T cells will be 
rendered useless in the tumor microenvironment. Therefore, combining immunotherapeutic 
agents may be strongly synergistic and be the key to increasing the number of responding 
patients. 
 
Another important improvement would be the discovery of predictive biomarkers.
394
 The 
discrepancy between the high proportion of patients that do not respond and the low 
proportion of patients that have a long lasting response clearly indicate subpopulations. If we 
can identify the patients with the potential to respond to certain immunotherapeutic 
treatments, a patient tailored treatment selection could be applied resulting in an overall 
higher number of responding patients. Additionally, biomarkers could also be used for 
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follow-up during treatment.
395
 Clinical response to immunotherapy can take a long time to 
develop, if surrogate biomarkers are developed that can evaluate sooner if the treatment is 
working, non-responding patients can be identified earlier and switched to another treatment.  
 
Also combination with non-immunotherapeutic treatments could significantly impact the 
response rate to immunotherapy. Firstly, non-immunotherapeutic treatments can work 
synergistically with immunotherapy. For instance, different chemotherapeutics and radiation 
induce immunogenic cell death and surgical debulking removes the gross 
immunosuppressive environment.
396-398
 Secondly, traditional treatments can just provide the 
time for immunotherapy to work. As said before, clinical responses to immunotherapy can 
take months to develop, and some patients with advanced disease do not have that time. On 
the other hand, optimal combinations and timing will have to be carefully determined. 
Chemotherapy and radiation therapy can result in immune depletion, and also surgery is 
associated with an immunosuppressive state.
399-401
  
 
In conclusion, immunotherapy makes the dream of curing cancer within reasonable reach, 
which justifies the excitement it currently receives. However, the low number of responding 
patients remains a sore point. Many potential strategies to increase this number can be 
hypothesized which will take considerable time to validate and optimize, but hopefully 
finally result in what has long seemed like a lost battle, a cure against cancer.  
 
2. Limitations and reflections 
In chapter 1 not all stand-alone therapies and possible combinations are evaluated, but 
instead the different groups were selected from a practical point of view. This was done to 
comply with the 3 R principles. No treatment groups without IL-12 were included, as there 
was ample prior knowledge that this would be the most potent component of the combination 
treatment. Two key questions needed addressing. First, has metronomic cyclophosphamide 
value as Treg depleting agent on top of IL-12? Although IL-12 has no direct effect on Tregs, 
it is possible that they deplete Tregs indirectly, for instance via their effect on MDSCs.
126
 
Therefore, groups with IL-12 stand-alone therapy and the combination of IL-12 and 
metronomic cyclophosphamide were included. It was concluded that only metronomic 
cyclophosphamide could deplete Tregs. Because of the known beneficial effects of Tregs 
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depletion for immunotherapy, and the low cost, easy administration and good tolerability, this 
information was enough to decide to include it in the combination therapy.
402
 Tumor 
vaccination is much more expensive and less convenient. Therefore, a direct comparison of 
IL-12 and metronomic chemotherapy and the full combination was deemed necessary, to 
provide a proof of concept that vaccination indeed could have and added value in this 
combination therapy, which was indeed the case. An important limitation is that the results 
were only obtained in one tumor model. Because of the restrictions of rodent tumor models, 
we plan to directly confirm the potential of this combination treatment in dogs, instead of 
evaluating it in more rodent tumor models.  
 
More information could potentially have been obtained from the clinical study in chapter 2. 
For metronomic temozolomide, the selection of only one dose was from a scientific point of 
view clearly not optimal, especially when one knows that no information is available in the 
literature about the optimal metronomic dose of temozolomide. In the same context, the 
evaluation of the angiogenic markers could have been much more informative if more doses 
of both chemotherapeutic drugs were included, allowing for a pharmacodynamic dose-
response to be evaluated. Both shortcomings in this chapter were a result of the limited 
number of canine cancer patients that were eligible for the study. This study was conducted at 
the university veterinary clinic (Ghent University) and metronomic chemotherapy was 
proposed next to other treatments to owners. Owners that visit the university veterinary clinic 
want the best treatment for their pets and are less inclined to choose for this palliative 
treatment. Accrual of patients in first-line veterinary practices may lead to higher patient 
numbers for metronomic chemotherapy, where convenience and costs are important 
considerations next to the chance and degree of efficacy. Another limitation of this study is 
the absence of a clinical follow-up. It was not deemed feasible to have enough patient 
numbers to include a control group. Moreover, also as a single-arm trial, the high 
heterogeneity of patients precludes meaningful conclusions of efficacy. Therefore, 
conclusions were restricted to the repeated measurements of biological parameters.  
 
The evaluation of the VEGFR-2 vaccine in chapter 3 and 4 and the MDSC cell line as 
vehicle for gene therapy in chapter 5 is only the beginning. More research is needed to 
clarify the mechanism by which VEGFR-2 vaccination promotes early liver micrometastases 
and its relevance in tumor models where the liver is an important site of metastases has to be 
determined. Moreover, despite the occurrence of an immune response, anti-tumor effects of 
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the vaccine are ranging from modest in a prophylactic setting to absent in a therapeutic 
setting. Therefore, at this moment, the positive result in chapter 3 regarding immunogenicity 
of the vaccine are very conditional on better efficacy of the vaccine by for instance 
combination treatment and better understanding of the pro-metastatic effects. For the MDSC 
cell line, further optimization of transfection and demonstration of tumor-specific migration 
in vivo are some of the following steps to be undertaken before therapeutic evaluation can be 
started.   
 
3. Perspectives 
The question is not if immunotherapy will become a mainstay in cancer treatment, but when. 
What is unique and very promising for immunotherapy compared to other treatments is not 
the proportion of patients that benefit from it, but the extent to which certain patients benefit. 
Patients with advanced disease, where all other treatment options fail, have experienced 
complete responses on immunotherapy.
392
 Most success has been achieved with ipilimumab. 
For example when melanoma patients are treated with ipilimumab around 20% survive up to 
3 years. Interestingly, after this time point survival curves form a plateau at least up to 10 
years, meaning that when achieving this milestone chance of dying of melanoma are 
minimal.
403
 Although long term survival does not automatically mean that patients are 
completely free from tumor, investigators have already introduced the concept of curative 
potential of immunotherapy.
404
 Although the extent to which patients might benefit is 
spectacular, the reality is that most patients do not. It is believed that the answer to increase 
responding patients lies in combinatory immunotherapy.  
 
The work in this thesis has set the first steps towards the evaluation of such a combinatory 
treatment in dogs. This is continued in the Laboratory of Gene therapy with clinical trials in 
dogs with intratumoral IL-12 gene therapy and the combination of intratumoral IL-12 gene 
therapy and metronomic cyclophosphamide ongoing. The latter combination will be 
complemented with a vaccination approach when this is available. Also the research on 
MDSCs as cellular vehicles for tumor targeted delivery of IL-12 will be continued.
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The use of the immune system as a therapy against cancer is an option explored since the late 
19
th
 century. However, so far results have been disappointing. This can be explained by the 
vast complexity of interactions between tumor and immune cells, of which many details still 
have not been elucidated. Indeed, earlier believes that the immune system fails to recognize 
the tumor as a malignant process and should thus be taught to do so have now been 
overthrown. Paradoxically, it is the actions of the immune system that select those mutated 
cells with strategies to evade attacks of the same immune system. These defensive strategies 
will often abuse those mechanisms used by the body to prevent autoimmunity and excessive 
immune responses. 
 
As these mechanisms work via different pathways, it can be understood that immunotherapy 
should likely address several of these pathways to be effective. Therefore, a combination 
immunotherapy based on three mechanisms is evaluated in this thesis. Firstly, tumor 
vaccination is used to address the deficient antigen presentation in tumors, which promotes 
tolerance rather than active immune responses. Secondly, interleukin-12 (IL-12) gene therapy 
is used to convert the immunosuppressive microenvironment, elicited by the tumor, toward 
immune stimulatory. Indeed IL-12 stimulation has the capacity to stimulate T cells, make NK 
cells cytotoxic and turn the normally immunosuppressive myeloid derived suppressor cells 
(MDSCs) into antigen presenting cells. As the final part of this combination therapy, 
metronomic chemotherapy will be included to diminish the effect of regulatory T cells 
(Tregs), also an important population of immunosuppressive cells. 
  
The final goal of this thesis is the evaluation of this combination therapy in dogs, both from a 
veterinary perspective and to maximize the potential of this species as a highly translational 
research model. 
 
Chapter 1 describes the application this therapy in a mouse model of melanoma. Mice were 
treated with IL-12 gene therapy alone, or with addition of metronomic cyclophosphamide 
(CPX), or with genetic human tyrosinase (hTyr) vaccination and metronomic CPX. These 
different groups were compared for both immunological effects and survival. The IL-12 gene 
therapy group showed a considerable clinical effect, with necrosis of the tumor already after 
one day. This resulted in complete disappearance of the tumor in 60% of the mice. Because 
of the rapidness of the onset of necrosis we investigated possible directly cytotoxic effects. 
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However, no direct cytotoxicity of IL-12 could be elicited in vitro. To confirm the 
involvement of the immune system we investigated in vitro if NK or CD8 cells were able to 
respond this rapidly to IL-12. Indeed, NK cells, but not CD8, showed heightened cytotoxicity 
towards tumor cells 24 hours after IL-12 exposure. The addition of metronomic CPX induced 
a reduction in the number of Tregs, not observed with IL-12 as monotherapy. This addition 
also resulted in longer survival in mice whose tumors never completely regressed, although 
the number of mice with such complete regression did not increase. The final addition of 
tumor vaccination did increase the number of mice with complete regression. Most of these 
extra mice had tumors that fully regressed only at later time-points, a phenomenon not 
observed without the vaccination addition. Furthermore, only in this group a specific cellular 
immune response was found after a tumor rechallenge in cured mice. A humoral immune 
response however, was present in all three groups after tumor rechallenge. 
 
Chapter 2 describes a clinical study in dogs, in which the potential of metronomic 
cyclophosphamide (12.5 mg/m
2
) and temozolomide (6.6 mg/m
2
), separately or combined, to 
decrease Tregs in cancer patients was investigated. Additionally, vascular growth factor 
(VEGF) and thrombospondin-1 (TSP-1), two important angiogenetic markers, were 
quantified to assess the anti-angiogenetic potency of this treatment. Regulatory T cells 
decreased significantly when dogs were treated with cyclophosphamide, but not for 
temozolomide. Since temozolomide was used for the first time with this purpose in dogs, the 
dosage was highly experimental. Therefore, it is very likely that this finding is a result of an 
inappropriate dose rather than unsuitability of this drug. Metronomic cyclophosphamide 
however, can be used with the current dosage for this purpose in dogs. Both treatments did 
not affect the angiogenetic biomarkers VEGF or TSP-1, but again both treatments should be 
used at different doses before inferring on the value of these markers in dogs.  
 
Chapters 3 and 4 describe the evaluation of a universal tumor vaccine, which would allow a 
broad application of this combination therapy in veterinary oncological patients. A target 
holding this promise is vascular endothelial growth factor receptor-2 (VEGFR-2), a receptor 
considerably expressed in tumor blood vessels. Therefore, the immunogenicity of a human 
VEGFR-2 plasmid was evaluated in healthy mice for different doses and vaccination 
schedules. This confirmed earlier reports that induction of a humoral immune response 
required higher doses and more boosts than the cellular immune response. The safety of 
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vaccination against VGEFR-2 was tested in two ways. On the one hand, wound healing, 
which is physiologically supported by VGEFR-2, was assessed and found to be normal. On 
the other hand two cell populations expressing VEGFR-2, i.e. Tregs and MDSCs, were 
followed and found to remain unharmed by the vaccination. Consequently, the same 
vaccination was evaluated in healthy dogs. Also in this species we were able to elicit both a 
cellular and humoral immune response, albeit only after the third vaccination. This 
experiment also made clear that light sedation and local anesthesia are not sufficient. 
However, no adverse effects were observed. 
 
Finally, in chapter 4 the vaccine was evaluated in a mouse model of breast cancer and 
melanoma in both a preventive and curative design. Although increased survival was only 
observed with preventive use, curative vaccination decreased bioluminescence compared to 
equally large control tumors probably indicating central necrosis. An unexpected finding was 
that both vaccination strategies increased the presence of micrometastases in the liver, even 
though no such effect was found in the lungs. Mice had to be euthanized before these 
metastases could become macroscopic. Therefore, to evaluate the progression of these 
metastases, an additional group was included were the primary tumor was surgically 
removed. Although metastases in the lung progressed, liver metastases remained 
microscopic. Additionally, liver metastases of control animals increased to the same level as 
those of vaccinated animals. The relevance of these early vaccine-induced liver metastases 
can thus not be sufficiently assessed with these data. Possible explanations based on literature 
can be the adaptation of the primary tumor to vaccine-induced hypoxia, not only stimulating 
metastasis formation, but also selecting cells that thrive under hypoxia. Indeed, relative 
hypoxia is known to be present in the liver, but naturally not in the lungs. The ultimate 
consequences of this metastasis induction should be evaluated with tumor models, contrary to 
the current ones, for which the liver is a natural metastatic site.      
 
Chapter 5 describes the first steps toward broadening the application of IL-12 therapy to 
tumors and metastases that are not accessible for electroporation. This poses a challenge 
since systemic administration of IL-12 is impeded by its toxic side-effects. A possible 
solution to this challenge is to use cells with the capacity to migrate to tumor tissue, that have 
been loaded with therapeutic agents. For IL-12, cells could be transfected in vitro with a 
plasmid encoding IL-12, be systemically infused after which they will migrate to the tumor 
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and express the plasmid locally. MDSCs migrate strongly towards tumor tissue and hence 
could be used for this approach. However they also have pro-tumoral effects. Therefore, the 
loaded therapeutic agent should have an effect great enough to (over)compensate for these 
effects. An advantage of IL-12 in this light is its ability to diminish the pro-tumoral 
characteristics of these MDSCs, apart from its own anti-tumor effects. In this chapter we used 
a murine MDSC cell line, and evaluate if this cell line has retained the ability to migrate 
towards tumor cells and if this cell line could be transfected with physical (electroporation) or 
chemical (lipofectamine 2000) methods. These transfection methods have the advantage to 
allow rapid evaluation of candidate therapeutic agents. However, electroporation induced 
extensive cell death, but only when MDSCs were transfected with plasmid. Previous research 
has indeed shown that large quantities intracellular plasmid after electroporation can induce 
apoptosis via immunological reaction of cells to the plasmid. No significant cell death was 
however observed with the chemical transfection vector that was used, i.e. lipofectamine 
2000. Using this method we observed a transfection efficiency of only 43% and a strong 
decrease of expression after 72 hours. However, during this time MDSCs could produce 
therapeutically relevant concentrations of IL-12. Moreover, MDSCs responded to their own 
IL-12 production by upregulation of CD80, which is associated with decreased 
immunosuppressive function. This was indeed confirmed in a preliminary in vitro 
experiment, but the final effect remained pro-tumoral. The in vitro migration assay confirmed 
that these cells strongly migrate towards tumor secreted factors. In conclusion, this promising 
method could be exploited if more efficient transfection would be achieved. Indeed, the 
majority of MDSCs are currently not transfected and thus do not contribute to therapeutic 
effect, leaving only their pro-tumor characteristics.  
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Samenvatting 
 
Kanker behandelen door het eigen immuunsysteem in te schakelen wordt reeds sinds 1890 
verkend, maar heeft lang enkel tot teleurstellende resultaten geleid. Dit is te verklaren door de 
enorme complexiteit van de interacties tussen tumorcellen en immuuncellen, die lang 
onvoldoende gekend was. Waar men vroeger dacht dat het immuunsysteem de tumor niet 
herkent als een indringer, en de sleutel tot succesvolle behandeling dus zou zijn om het 
immuunsysteem hiervan bewust te maken, weet men nu dat dit allesbehalve waar is. Een 
tumor is niet onzichtbaar voor het immuunsysteem, maar heeft in de loop van zijn 
ontwikkeling allerlei strategieën ontwikkeld om zich te beschermen tegen een aanval van het 
immuunsysteem. Het misbruikt hierbij mechanismen die fysiologisch aanwezig zijn in het 
lichaam om het immuunsysteem te controleren, om auto-immuniteit en een overdadige 
immuunrespons te voorkomen.  
 
Daar de tumor een effectieve immuunrespons op verschillende niveaus verhindert, moet 
immuuntherapie ook op verschillende niveaus ingrijpen om deze situatie weer om te keren. In 
deze thesis werd een combinatietherapie geëvalueerd die aan deze voorwaarde voldoet. 
Tumor vaccinatie werd geïncludeerd omdat antigen presentatie in de tumor inefficiënt 
gebeurt, wat aanleiding geeft tot tolerantie in plaats van activatie. Interleukine-12 (IL-12) 
gentherapie helpt de lokale micro-omgeving van de tumor te converteren van 
immuunsuppressief naar immuunstimulerend. IL-12 kan het effect van vaccinatie versterken 
door T cellen lokaal te stimuleren en ook complementeren door daarnaast NK cellen aan te 
zetten tot cytotoxiciteit. Verder werden myeloid derived suppressor cells (MDSCs), 
immunosuppressieve cellen gerekruteerd door de tumor, onder invloed van IL-12 omgezet 
naar niet-immunosuppressieve antigen-presenterende cellen. Ten laatste werd metronomische 
chemotherapie aan de combinatiebehandeling toegevoegd om zo ook het effect van 
regulatorische T cellen (Tregs), de tweede belangrijke populatie van immunosuppressieve 
cellen, te kunnen verminderenen. Het uiteindelijke doel is de evaluatie van deze 
combinatiebehandeling in honden, zowel voor de hond als doeldier als voor model voor de 
mens. 
 
In hoofdstuk één werd deze combinatie getest in een melanoma muismodel. Muizen met een 
tumor werden behandeld met IL-12 gentherapie, IL-12 gentherapie en metronomische 
cyclofosfamide of IL-12 gentherapie, metronomische cyclofosfamide en genetisch vaccinatie 
met human tyrosinase. De immunologische effecten in de verschillende groepen werd 
nagegaan, en overleving vergeleken. IL-12 gentherapie had op zichzelf een zeer sterk 
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klinisch effect. Eén dag na de behandeling trad er al een duidelijke necrose van de tumor op. 
Bij ongeveer 60% van de muizen verdween de tumor uiteindelijk ook volledig. Dit zeer 
snelle effect zou kunnen duiden op een rechtstreeks effect van IL-12 op de tumorcellen, 
zonder tussenkomst van het immuunsysteem. Dit werd nagegaan in een in vitro test, maar een 
direct cytotoxisch effect van IL-12 op de tumorcellen was afwezig. In een andere in vitro test 
werd nagegaan of NK cellen of CD8 cellen zo snel kunnen reageren op IL-12 stimulatie en 
dit dus een mogelijke verklaring is voor het snelle in vivo effect. Daaruit bleek dat NK cellen, 
maar niet CD8 cellen binnen 24 uur verhoogde cytotoxiciteit ten opzichte van de tumorcellen 
vertoonden onder invloed van IL-12. IL-12 behandeling op zichzelf had geen effect op Tregs, 
wat wel gezien werd in de combinatiegroep IL-12 gentherapie + metronomische 
cyclofosfamide. Toevoeging van metronomische cyclofosfamide resulteerde niet in een 
verhoogd aantal muizen waarbij de tumor volledig verdwijnt, maar wel in een langere 
overleving van de muizen waarbij de tumor niet volledig verdween. Als het vaccin werd 
toegevoegd aan de behandeling, leidde dit tot een verhoogd aantal muizen waarbij de tumor 
volledig verdween. Dit laatste werd gekarakteriseerd door bijkomende muizen met een 
regresserende tumor op een later tijdspunt dan zonder het vaccin. Alleen in de gevaccineerde 
groep kon een specifieke cellulaire immuunrespons aangetoond worden na een rechallenge in 
de genezen muizen. In de groepen die geen vaccin kregen toegediend, was er op dat moment 
enkel een humorale immuunrespons aanwezig.  
 
In een eerste klinische studie werd nagegaan of metronomische cyclofosfamide (aan een 
dosis van 12.5 mg/m
2
) ook bij honden met kanker de Tregs kan doen dalen. Een tweede 
chemotherapeuticum met een effect op Tregs bij muizen en mensen, temozolomide (aan 6.6 
mg/m
2
) werd eveneens geëvalueerd, net zoals de combinatie van beide geneesmiddelen. 
Naast het effect op Tregs in het bloed, werden ook twee belangrijke angiogenetische merkers  
(vascular endothelial growth factor en thrombospondine-1) geëvalueerd. Het is immers 
gekend dat metronomische chemotherapie ook een anti-angiogenetische werking heeft. 
Metronomische cyclofosfamide resulteerde in een significante daling van Tregs. 
Metronomische temozolomide had geen effect op de hoeveelheid Tregs, waarschijnlijk door 
een te lage dosis. Beide chemotherapeutica hadden geen effect op de angiogenetische 
merkers. Er kan geconcludeerd worden dat metronomische cyclofosfamide aan de 
geëvalueerde dosis bij honden kan gebruikt worden als Treg depleterende behandeling in 
immunotherapie. Voor metronomische temozolomide is meer onderzoek vereist met hogere 
dosissen. Aangezien beide metronomische chemotherapeutica geen effect hadden op de 
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angiogenetische merkers, maar ook maar één dosis geëvalueerd werd, kunnen er geen 
conclusies getrokken worden over de farmacodynamische waarde van deze merkers bij de 
hond. 
  
Om de combinatiebehandeling ruimer toepasbaar te maken dan enkel melanoma zou een 
universeel kankervaccin nodig zijn. Daarom werd in hoofdstukken 3 en 4 een universeel 
tumorvaccin geëvalueerd. Dit bestaat uit een plasmide coderend voor humaan vascular 
endothelial growth factor-2 (VEGFR-2), toegediend in combinatie met elektroporatie. 
VEGFR-2 wordt in belangrijke mate tot expressie gebracht in tumorale bloedvaten. In 
gezonde muizen werd de immunogeniciteit van human VEGFR-2 DNA vaccin bij 
verschillende dosissen en vaccinatieschema’s bestudeerd. Hierbij werd duidelijk dat de 
ontwikkeling van een humorale immuunrespons een hogere dosis en meer boosts nodig had 
dan de ontwikkeling van een cellulaire immuunrespons. Dit is een gekend fenomeen bij 
genetische vaccinatie. Aangezien VEGFR-2 de wondheling ondersteunt werd door middel 
van een wondhelingassay de veiligheid van het vaccin nagegaan. Geen vertraagde 
wondheling werd waargenomen. Ook bleven de percentages van Tregs en MDSCs, die 
eveneens VEGFR-2 tot expressie kunnen brengen, onveranderd bij gevaccineerde muizen. 
Vervolgens werd het vaccin geëvalueerd in gezonde honden. Hierbij werd duidelijk dat het 
voorziene protocol van lichte sedatie en lokale anesthesie niet aan te raden is voor 
elektroporatie bij honden. Heftige schrikreacties werden uitgelokt, die weliswaar van zeer 
korte duur waren. Een cellulaire en humorale immuunrespons kon worden opgewekt, zij het 
enkel aantoonbaar na de derde vaccinatie. Het vaccin werd vervolgens geëvalueerd in muizen 
met kanker, in een borstkankermodel en melanomamodel. Effect op tumorgrootte en 
overleving was matig wanneer profylactisch werd gevaccineerd en afwezig wanneer 
therapeutisch werd gevaccineerd. Bij de therapeutische vaccinatie werd wel een verschil in 
bioluminescentiesignaal van de tumor opgemerkt, suggestief voor het optreden van necrose. 
Onverwacht was er in beide tumormodellen, zowel bij profylactische als therapeutische 
vaccinatie, een sterkere aanwezigheid van micrometastasen in de lever. De micrometastasen 
in de longen waren niet verschillend tussen gevaccineerde en niet-gevaccineerde muizen. Om 
dit effect op levermetastasen verder te kunnen opvolgen, werd vaccinatie herhaald in 
combinatie met chirurgische verwijdering van de primaire tumor. Hoewel de longmetastases 
verder waren ontwikkeld, bleven de metastases in de lever microscopisch en kwamen tot op 
hetzelfde niveau in niet-gevaccineerde en gevaccineerde muizen. Beide tumormodellen 
geven inderdaad geen aanleiding tot macrometastasen in de lever. De relevantie van het 
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optreden van vervroegde micrometastasen in de lever kan dus niet voldoende beoordeeld 
worden. Meer onderzoek is nodig om het mechanisme van dit effect te onderzoeken, wat op 
basis van de literatuur zou kunnen verklaard worden door adaptatie van de cellen in de 
primaire tumor aan hypoxie, wat ook in zekere mate aanwezig is in de lever. Het uiteindelijk 
effect zou eveneens moeten beoordeeld worden in een model waar de lever een belangrijk 
orgaan voor metastases vormt.  
 
Aangezien IL-12 gentherapie zoals toegepast in hoofdstuk 1 enkel toepasbaar is voor 
tumoren die uitwendig bereikbaar zijn voor elektroporatie, werd ook op dit vlak de eerste 
stappen gezet naar een bredere toepasbaarheid. Aangezien IL-12 toxisch is bij hoge 
systemische concentraties, is de uitdaging om bij systemische toediening toch enkel 
intratumoraal hoge concentraties te krijgen. Een mogelijke oplossing is het gebruik van cellen 
die na systemische toediening migreren naar tumorweefsel, die zo gebruikt kunnen worden 
als transportmiddel voor geneesmiddelen. In het geval van IL-12 kunnen deze cellen in vitro 
getransfecteerd worden met plasmide coderend voor IL-12, systemische toegediend worden 
waarna zij naar de tumor zullen migreren en daar het plasmide tot expressie brengen. MDSCs 
migreren zeer sterk naar tumorweefsel en kunnen dus voor dit doeleinde gebruikt worden. 
Een nadeel van MDSCs is echter dat ze tumorgroei sterk stimuleren, het antitumor effect van 
het therapeuticum moet dit dus sterk kunnen compenseren. Een voordeel van het gebruik van 
deze cellen voor de toediening van IL-12 is dat IL-12 in staat is om de protumor 
eigenschappen van MDSCs te verminderen. Er is een muriene MDSCs cellijn ontwikkeld. 
Het gebruik van deze cellijn in plaats van vers geïsoleerde MDSCs vergemakkelijkt sterk het 
preklinische onderzoek, zowel qua tijd, reproduceerbaarheid en benodigde dieren. In het 
laatste hoofdstuk van deze thesis werd in vitro nagegaan of deze cellijn de eigenschap heeft 
behouden om te migreren naar tumorweefsel. Dit bleek het geval te zijn, waaruit werd 
besloten dat verder onderzoek met deze cellijn voor het beoogde doeleinde interessant is. Een 
vereiste hiervoor is dat de cellen in vitro getransfecteerd kunnen worden met een 
therapeutisch plasmide. Niet-virale transfectie is hiervoor interessant daar met deze techniek 
een snelle initiële evaluatie van kandidaat therapeutica kan gebeuren. Elektroporatie werd 
geëvalueerd maar bleek niet geschikt daar er een sterke celdood optrad wanneer MDSCs met 
plasmiden werden geëlektroporeerd. Voor gelijkaardige cellijnen is reeds aangetoond dat de 
massale hoeveelheden intracellulair plasmide na elektroporatie apoptose induceert via een 
immunologische reactie van de cellen. Daarom werd overgestapt naar een chemische vector 
voor transfectie, namelijk lipofectamine 2000. Hierbij werd geen significante celdood 
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waargenomen. De transfectie-efficiënte bedroeg echter slechts 43% en de expressie van het 
transgen was na 72 uur fors gedaald. Wanneer de cellen op deze manier werden 
getransfecteerd met IL-12, konden therapeutisch relevante hoeveelheden geproduceerd 
worden. De MDSCs zelf reageerden ook op deze IL-12 productie met een opregulatie van 
CD80. Een opregulatie van CD80 op MDSCs o.i.v. IL-12 is in de literatuur beschreven en is 
geassocieerd met een vermindering van hun immunosuppressieve functies. Echter, een 
preliminaire in vitro proef suggereerde dat de immunosuppressieve functies inderdaad 
verminderd waren in aanwezigheid van IL-12, maar dat dit effect niet sterk genoeg was om 
de protumor eigenschappen van MDSCs te compenseren. Een efficiëntere 
transfectiemethode, waarbij er eenzelfde concentratie van IL-12 kan geproduceerd worden 
door minder MDSCs, zou dit evenwicht kunnen meer kunnen laten omslaan naar een 
therapeutisch effect. 
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